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To my Mother and Father
ABSTRACT
The morphine metabolite morphine-6-glucuronide is a more effective and longer 
lasting analgesic drug than morphine with fewer side effects. Unfortunately, morphine 
is also metabolised to morphine-3-glucuronide, a compound which antagonises the 
analgesic effect of morphine. Since the 3-glucuronide is formed in greater abundance 
than the 6-glucuronide, there is much interest in using the latter, rather than morphine, 
as a pain killing drug.
Syntheses of morphine- and codeine-6-glucuronides have been reported by Yoshimura 
118et al. , but we have been unable to reproduce the methods described and to obtain 
the products in a pure form. We have significantly improved the coupling procedure 
by boiling 3-acetylmorphine and methyl bromo-2,3,4-tri-0-acetylglucopyranosyl 
uronate in toluene in the presence of silver carbonate on Celite (1:1), giving the adduct 
which can be deprotected by treatment of sodium hydroxide and purification by elution 
through a C-18 cartridge to afford pure morphine-6-glucuronide. Also described are 
syntheses of the related morphine-6-glucoside, codeine-6-glucuronide, and codeine-6- 
glucoside using similar methodology.
Other targets are CH2 isosteres of morphine-6-glucuronide which may provide 
valuable insight into the nature(s) of the opioid receptors. Athough we were unable to 
complete these syntheses in the time available, some useful investigations were carried 
out which may provide more focussed direction in future work.
ACKNOWLEDGEMENTS
The work described in this thesis was carried out in the Organic Chemistry Department 
of the University of Bath between October 1991 and September 1994. Financial 
support from Macfarlan-Smith is gratefully acknowledged.
I am most grateful to Prof. Malcolm Sainsbury, my supervisor, not only for handing 
me this project but for his trust, calming influence, and constant source of 
encouragement and ideas. Special thanks to Prof. Grant Buchanan for providing me 
with much appreciated help and references in sugar chemistry, and to Dr. Richard 
Kinsman for his help with the use of C-18 cartridges. I must also thank my industrial 
supervisors Dr. John Davies and Dr. Mike McPherson for their patience, interest, and 
helpful discussions.
My appreciation goes to the technical staff at the University of Bath for then- 
invaluable services. Special thanks go to Mr. John Bradley and Mr. Russel Barlow 
(organic stores), Mr. Dave Wood and Mr. Harry Hartnell (n.m.r. spectroscopy), Mr. 
Alan Carver (elemental microanalysis), Mr. Chris Cryer (mass spectrometry), Mrs. Jo 
Curtis, and especially to June and Freda
Finally, 1 must respect my good friends Matthew Sage, Alan Graham, Simon Diston, 
Kevin Williams, and Andrew Gaskell for keeping me wild, Sarah Cosway for keeping 
me tame, and everyone else 1 worked with, especially Dave Brown, Ali Ninan, Martin 
Wills, and Matthew Fletcher, for being there when I needed them. Good luck to 
Maxson Liu with the future work from this project
ABBREVIATIONS
Ac acetyl
AUC area under curve
BF3.Et20 boron trifluoride etherate
(3 LPT P lipotropin
Bn benzyl
Bu butyl


































































t.l.c. thin layer chromatography
TMS trimethylsilyl (or tetramethylsilane as n.m.r. standard)
t x a 2 thromboxane-A2
UDP uridine diphosphate
UDPGA uridine diphosphate glucuronic acid



















1. Pain and Analgesia 1
2. Opioids and their Receptors 6
2.1. Agonist-Antagonist Behaviour of Oioids 6
2.2. Endogenous Opioids and Opioid Receptors 7
3. History of Morphine and Analogues 13
4. Modifications and Effects of Morphine 16
4.1. Hydroxyl Groups at C-3 and C-6 16
4.2. Geometric Modifications 17
4.3. Nitrogen Substituents 18
5. Metabolism of Morphine and Analogues 20
6. Conjugation of Glucuronic Acid 23
6.1. Glucuronides of Exogenous Compounds 23
6.2. Types of Glucuronic Acid Conjugation 23
6.3. Effects 25
7. Glucuronides of Morphine 26
7.1. Morphine-6-Glucuronide (M6G) 27
7.2. Morphine-3-Glucuronide (M3G) 30
8. Goals 32
8.1. Current Knowledge on M6G Synthesis 32
8.2. CH2 Isostere Targets 34
B. RESULTS AND DISCUSSION 37
1. Morphine-6-Glucuronide Synthesis 37
1.1. Attempted Reproduction of Prior Art 37
1.2. Mitsunobu Reaction 40
1.3. Attempted Coupling Using Acetyl Activation 42
1.4. Other Activation Methods 44
1.5. Coupling Attempts With Benzylated Sugars 45
1.5.1. Alternative Syntheses of Methyl-2,3,4- 
tri-O-benzylglucopyranosyl uronate 48
1.5.2. Attempted Couplings 57
1.6. Nucleophilic Displacement of Chloride From
a-Chlorocodide 59
1.7. Attempted Glucoside Couplings 61
1.8. Attempted Koenigs-Knorr Glucosidation 63
1.9. Attempted Enzymic Coupling 64
1.10. Couplings Using Silver Carbonate On Celite 65
1.10.1. Deprotection of Glucopyranoside Products 67
1.10.2. Glucuronidation Using Silver Carbonate On
Celite 68
1.11. Alternative Claims 73
2 . CH2 Isostere Targets 75
2.1. Attempted Synthesis of Morphine-6-pseudoglucuronide 75
2.1.1. Pseudosugar Methodology 75
2.1.2. Synthesis of Epoxide Precursor 77
2.1.3. Investigation of Coupling Methodology 80




1. Pain and Analgesia
Analgesia is an altered behavioural response to pain with diminished ability to perceive 
pain impulses without loss of consciousness. Pain is the body's defence mechanism, 
informing the individual of tissue damage during or after its occurrence so that he or 
she can take evasive action and prevent further damage. However, the mechanism of 
pain is very complex and the degree of pain is not necessarily proportional to the 
degree of tissue damage. Often pain exists to a far greater extent than is necessary for 
its purpose and it is therefore desirable to reduce or abolish its effects. This has been 
the case since ancient times either with medicines or by more natural means such as 
meditation. Today, the Western World quite typically prefers the use of medicines and 
a large area of science is devoted towards discovering new analgesic drugs which are 
more powerful or less toxic (or both) since the problem is still a vast one. Knowledge 
of the mechanism of pain is essential if one is to consider the mechanisms of analgesic 
drug actions. Analgesics acting at peripheral sites such as aspirin 1 are known as anti­
inflammatories and this type of analgesia is completely different from the depressant 
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Pain can be separated into two types: ‘acute’ and ‘chronic’.
Acute pain is activated by strong external stimuli, maybe causing or threatening tissue 
damage, e.g. a burn or a cut. Its simplified mechanism is as follows. Signals 
(nociceptive impulses) are sent from the point of stimulus, through nerves, mostly to 
the spine (neural network) and interpreted in the CNS so that site of origin, severity, 
and type of pain can be established. By passing through the neural network, pain (and 
other) signals must pass through synapses, whether in peripheral locations or in the 
CNS. Synapses are very small gaps present at intervals throughout a nerve. The nerve 
cells (neurons) either side of a synapse are called a presynaptic and a postsynaptic cells. 
When a pain signal of large enough intensity is transmitted to and excites a presynaptic 
cell, the cell releases a neurotransmitting substance (excitatory neurotransmitter) which 
diffuses across the gap (synaptic cleft) and interacts with and excites the postsynaptic 
cell thus allowing transmission of the pulse to continue.
This process may be mediated by the presence of neurotransmitters called presynaptic 
inhibitors or postsynaptic inhibitors. Presynaptic inhibitors interact with presynaptic 
cells and block the release of the excitatory neurotransmitter from the presynaptic
3terminals. Postsynaptic inhibitors interact with the postsynaptic membrane and 
decrease the excitability of the postsynaptic neuron1.
Chronic pain is more difficult to understand and to treat. Its causes are often, in part, 
psychological, created by depression and anxiety, following surgery or some other 
cause of intense acute pain. As a result, pain awareness is raised in the CNS so that 
weak pain signals are subsequently interpreted as a strong pain.
NCOCH
Ibuprofen 4Paracetamol 3
Pain may be tackled chemically either at the periphery or within the CNS. Blocking at 
the periphery prevents nociceptive impulses from being transmitted to the CNS. 
Examples of drugs which act at the periphery include aspirin 1, paracetamol 3 and 
ibuprofen 4, all of which are also anti-inflammatories. In practice, these appear to have 
both peripheral and central analgesic actions although this is not firmly established. 
Such drugs are known to act by blocking the biosynthesis of prostaglandins and related 
metabolites which cause pain, fever and inflammation. As indicated above they may 
also have a role to play in the neural transmission of pain, but direct evidence for this is 
missing2.
Tackling pain at the CNS is the normal way our bodies tackle pain overload. Pain 
perception and behavioural response to pain is controlled by peptides called
enkephalins (section 2.2.) which are inhibitory neurotransmitters, almost certainly 
acting by binding with specific receptors in presynaptic cells in the CNS. This prevents 
the release of pain neurotransmitters in the CNS. These neurotransmitters are 
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The CNS then reduces the appreciation of pain relative to the level of nociceptive 
impulses. High levels of enkephalins or low levels of synaptic neurotransmitter may 
block enkephalin release3'6. Narcotic analgesics such as morphine and related opioids 
are centrally acting and mimic the action of enkephalins by binding at the same opioid 
receptor sites. Awareness of pain may persist but the ability to interpret, integrate and 
react to pain is decreased with sedation, euphoria, and reduced anxiety and suffering. 
However, this type of analgesia has its drawbacks. Such euphoria gives the opioids 
abuse potential and it is known that opium has been used for euphoric purposes for 
centuries.
In addition, following the euphoria often comes depression (itself producing chronic 
pain) which is only alleviated by taking more of the drug, resulting in physical 
dependence. Speculations have been made that since high levels of narcotic analgesic 
or low levels of synaptic neurotransmitter may block enkephalin release3'6, this would
,NH, HO
sn:
5result in low levels of enkephalins once the effects of narcotic have worn off. Other 
side-effects of opioids will be discussed later.
Analgesics which act at the CNS are generally regarded as very potent compared with 
the peripherally acting anti-inflammatory pain killers and are frequently used to treat 
both acute and chronic pain. However, due mainly to the dependence liability, opioids 
are only used to treat acute pain if it is too severe for peripherally active drugs to have 
an effect. Chronic pain is almost exclusively treated with CNS depressants, the 
psychological and emotional effects in addition to analgesia of such drugs being ideal 
in such cases. Anti-inflammatory drugs are generally used for acute pain. For 
example, labour pains can be treated with an epidural of a peripherally acting pain­
killer which repeatedly completely blocks the initiation of pain signals locally, while 
opiates only partially alleviate such pain making it acceptable.
62. Opioids and their Receptors
2.1. Agonist-Antagonist Behaviour of Opioids
An agonist is a substance which binds to an active site, promoting a pharmacological 
response.
An antagonist is a substance which competes with an agonist to bind to an active site 
and inhibit a pharmacological response.
The terms when applied to opioids complicate the issue somewhat. Although 
morphine inhibits a pharmacological response (pain), the effect of analgesia must also 
be considered, since this is due to the effect morphine has at the ‘so called’ opioid 
receptors (section 2.2.). Thus, morphine acts as an agonist, at some of these sites, at 
least.
Compounds such as naloxone 8 compete with morphine, reversing the analgesic effect 
and are thus termed opioid antagonists. Naloxone is an example of a pure opioid 
antagonist because it has no analgesic activity itself. However, compounds exist (e.g.
Naloxone 8 Nalorphine 9
7nalorphine 9) which block the action of morphine but also exhibit some analgesic 
activity. These compounds are termed ‘mixed agonist-antagonists’ or ‘dualists’.
2.2. Endogenous Opioids and Opioid receptors
Opioid receptors were originally conceived as specific sites in the CNS that form a 
crucial link in the mechanism of pain perception and that fail to function in this respect 
when bound to certain ligands (analgesics). Before 1970 there was no direct evidence 
for opioid receptors. Their existence had been inferred from stereochemical structure- 
activity relationships of narcotic analgesics and their specific antagonists. It was not 
until the early 1970’s that direct evidence of their existence and location came to light 
thanks to stereospecific binding studies by Goldstein et a l \  which pioneered work in 
this area. Following the demonstration of the existence of opioid receptors came the 
question of their physiological role. It is unlikely that the receptors should have 
evolved uniquely for reaction with substances exogenous to the body, and it is logical 
to postulate the existence of natural morphine-like substances that associate with 
opioid receptors in an interaction that has some physiological function, such as the 
transmission or modulation of nerve impulses.
This prediction, first made by Goldstein8, stimulated an intensive search for substances 
of natural occurrence with opioid-like properties. During 1974-5 several groups 
isolated substances from brain tissue that acted as agonists at opioid receptor sites9. 
Isolation techniques by Hughes et al.10,11 led to the discovery and isolation of a peptide 
called enkephalin in pig brain. Later it was deduced that this compound was a mixture
8of methionine enkephalin (met-enkephalin 10) and leucine enkephalin (leu-enkephalin 
11 ) in the ratio 3-4: t.
tyr-gly-gly-phe-Ieu
Met - Enkephalin 10 Leu - Enkephalin 11
The enkephalins share the same sequence of four amino acids (tyr-gly-gly-phe***), but 
are terminated by methionine or leucine residues, respectively. Their precursors, called 
dynorphins12 and endorphins, polypeptide fragments of (3-lipotropin ((3-LPT, 91 
residues), of whici (3-Endorphin (61-91 residues) is 20-30 times as potent as 
r ' ' eL\  have also been elucidated. Endorphins have limited drug use since they 
are rapidly hydrolysed in tissues, especially in the brain. It is assumed that they adopt 
conformations which fit opiate receptors. The story does not end here and to date 
some 20 endogenous opioids are known. These are biosynthesised from pro- 
epiomelanocortin, pro-enkephalin, and pro-dynorphin at the site where they are 
required14'16. These findings and research with synthetic agonists and antagonists 
provides evidence for multiple receptors. Martin et a /.17’18 postulated the existence of
8972
9distinct p, k, and a  opiate receptors based on differential behavioural and 
neurophysiological responses to morphine (p agonist prototype) and two 
benzomorphan derivatives, ketocyclazocine 12 (k agonist prototype) and N- 
allylnorphenazocine 13 (a  agonist prototype).
HO.
N-allylnorphenazocine 13
Thanks to the discovery of enkephalins, new ligands for pharmacological experiments 
became available to test opiate receptors and a new receptor-ligand interaction was 
revealed in mouse vas deferens19. The new receptor was termed 8, its agonist 
prototype being leu-enkephalin. Similarly a P-endorphin selective ‘e’ receptor was 
found in rat vas deferens20 and has been suggested to occur in the peripheral nervous 
system21, and another, dynorphin selective receptor (no Greek letter) was found in 
mouse vas deferens by Wuster et al.22.
At synapses, neurotransmitting substances are required to pass between the pre- and 
post-synaptic terminals in order that the signal continues towards the CNS. It is 
known that p. receptors mediate the release of noradrenalin, k receptors mediate 
dopamine and 8 receptors mediate acetylcholine23'25. P-Endorphin, generated from 
proepiomelanocortin, has been shown to interact equally well with central p and 8 
binding sites, with very low affinity for k sites in rat brain membranes26.
10
\i Receptors are proposed to mediate analgesia, a behavioural pattern (the variability 
depending on the species) and well defined alterations of vegetative functions (i.e. 
those which are independent of the brain)17’18.
Tolerance to these agonist effects can be developed by chronic administration of 
morphine-like drugs, and the agonist effects can be readily antagonised by naloxone 
and naltrexone 14. The jx receptor appears to be simple in type and is not particularly 
selective. It prefers relatively rigid ligands, whether they are peptides or morphine 
surrogates27,28. Two distinct sub-types of \x receptor are now known29,30. The type for 
which morphine is the prototype ligand is designated jj,2 while fii is a high affinity 
receptor located in supraspinal regions and found to a large degree in periaqueductal 
grey. High affinity binding to jii is achieved equally by morphine and leu-enkephalin 







Naltrexone 14 Apomorphine 15 Diprenorphine 16
j l l 2 Receptors appear to mediate respiratory depression rather than analgesia as effected 
by |ii agonists. Certain breeds of mice, which are considered insensitive to opioid 
antinociception, have a lower composition of |Hi in periaqueductal grey30.
11
k Agonists produce analgesia, but fail to substitute for morphine in suppressing 
morphine withdrawal symptoms17,18. Naloxone and naltrexone are considerably less 
effective antagonists against the effects of k agonists, than they are against those of p
 . .  17,18,31,32agonists .
The a  agonist N-allylnorphenazocine has no significant analgesic action in dogs, but 
precipitates abstinence syndrome in morphine dependent animals due to its affinity for 
the p receptors33. Behaviour in dogs to this drug is quite different from that attained 
by p or k agonists, sharing features with the dopamine receptor stimulant, 
apomorphine 15. The behavioural pattern (naltrexone reversible) in dogs is 
characterised as mania17,18 but shares similarities with hallucinogenic effects of certain 
opiates in other species.
The 8 agonist, leu-enkephalin may elicit epileptic seizures following in vivo 
administration34,35 to mammals. The high 8 selectivity of 8 agonists causes the high 
relative agonist potencies shown by them in mouse vas deferens (high 8 composition) 
compared with the guinea-pig ileum19,32. Antagonist potencies of naloxone and 
naltrexone at these sites are significantly lower than at p receptors32’36’37. 
Diprenorphine 16 has been reported to have higher relative antagonist potency than 
naloxone at 8 receptors38. 8 receptors accept flexible ligands more readily than rigid 
ones27,28 (c.f. p) and no cross tolerance is observed between p and 8 receptor 
prototypes39,40.
The above summary is a very simplified view of opioid receptors. The actual situation 
is far more complicated with variable effects between species and even the type of 
administration of test compounds since this affects the localisation of concentration of 
the test compound. Subtle differences may exist between receptors of a given type
11
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12
depending on the cellular environment, especially when considering the binding effects 
of bulky ligands (such as (3-Endorphin). This may give rise to receptor sub-types, e.g. 
(3-endorphin shows >100 times binding affinity to presynaptic j1 receptors in rat 
neocortex (noradrenalin nerve terminals) than presynaptic 8 receptors in rat striatum, 
but shows equal affinity at ji and 8 sites in rat brain. Certainly this suggests that there 
are different \1 sub-types41.
13




Opium has been used for centuries as a narcotic agent and as a pain killing substance. 
In 1805, the German pharmacist Serturner isolated the main active constituent and 
named it morphine 2 after Morpheus, the God of sleep and dreams. It was not until 
1925 that Gulland and Robinson42 deduced the correct structure as that in figure 1. 
Also isolated from opium in 1832 was codeine 17, and later, thebaine 18, narceine 19, 
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The opposite enanliomer of morphine elicits no opioid pharmacological responses. 
The effects of morphine are on the CNS and upon the gastro-intestinal tract (GIT). 
Most important is its ability to suppress pain without the patient losing conciousness, 
but in addition it induces drowsiness, respiratory depression (fatal overdoses are 
almost always due to this effect), mood changes leading to physical dependence, 
reduction in propulsive movements of the intestine (GIT motility) and causes nausea
. 43-49and vomiting
Over the past 70 years or so there have been numerous attempts to synthesise 
analogues to suppress the undesirable actions of morphine whilst maintaining a high 
level of analgesic activity. One of the earliest was acetylation to diacetylmorphine50 
(heroin) 22 which was initially claimed to be a non-addictive drug, but actually 
produces the same effects at approximately 2!4> times the potency of morphine. (-)-
15
Morphine (the natural enantiomer) was first synthesised in the early 1950's by Gates & 
Tschudi51,52, and subsequently, several syntheses of morphine and analogues have been 
reported. These studies have led to the discovery of new derivatives showing a range 
of activities of the opioid nature53. In the 1960's Bentley and co-workers decided that 
greater complexity and rigidity could be important for greater analgesic activity and 
selectivity. This conclusion led to the introduction of a class of compounds called 
oripavines54. These are synthesised from thebaine using Diels-Aider chemistry. Of 
particular mention in this class is the compound etorphine 23 which has a potency 
greater than 2000 times that of morphine, but with no greater selectivity of action55. A 
related compound buprenorphine 24, however, does show a lower level of side-effects 
compared to its analgesic effect and is now used widely36.
HO
\  / \ / ^ N M e
x  i i j i " , 7 T
M eO1





Etorphine 23 Buprenorphine 24
16
4. Modifications and Effects of Morphine




17 Me H codeine
25 Et H ethylmorphine
26 *Bu H
28 H Ac 6-acetyImorphii
27 ^ ^  H pholcodine
O N
R -O 1'"
The phenolic 3-hydroxyl group of morphine may augment through hydrogen bonding 
the binding of the opiate aromatic pharmacophore to its receptor binding site. 
Masking of the 3-OH group by conversion to the methyl ether 17 (codeine) or ethyl 
ether 25 (ethylmorphine) groups that are not easily hydrolysed in vivo give analgesics 
with about one tenth the activity of morphine. Although codeine probably exerts an 
analgesic activity in its own right, the controversial view that it requires prior 
metabolic conversion to morphine has been expressed57. The 3-fbutyl ether of 
morphine 26 has been shown to be stable to metabolism in rats58 and although in vitro 
its receptor binding capacity is similar to codeine, it is inactive in rat tail flick test or 
weakly active in the mouse writhing assay.
3-Morpholinoethylmorphine (pholcodine) 27 has found wide application as a cough 
suppressant (antitussive agent)59.
In contrast to the reduction in activity when the 3-OH is protected, the 6-sulfate ester 
and 6-glucuronide have been shown to have greater analgesic potency60,61. Heroin has
17
been shown to be rapidly hydrolysed to 6-acetylmorphine 28 in vivo and this accounts 
for its activity62. 6-Acetylmorphine is itself about 4 times as potent as morphine63.
4.2. Geometric Modifications
HO
Structural representation of m orphine
Figure 2.
The stereochemistry of morphine was finally established unambiguously from an x-ray 
crystallographic analysis of the hydrocodide dihydrate salt in 195564. In the solid state, 
the piperidine ring exists in a chair conformation with the NMe group oriented 
exclusively equatorially. Morphine has 5 asymmetric centres; 5(R), 6(S), 9(R), 13(S) 
and 14(R). 13C Nmr studies suggest that the solution conformation may differ from the 
solid state form63. The simplest geometric change can be studied at C-6. The C-6 
epimer of morphine is a-isomorphine, which has antinociceptive actions similar to 
morphine, but with reduced toxicity while isocodeine is less active than codeine. 
Stereochemistry at C-14 gives morphine a B/C cis ring fusion. Inversion gives B/C 
trans morphine, which has lower antinociceptive activity than morphine66,67. Both
18
have C-ring boat conformations due to constraint by the 4-5 epoxide bridge. Without 
the epoxide bridge, morphinans have a chair conformation for the C ring and B/C trans 
morphinans have higher activity than B/C cis morphinans. (+)-Morphine, (+)-codeine, 















It was once believed that a tertiary N bearing a relatively small alkyl substituent was 
necessary for the activity of narcotic analgesics69,70. However, normorphine71 29 (N- 
H) shows higher analgesic activity than morphine when administered to mice. 
Replacement of N-Me with N-ethy] 30 resulted in only a slight fall in analgesic 
response while increasing the hydrophobic series with propyl 31, pentyl 32 and 
phenylethyl 33 groups give an increase in activity (6 times for the latter)72,73. N-Amyl 
34 and N-hexyl 35 have similar activity as N-methyl substituents. N-Allyl codeine is 
shown to antagonise the sedatory and respiratory depression effects of morphine74. N-
19
Allyl normorphine (nalorphine 9) was prepared in 1941 and shows dualist properties. 
It is an analgesic with low respiratory depression properties, but powerful morphine 
antagonist activity75,76. N-Propylnormorphine 31 is also a good antagonist72. These 
findings lead to a new area of research into analgesics which possess agonist and 
antagonist properties without the undesirable effects similar to morphine77’78. Evidence 
suggests that normorphine is an antagonist at |i  receptors and an agonist at either k or 
a  receptors78. It has roughly equal agonist activity to morphine and reverses actions of 
morphine on GIT and CNS, reversing respiratory depression, but by itself it gives rise 
to respiratory depression, anxiety, hallucinations, nausea, difficulty in focusing and 
insomnia79. N-(2-Methylallyl) 36 and N-CPM80 37 analogues are more potent 
antagonists than nalorphine, the latter by 3 times, but also 3 times more active as an 
agonist than morphine. It seems that N-substituents with straight chains of 3 carbons 
gives optimum antagonist activity. Increasing the chain length by one carbon lowers 
activity, and by two or more carbons restores agonist activity79.
20
5. Metabolism of Morphine and Analogues
The metabolism of morphine is very rapid after parenteral administration but 
unpredictable after oral dosage. The pathway is summarised in scheme l 81.
Conjugation with glucuronic acid 38 is the major elimination route that occurs at the 3- 
OH and to a lesser extent at the 6-OH positions of morphine, giving 39 and 40 
respectively, and at the 6-OH position of codeine giving 41. This route accounts for 
65% of morphine in urine of humans83.
Morphine-6-glucuronide 40 has been proposed as an active metabolite of morphine84. 
It is stable in vivo and has up to 4 times the analgesic potency of morphine with about 
twice the duration of activity. It has also been shown to have 45 times morphine's 
response upon intracerebra] injection and stereospecific receptor binding affinity 
studies demonstrate this metabolite to have higher receptor binding affinity than 
morphine (see later). Similar results were reported for morphine-6-sulfate85. 
Morphine-3-glucuronide 39 and the corresponding 3-sulfate 42 had no MHP activity 
and morphine-3-phosphate and morphine-6-phosphate were similar to morphine in 
their responses. These activities were reflected in increased agonist potencies (3x) 







































Heroin is rapidly metabolised in humans86 and other species to 6-acetylmorphine 28 
and to morphine, the active metabolites87. Compounds lacking a free 3-OH function 
bind poorly to opioid receptor preparations and heroin is no exception. Morphine and 
6-acetylmorphine bind well to receptor preparations and the binding of the latter 
accounts for all the apparent binding of heroin. In addition to 6-acetylmorphine and 
morphine, morphine-3-glucuronide occurs as a major metabolite of heroin and minor 
quantities of morphine-6-glucuronide and normorphine 29 and its glucuronide 43 have 
also been detected in human urine after heroin administration88.
N-Demethylation is a significant metabolic route in animals leading to normorphine 
from morphine and to norcodeine 44 from codeine. These metabolites may in turn be 
eliminated as their 3 and 6-glucuronides, 43 and 45 respectively. Oxidative removal 
of an N-methyl function appears to be only a minor metabolic process in humans and is 
unlikely to contribute to the analgesic effects of morphine to any extent71.
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6. Conjugation of Glucuronic Acid89
6.1. Glucuronides of Exogenous Compounds
The majority of foreign compounds undergo metabolic transformations in the animal 
body and these play an important role in any therapeutic action or toxicity displayed by 
such compounds. Compounds may undergo oxidations, reductions, or hydrolyses but 
usually (frequently following such transformations) a conjugation reaction occurs 
during metabolism. The main conjugation reactions which occur in laboratory animals 
are those involving glucuronic acid 38, sulfate, glycine, cysteine, methylation and 
acetylation. Of these, glucuronic acid conjugation is probably the most important for it 
occurs extensively in man and all laboratory animals except the cat. Conjugations are 
generally regarded as detoxification mechanisms since the products are usually less 
toxic and more rapidly excreted than their precursors.
6.2. Types of Glucuronic Acid Conjugation
Glucuronic acid conjugation can occur with several types of hydroxyl, amino and 
carboxyl groups and with sulfhydryl groups. If a drug contains one of these groups 







Glucuronic acid 38 Morphine-6-glucuronide 40
If it does not contain such a group or the group is unreactive to conjugation (due to 
steric hindrance for example), it may acquire one by a metabolic reaction (oxidation, 
reduction or hydrolysis). Examples of drugs capable of forming the glucuronide 
directly are widespread, but include morphine 2 and paracetamol 3 thanks to their 
hydroxyl functions.










The drug couples in one step to uridine diphosphate-(UDP)-glucuronic acid 46 using 
one of the enzymes in the family of UDP glucuronosyl transferases (UGT’s). The
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highest activity of UGT’s is found in the liver but several other organs contain them. 
Detoxification can occur in the skin, lung, kidney, and small-intestine, which is useful 
since they are directly exposed to xenobiotics or toxins. Evidence suggests that UGT's 
exist in multiple forms in most species. Eight hepatic UGT’s have been isolated in 
humans.
6.3. Effects
The effect of conjugation of a drug with glucuronic acid 38 is to produce a strongly 
acidic compound, which is more water soluble at physiological pH than the precursor - 
most glucuronides showing pKa values between 3 and 4. Morphine glucuronides have 
low pKa values (3-glucuronide = 2.83, 6-glucuronide = 3.23). The pharmacological 
activities of virtually all glucuronides show no or much less activity than their 
precursors. There have been a few exceptions to this reported over the last 15 years, 
the most well documented of these being morphine glucuronides.
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7. Glucuronides of Morphine
Morphine is conjugated in a stereospecific manner to morphine-3-glucuronide (M3G) 
and morphine-6-glucuronide (M6G) in the liver90. Rane et al.91 suggested that in 
addition to the known ‘morphine-UGT’, another UGT isoenzyme is present in rat liver 
since (-)-morphine is metabolised to (-)-M3G only, while (+)-morphine is converted to 
both (+)-M3G and (+)-M6G in the ratio 1:3 respectively. Prior treatment with 
phenylbarbitone (which induces morphine-UGT) increases this ratio to 1:7.4 
suggesting that morphine-UGT is not involved with formation of (+)-M3G. Coughtrie 
et a l92 confirmed the existence, in rats, of two UGT isoenzymes both involved with 
regio- and enantioselective glucuronidation of morphine and speculated that morphine- 
UGT is involved in (-)-M3G and (+)-M6G formations while the UGT involved with 
(+)-M3G was consistent with bilirubin-UGT but may be a previously undescribed type. 
In humans, they discovered that the kidney metabolised both (+)- and (-)-morphine 
almost exclusively to the 3-glucuronide which suggested absence of at least one UGT 
isoenzyme responsible for (+)-M6G and probably (-)-M6G. The liver gave different 
results with (-i-)-morphine metabolised to (+)- M6G and (+)-M3G in the ratio 3.72:1 
and (-)-morphine to (-)-M6G and (-)-M3G in the ratio 0.16:1. These results were 
mean values from such a varying range of results that the standard deviation was 
>100%. The cause for this could not be confirmed but could be due to variation in 
time after death of organs used, drug use or environmental factors, or a combination of 
these. Other obvious factors such as age and sex did not show any correlation. From 
other physiological studies they confirmed the existence of at least two UGTs, one for 
M3G and one for M6G (absent in kidney) which again could be bilirubin-UGT.
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It was later shown that differential inhibition of these UGTs in vitro was effected by
metal ions in guinea-pig liver in the conversion of (-)-morphine to its glucuronides.
, 2+ 2+
Cu , Cu , and Cd were able to inhibit the production of M3G with less effect on 
M6G production93.
7.1. Morphine-6-Glucuronide (M6G1
There have been several reports since 1970 which show M6G to have high activity. In 
1971, Shimoumura et al.60 observed that M6G had direct analgesic effects in the hot 
plate assay and their subsequent research showed that both M3G and M6G can 
penetrate the blood brain barrier in rats94. They speculated that the inactivity of M3G 
compared with M6G must be due to differences in receptor binding. However, it took 
more than a decade for the potential clinical importance of these metabolites in the 
analgesic actions of morphine to be appreciated further.
A wealth of reports have been published illustrating the increased analgesic activity 
displayed by M6G versus morphine. A rat tail flick (heat) test showed that M6G was 
20 fold more potent than morphine after direct microinjection into the periaqueductal 
grey while M3G was inactive95. Another test showed that after peripheral 
administration to rats, M6G had twice the analgesic effect of morphine but incredibly, 
after intrathecal administration, M6G was 650 times more potent than morphine96. 
Hanks et al.97 recognised reports that, in humans, single oral doses are 6-8 times less 
potent than direct morphine injections, but after long-term treatment with orally 
administered morphine, its effects were only 2-3 times less potent than by injection. 
They found that after a single oral dose, the main metabolite was M3G with very small
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amounts of M6G, but after long term treatment, the average ratio of M6G to morphine 
concentrations was 4:1 in plasma.
By assembling these facts one may speculate that the increased analgesic activity of 
chronic morphine treatment may be due to a build-up of M6G. Paul et al.96 gave 
subcutaneous (s.c.) injections of morphine and M6G to mice. They observed that 
M6G had a longer onset but higher peak analgesia with much longer duration. Frances 
et a /.98 gave s.c. and intracerebroventricular (i.c.v.) injections of morphine and its 6- 
glucuronide into mice. They also found that following s.c. injection, M6G was slightly 
more effective than morphine at peak levels but lasted 10 times longer. If the analgesic 
potency was measured by integrating the analgesia/time curve (AUC), M6G was 11 
times more active. Following i.c.v. injection, however, interestingly M6G was 48 
times more active than morphine at peak activity in the acetic acid-writhing test but an 
astonishingly 360 times more efficient than morphine in the tail flick test. Both 
compounds were more effective in preventing writhing but since the M6G:morphine 
potency ratio is greater in the thermal test (7-8 times) variability in receptor selectivity 
and/or distribution of concentration is apparent.
As for human tests, two detailed tests on cancer patients have been carried out. In 
1991, M6G was tested on its effects on respiratory depression, the most important 
factor limiting opioid use". It was found that M6G effected less respiratory 
depression at its analgesic dose than morphine at its analgesic dose or put simply, 
LD50/ED50 ratio was 3 times higher for M6G than morphine100. In 1992, Osbome et 
al. published a detailed paper on the analgesic activity of M6G in 20 human cancer 
patients101. Variability was such that no correlation could be made between dosage 
and levels or duration of pain relief. The mean half life was calculated as 3.2 h but the
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range was 1-7.1 h ! This was probably due to variations in renal function (see below). 
Most impressive, though, was the absence of morphine's side effects, even at the top 
dose of 4mg / 70kg. None of the patients experienced euphoria, sedation, respiratory 
depression, nausea or vomitting. Intravenous administration was well tolerated at all 
dose levels. Heavyness and mild aching in limbs during and for 5 minutes after 
administration was experienced by patients at 2 and 4mg / 70kg doses but this is 
consistent with morphine administration.
A better understanding of these effects can be obtained after studying receptor binding 
affinities. In 1992, an in vitro binding study showed that M6G occupied 10 times 
fewer opioid sites than morphine for the same writhing analgesia and 50 times fewer 
sites for equal tail flick analgesia showing that M6G has a higher intrinsic efficacy than 
morphine98. Cross tolerance between M6G and morphine suggests that the same 
binding sites are involved102. The variability in effects is due to a variation in binding 
affinities at the different receptors. The use of specific agonists and, more importantly, 
antagonists has shown that respiratory depression and GIT motility is mediated 
through q2 (spinal) sites rather than p,i (supraspinal) or 8 sites103’104. Also, thermal 
analgesia at the spinal level is mediated mainly through 5 receptors98. It has been 
found that M6G shows a 4 fold lower affinity for \Xi than morphine, slightly lower (i2 
affinity than morphine (both much lower than jLii), higher 8 affinity than morphine and a 
very low k  affinity (lower than morphine)95. The fact that M6G has lower binding 
affinity to \i receptors but higher antinociceptive potency than morphine disproves the 
relationship between ji affinity and analgesia. With respect to thermal pain, |i/K 
selectivity may be a better indication since k  selective agonists fail to block thermal 
pain98,105’107. Both \x and k  sites are involved with suppressing writhing in mice105'107.
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All this information which has now been obtained explains many findings in earlier 
papers when the importance of M6G was not as fully understood. In 1982, Svensson 
et al.m  discovered that morphine glucuronides accumulate in blood, with chronic 
dosing of morphine, to levels greater than those of morphine. In 1984, research on 
patients following kidney transplants implicated the kidney as the major organ of 
morphine metabolism in humans109 and Joel et al. stressed the importance of intact 
kidney (renal) function in morphine elimination110.
There now exists a large body of evidence to suggest that patients with impaired renal 
function are particularly sensitive to morphine because of unusually high levels of M6G 
in plasma101’110'113. It has been suggested that this is due to diminished elimination of 
the glucuronides rather than an alteration in the biotransformation of morphine95. The 
lingering M6G can then be reabsorbed into plasma thus maintaining its relatively high 
concentration over longer periods. Several papers support the above findings. In 
1992, it was demonstrated that patients receiving long-term epidural morphine 
treatment had expected high levels of glucuronides associated with long-term 
treatment with much higher concentrations of 3-glucuronide but the concentration of 
M6G peaked in lh and remained higher than that of morphine which peaked in well 
under lh and declined fairly sharply114.
7.2. Morphine-3-Glucuronide (M3G)
As mentioned earlier, it was reported in the early 1970’s that both M6G and M3G can 
penetrate the blood-brain barrier in rats but M3G seems to show no analgesic activity, 
in contrast to M6G. However, in 1990, Smith et al.ns reported that M3G is a potent
31
antagonist of morphine and M6G analgesia in rats and, in 1992, this was confirmed 
when it was shown that M3G antagonised M6G analgesia in hot-plate, tail flick, and 
writhing assays of rats especially after intrathecal administration116. Also, central 
respiratory depression was reversed. Since the rat liver converts morphine to 55% 
M3G and 15% M6G, the concentration of M3G in CSF is high enough after chronic 
oral doses to have a large effect on the overall analgesic effect116. Contradictory to 
this, however, was a report on the failure of M3G to antagonise spinal antinociception 
by morphine or M6G in rats117.
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8. Goals
The synthesis and subsequent administration of morphine-6-glucuronide would now 
seem to be enormously beneficial. Not only is the ratio of desired effects to unwanted 
effects greater but the higher and longer duration of activity of M6G may result in 
greater efficiency of morphine per se if a simple procedure for 6-glucuronidation is 
available. Furthermore, administration of M6G would by-pass the in vivo production 
of M3G which may have antagonist potential in humans, based on findings in rats. In 
any case, the production in high yields of M6G would be beneficial for further tests on 
the overall effects of this extremely active and useful metabolite.
8.1. Current Knowledge on M6G Synthesis
The syntheses of morphine- and codeine- 6-glucuronides 40 and 41 have been reported 
in fair yields (~30%, and ~20%) from 3-acetylmorphine 47 and codeine 17 respectively 











47 R = Ac 
17 = Me
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40 R = H
41 = Me
Scheme 3.
Several groups who performed the pharmacological tests sited above used this 
procedure without reporting yields, or obtained the metabolite from an outside source. 
It is common knowledge from the various manufacturers of this metabolite that this 
procedure gives much lower yields than reported, is difficult to perform and the 
product is frequently contaminated with metal salts. Macfarlan-Smith, who funded our 
work, actually failed to produce any of the desired product via this route, hence their 
interest in finding an alternative synthesis.
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8.2. CH? Isostere Targets
It was reported in 1991 that both M6G and to a lesser extent M3G display lipophilicity 
measurements almost as high as morphine itself over a wide pH range119. This does 
not correlate with the predicted values or with the values for most other glucuronides 
and an attempt was made to explain the reasons for this unexpected high lipophilicity 
using theoretical conformational studies. A conclusion was arrived at proposing that 
the two glucuronides exist in conformational equilibria between extended and folded 
forms. The extended conformers efficiently expose their polar groups, thus 
predominating in polar media such as water, whereas the folded conformers mask part 
of their polar groups, thus being more lipophilic and more likely to predominate in less 
polar media such as biological membranes. This would explain how these metabolites, 
especially M6G, have a greater ability to cross the blood-brain barrier than expected. 
Not discussed in this report, however, is the possibility that the glucuronides may exist 
in an equilibrium between closed-ring and open-chain forms in which the latter may 
have more freedom to expose or mask its polar groups to a greater extent than the 
former proposed above. Alternatively, it is possible that an open-chain form is simply 
more polar and it is this equilibrium which gives these metabolites the variability in 
polarity and lipophilicity which allows a high level of blood transport with the ability to 
pass into biological membranes.




















The first two targets 51 and 52 should be unable to exist in open-chain forms and may 
only equilibrate between extended and folded forms of the type mentioned by Testa et 
al,119. Should these targets show poor biological and physical results, the third target 
53 may exist in an open-chain form and a different set of results would be interesting.
In addition to giving more insight into the conformational chemistry of M6G, some of 
these targets may be expected to show biological activities more or less M6G-like than 
morphine, thus giving a greater insight into the opioid receptor variables about which, 
still, relatively little is known. Even if these targets should give poor biological results, 
a successful synthetic method will open the door to research into a wide range of 
analogues which may provide vital clues into opioid receptor multiplicity and effects.
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This is more justifiable when considering the more favourable clinical effects of M6G 
compared with morphine.
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B. RESULTS ANI) DISCUSSION
1 MORPHINE-6-GLUCURONIDE SYNTHESIS
1.1 Attempted Reproduction of Prior Art.
Following the problems encountered by our colleagues at Macfarlan Smith to 
reproduce the coupling reactions reported by Yoshimura et al.ns (scheme 3. Chapter 


















57 R = *BDMS 
17 R = Me
Scheme 4.
Synthesis of the glucuronate precursor, methyl (bromo-2,3,4-tri-0- 
acetylglucopyranosyl) uronate 48, was successfully achieved from glucurono-6,3-
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lactone 54 via methyl glucopyranosyl uronate 55 and methyl tetra-O-acetyl 
glucopyranosyl uronate 56, as previously described120,121. Two attempts, one to couple 
3-'butyldimethylsilylmorphine 57, and one to couple codeine 17 to the glucuronate 48 
were attempted using freshly prepared, oven-dried silver carbonate122. In both cases 
no new products were formed after 20 hours at reflux and starting materials (opioid 
and glucuronate) were recovered. It is known that the glucuronate 48 is unstable but 
this does not explain the total lack of reaction. The fact that 48 was recovered 
suggests that this compound is insufficiently reactive, even with the activating reagent 
silver carbonate present in excess.
Consequently, an alternative route was sought. An extensive literature search resulted 
in the discovery of a multitude of possibilities when applied to glucoside couplings, but 
few in the area of glucuronides.
Following a similar line to that used by Yoshimura, we decided that the glucuronate 
precursor should have the carboxylate group protected as a methyl ester, which is 
stable to basic and moderately acidic conditions, and to have the non-anomeric 
hydroxyls (2, 3, and 4) protected as acetate groups. One important feature is that an 
acyl group at C-2 would control the facial selectivity of the coupling process and give 
the desired anti stereochemistry as a result of the neighbouring group effect123.
39





Thus, in the case of a glucuronate derivative, the presence of an acyl group at C-2 
should result in (3-glucuronide formation.
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1.2 Mitsunobu Reaction
First attempts by us were based on the Mitsunobu reaction124 (c.f. TXA2 synthesis125). 
This has been used in glycosyl couplings before126 and, despite the above 
stereochemical rationalisation, we first tried to couple the O-silylmorphine 57 and 
methyl glucopyranosyl uronate 55 in tetrahydrofuran (THF) with 1.2 eq 
diethylazodicarboxylate (DEAD) and 1.5 eq triphenylphosphine, hoping that the lack 
of protection would not present a problem, but would have the maximum efficiency 



















In the event, however, only starting materials and triphenylphosphine-DEAD complex 
were recovered, indicating that none of the hydroxyl groups on the glucuronate 55 
were sufficiently reactive to form the alkoxyphosphonium salt. Since carbohydrates 
with no hydroxyl protecting groups present tend to equilibrate between open chain and 
5 and 6 membered ring forms, it was decided that only suitably protected glucuronate 
precursors should be used in future. However, an attempted coupling with methyl 
2,3,4-tri-O-acetylglucopyranosyl uronate 58 and silyl-morphine 57 failed, as did a 
similar reaction using mercuric bromide (1.2 eq) as a promoter126.
With consideration to the wastage of the expensive and scheduled substance morphine, 
the following coupling methodologies were investigated using cyclohexanol 59 as a 
cheap model and the glucuronate 58 as the glycon.
Once again, the Mitsunobu method failed, with or without mercuric bromide present, 
and similar attempts were tried with tributylphosphine in place of triphenylphosphine. 
It is considered that this reagent gives a DEAD complex which is more reactive 
towards hydroxyl groups and it affords a more reactive alkoxyphosphonium salt127 
Unfortunately, the reaction failed, although the hydrazine formed by the reduction of 
DEAD was isolated. During the reaction, on addition of cyclohexanol at -78°C, the 
solution immediately turned red, indicating a reaction between the tributylphosphine- 
DEAD complex and cyclohexanol rather than with the glucuronate as desired. We 
assume that in this case, dehydration of cyclohexanol occurred, accounting for the 
formation of the hydrazine. However, when the reaction was repeated with mercuric 
bromide present, DEAD remained unchanged.
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The former of these two reactions was repeated using acetonitrile as solvent since this 
is said to promote the reaction by stabilising the intermediate oxonium species as a 
complex128 (figure 3).
Indeed the red colouration appeared when the solution was warmed to 0°C, prior to 
addition of cyclohexanol, and the hydrazine reduction product from DEAD was again 
obtained. No coupling products were recovered, however, indicating a lack of 
reactivity between the alkoxyphosphonium salt of the glucuronate precursor 58 and 
cyclohexanol 59.
1.3 Attempted Coupling Using Acetyl Activation
The Mitsunobu methodology was abandoned so that other techniques could be 
investigated. Virtually all glycosyl ether linkages utilise excellent leaving groups at the 
anomeric carbon. These may be stable groups which are activated in situ by a Lewis 
acid. The majority of such methods are carried out upon glycons with non-acyl 




between a thiol and methyl tetra-O-acetyl glucopyranosyl uronate 56 activated with the 














In principle, thiols are softer and more nucleophilic than alcohols, but we were still 
motivated to investigate this methodology using our silylmorphine derivative 57. The 
first attempt was carried out using 1.2 eq boron trifluoride etherate, but this failed and 
it seems likely that most of the reagent was used up by binding to the basic nitrogen 
atom of the silyl-morphine 57. To overcome this, the reaction was repeated using 
2.7eq boron trifluoride etherate to give sufficient excess to activate the glucuronate 56. 
The only result, however, was the desilylation of 57 to give morphine 2.
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1.4 Other Activation Methods
R" R'
62 tin CHiOBn
65 Ac CO jM e
Scheme 6.
We next investigated three glucosidation methods which have been used to couple the 
benzyl derivatives 60, 61, and 62130’131. In our case, however, the sugar analogues 
were the 2,3,4-triacetyl derivatives 63, 64, and 65 with COzMe in place of the 
CH:OBn group. The reported methods are shown below:
Sn(O Tf)2
MeCN
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MeCN
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Our precursors 63, 64, and 65 had to be synthesised from methyl 2,3,4-tri-O- 
acetylglucopyranosyl uronate 58 using similar methods to those reported in the 
literature130,131. We were disappointed when these attempted syntheses all failed, since 
the impression we gained from reading the papers was that the methodology is 
generally applicable and should have worked well for our targets.
1.5 Coupling Attempts With Benzvlated Sugars
The lack of reactivity we had experienced this far was likely to have been due to the 
presence of a C-2 acetoxy group which ‘disarms’ the glycoside132 and this caused us to 
examine non-acylated analogues, even though we recognised that this would result in 
the loss of stereo-control. There are a few exceptions where this does not occur, 
however, and there is a claim that the glycon methyl(trichloroacetimidyl-2,3,4-tri-0- 
benzylglucopyranosyl) uronate 66 reacts with androsterone 67 to yield the p- 
glucuronide almost exclusively133.
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We therefore set about the synthesis of 66 from methyl glucose 68 via methyl-2,3,4-tri-
0-benzylglucopyranosyl uronate 69, following the literature methods134’135.
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All the steps worked as planned up to the formation of methyl (methyl-2,3,4-tri-<9- 
benzylglucopyranosyl) uronate 70, however, the next reaction, namely O- 
demethylation/acetylation using glacial acetic acid and acetic anhydride to produce the
1-acetyl derivative 7113'\ failed. In our hands, the treatment returned only starting 
material. Even heating the reagents with 1.1 eq conc. sulfuric acid at 40°C for 24 
hours was insufficient to effect the required reaction and after stirring overnight at 
60°C the sugar was destroyed and subsequent treatment with sodium methoxide gave 
at least 6 compounds.
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We also investigated other demethylation procedures. Trimethylsilyl iodide has been 
widely reported as a 0 -demethylating agent, but shows little selectivity between esters 
and ethers136. This was indeed the case when we tried to use this reagent in either 
excess or a near stoichiometric amount. In both cases, t.l.c. showed the presence only 
of baseline material.
Boron tribromide has also been recommended for this type of demethylation137 and we 
tried to use this in DCM as solvent. After one hour, t.l.c. analysis indicated complete 
conversion of the starting material to a compound with a higher RF. However,when 
the reaction mixture was quenched with sodium hydrogen carbonate, t.l.c. analysis 
now showed that further conversion had occurred and only a baseline spot was visible. 
(N.B. our target runs with an RF ~ 0.3 using the same mobile phase).
1.5.1 Alternative Syntheses of Methvl-2.3.4-tri-O-benzyl glucopyranosyl uronate 69
We decided that, since our attempts using this route were fruitless, another pathway 
was required. An alternative synthesis of the glucuronate 69 from glucose 72 is shown 
later in scheme 11. It utilises O-allyl protection, rather than O-methylation, in the key 
intermediate 73138. However, this is another tedious procedure involving 7 steps 
including a diazomethane methylation. In order to circumvent this we considered 
benzylating all four hydroxyl groups of methyl glucuronate 55, followed by specific O- 







We attempted this first by reacting methyl glucopyranosyl uronate 55 with benzyl 
bromide and sodium hydride139 in dimethoxyethane (DME) at reflux, but no reaction 
was observed after three days, possibly due to the lack of solubility of the carbohydrate 
tetra-sodium salt. The phase-transfer catalyst tetrabutylammonium iodide140 was 
added and the reaction was continued for one day, however this did not cause any 
reaction to occur either.
The reaction was attempted in the more polar solvent DMF at 100°C and the sodium 
hydride and benzyl bromide were added in portions of 1.1 and 2.0 eq respectively to 
the solution of carbohydrate 55. After 10 hours with only one of each portion added, 
no reaction was observed. Second portions were added and the reaction was 
continued, but again no new products were formed.
Also attempted was the tetra-O-benzylation of 55 using benzyl trichloroimidate and 
catalytic boron trifluoride etherate in DCM141. However, this was also unsuccessful 
with no conversion of the starting material.
Our concern over pursuing this work was tempered by the fact that O-debenzylation 
requires relatively harsh conditions and, after considering all the known 
techniques136’142, it was obvious that the required specificity for the anomeric centre
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could not be achieved. The anomeric effect only weakens the glycosyl bond and this is 






Hence, our strategy was to use methyl-2,3,4-tri-O-acetylglucopyranosyl uronate 58 
and to protect the anomeric position with a 'butyldimethylsilyl group143.








Methyl tri-O-acetylglucopyranosyl uronate 58 was synthesised, as before, from 
glucurono-6,3-lactone 54, but the previous two steps (bromination and hydrolysis) can 
be short-cut by a simple acyl hydrolysis step. This is performed by bubbling dry 
ammonia gas through a solution of methyl tetra-(9-acetylglucopyranosyl uronate 56 in
51
cold DCM144. O-Silylation of 58 was achieved using the reagents 'butyldimethylsilyl 
chloride (1.1 eq) and imidazole (3.0 eq) in THF143 and purification was effected by 
extraction. This gave silyl glucuronate 74 in 92% yield.
Deacetylation of the product proved to be much more difficult than expected, but not 
because of silyl migration, as might have been suspected. Several techniques were 
tried and the yields are shown in the table.
Reagent Solvent Yield of 75 (%)
sodium methoxide methanol dry 33
potassium carbonate methanol/water 1:1 0
potassium carbonate methanol/water 9:1 0
triethylamine methanol dry 33
2M ammonia methanol 25
The first choice of reagents for the reaction is catalytic sodium methoxide in dry 
methanol145 since this should not affect the methyl ester functionality and product 
isolation is simple. However, in practice, treatment with 0.1 eq sodium methoxide 
gave only partial conversion (by t.l.c.) after one day and no further conversion with 0.2 
eq present after a further two days. In both cases, we had evidence that at least two 
minor side products were forming but starting material was still present. Sonification
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of the reaction mixture for a further two days caused no further conversion, but flash 
chromatography of the crude reaction product gave the O-deacetylated product 75 in 
33% yield, while starting material 74 (only 2%) and by-products (10% of starting
mass) were also recovered.
Consequently, other reagent systems were investigated. Aqueous potassium carbonate 
is known to be effective in deacetylation reactions, but it may also hydrolyse methyl 
ester functions146. Since potassium carbonate is insoluble in methanol, some water is 
required, but when we used this base in a 1:1 mixture of methanol and water we found 
that the starting material was insoluble and was completely recovered. However, when 
a 9:1 mixture of methanol and water was used, the starting material was destroyed 
within 5 minutes.
Two other, lesser known techniques were also tried. Dry triethylamine (5 eq) in 
methanol147 showed similar results to sodium methoxide, reaching a quick (< 1 day) 
but premature end-point, i.e. only partial conversion was achieved. Unfortunately, 
besides the assumed product spot, t.l.c. showed that four by-products were also 
present with similar RF values to those obtained from the sodium methoxide reaction. 
Flash chromatography of the reaction mixture gave impure product 75 in 68% yield, 
starting material in 24% and the close running by-products as 18% of the starting 
mass. The RF values of the by-products were too close to encourage us to make a 
determined effort to separate them. Eventually, compound 75 was crystallised from 
isopropyl ether affording the pure product in 33% yield as colourless prisms.
Another method using 2M ammonia (7 eq) in methanol (0.5M ammonia)148 was 
examined. After four days reaction time this gave a greater conversion of the starting
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material to the product than any of the other sets of reaction conditions, but also a 
greater level of decomposition products. When higher concentrations of ammonia 
were used, the decomposition processes were enhanced. Under the best conditions we 
only obtained a yield of 25% for product 75.
After this we decided not to continue the investigation further. We accepted the low 
yield and next examined the O-benzylation of 75. This also proved to be a very 
difficult process.
Originally, we reacted glucuronate 75 with benzyl trichloroacetimidate (4 eq)141 and 
boron trifluoride etherate (0.4 eq) in DCM at room temperature, but after 1 hour the 
reaction mixture contained at least 5 compounds. There was little change after 17 
hours, even when more boron trifluoride etherate was added, and we were unable to 
isolate any tangible products from the reaction mixture. It is reported that boron 
trifluoride etherate does not always effect clean benzylation and the reaction products 
are frequently complex mixtures. Better results are claimed for the use of 
triflu oro me thane sulfonic acid (triflic acid)141 promoted reactions, but we were 
concerned that such a strong acid might desilylate our compound. Notwithstanding 
this concern we attempted the benzylation using 11 eq benzyl trichloroacetimidate and 
0.2 eq triflic acid in DCM. In order to minimise the probability of desilylation, the 
triflic acid was first added to a solution of benzyl trichloroacetimidate in DCM and 
stirred for 10 minutes before a solution of glucuronate 75 in DCM was added dropwise 
over half an hour. It was our premise that this slow addition would minimise the 
concentration of 75 present in the reaction mixture since 0 -benzylation should be 
almost instantaneous. In the event, however, a mixture of products was formed.
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Other, more traditional methods for benzylation were also tried. The first of these 
employed benzyl bromide (3.5 eq) and sodium hydride (3.5 eq)139 in dimethoxyethane 
(DME). After boiling the solution for 24 hours, t.l.c. indicated no conversion so 
further portions of benzyl bromide and sodium hydride were added and the reaction 
continued overnight. After this time, t.l.c. showed two, u.v. active spots with high RF 
values. Flash chromatography of the reaction products gave both compounds as oils, 
but their n.m.r. spectra were incompatible with benzylated carbohydrates. The yields 
obtained were very low, so further work on these products was not continued.
A similar reaction was attempted using DMF instead of DME as solvent, a choice 
forced upon us since we observed that glucuronate 75 was incompletely soluble in the 
latter solvent even at reflux. This, we thought, might have been partly responsible for 
the poor reactivity, in the event, however, this change was ineffectual and again no 
benzylation of 75 was observed.
At this point we felt that a change of tactic was necessary and we sought to increase 
the reactivity of the benzyl bromide by adding silver oxide to the reaction mixture149. 
Thus, a solution of glucuronate 75, silver oxide (4.5 eq) and benzyl bromide (4.5 eq) in 
DMF were reacted together at room temperature during 4 days. After this time, t.l.c. 
analysis showed 3 u.v. active spots and a large amount of starting material. The 
solution was stirred at 100°C overnight, but no further change was observed. After 
this time, more benzyl bromide (2 eq) was introduced and the reaction was continued 
but again to no avail. More additions of 10 eq of both silver oxide and benzyl bromide 
were made and the solution was stirred at 130°C for a further 24 hours. Again u.v. 
active spots were in evidence from t.l.c. but now these seemed much more prominent
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than before. Flash chromatography enabled us to obtain trace amounts of crude 
samples of these materials, but there was no evidence that they contained carbohydrate 
units. It is known that benzyl bromide in the presence of Lewis acids can couple to 
form arylalkanes and arylalkenes and we assume that this is what these compounds are.
Yet another attempt at O-benzylation was made using benzyl chloride (9 eq) and 
sodium hydride (4.5 eq) in dimethyl sulfoxide (DMSO)150. This combination has been 
reported to promote, the rate of this type of substitution reaction. To the mixture was 
added 75 in the same solvent, but once more no benzylation occurred, even though 
aromatic side products did form. In desperation we raised the temperature to 120°C 
for 8 hours at which point a strong smell of dimethyl sulfide was noted. An 
examination of the t.l.c. of the products showed that the desired alkylation had not 
occurred and only a baseline of fluorescent spots was observed.
Since the deacetylation and benzylation steps had been so disappointing, the alternative 
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Scheme 11.
Ally 1-glucose was prepared from glucose 72151 on a large scale (lOOg) in 25% yield. 
The 6 remaining steps from allyl-glucose leading to 69 were all successfully followed in 




Separate coupling reactions were attempted between the acetimidate 66 and the 
aglycons codeine 17, silylmorphine 57, and cyclohexanol 59, using boron trifluoride 















Of these reactions only cyclohexanol gave a positive result and a 12% yield of the 
coupled product methyl (cyclohexyl-2,3,4-tri-0-benzylglucopyranosyl) uronate 76. 
Unfortunately, this product proved to be an anomeric mixture of 31:69 (3:a. The 
analysis of the mixture is expedited since in the *H n.m.r. spectrum, the signal of the 
anomeric (3-proton is exhibited as a distinctive doublet at around 5 p.p.m with 11.5 Hz
coupling constant, hence the p-lH integration was calculated and compared with the 
methyl ester peaks, which give a 3H integration total for both anomers. It should be 
noted that to achieve even this modest level of coupling it was necessary to allow the 
reaction mixture to rise from -23°C (the recommended temperature) to room 
temperature. It is possible that this extra warming may have adversely affected the 
stereoselectivity, since Schmidt claims that p selectivity is optimised at low 
temperature133. We spent some time investigating this problem, but our results serve 
only to confirm that our reaction does not occur even at 0°C. The only conclusion to 
be gained from these experiments is that codeine 17, and silylmorphine 57 are less 
nucleophilic than cyclohexanol, but even so cyclohexanol is still very unreactive under 
the conditions selected.
As a means of increasing the nucleophilicity, codeine 17 was treated with sodium 
hydride in THF to give the sodium salt, and to this reaction mixture was added 
dibenzo-18-crown-6 in benzene152 (scheme 13). It was hoped that this would 
solubilise the salt in the benzene phase. The reaction mixture was cooled to -15°C and 
















Unfortunately, the desired reaction was not observed, although this could be due to a 
variety of factors not least of all the incompatibility of the boron trifluoride etherate 
and the crown ether.
1.6 Nucleophilic Displacement of Chloride From q-Chlorocodide.
At this point, we investigated the possibility of using an electrophilic opioid which 







a-Chlorocodide (6(3-chlorocodide) 77 was formed from the reaction of codeine and 
phosphorus pentachloride in 75 %153. As a model reaction we attempted to couple this 
mixture with cyclohexanol (sodium salt). A solution of 77 in THF was added 
dropwise to a solution of cyclohexanol and sodium hydride in THF at 0°C. We 
anticipated either direct Sn2 displacement of the halide ion giving a 6-ether linkage or a 
Sn2’ reaction giving an ether coupling at C-8. Unfortunately, after stirring the
reactants for 8 hours at 20°C no reaction occurred.
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1.7 Attempted Glucoside Couplings.
The only possible way forward was to synthesise a suitably protected morphine-6- 
glucoside using a tetra-0-benzylglucose derivative such as l-(9-(2-ethylcarboxylate-l- 
phenylethenyl)-2,3,4,6-tetra-(9-benzylglucose 60 and 1 -0-(2-pyrimidyl)-2,3,4,6-tetra- 
(9-benzylglucose 6K both formed from methyl glucose 68134, activated with 
trimethylsilyl triflate as shown earlier in scheme 6130’131.
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The attempted coupling between codeine 17 and the carbohydrate 60 resulted in the 
decomposition of codeine, while the carbohydrate was unaffected. However, coupling 
was achieved between codeine and carbohydrate 61 to produce the benzylated codeine 
glucoside 78 in 35% yield, but as a 1:1 anomeric mixture. Success at last, but the 
formation of this anomeric mixture posed a major problem to us since the anomers 
were extremely close running, ruling out chromatographic separation (bearing in mind 
the highly polar mobile phase which would be required). In addition, the low overall 
yield was disappointing. The same method was applied in an attempt to couple 
silylmorphine 57 and carbohydrate 61, but this was totally unsuccessful and 
deprotection of 57 to morphine occurred. This, of course, is not unexpected in the 
presence of trimethylsilyl triflate.
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1.8 Attempted Koenigs-Knorr Glucosidation
As with the glucuronidation, a stereoselective glucosidation using the Koenigs-Knorr 
reaction has been reported to occur between bromo tetra-O-acetylglucopyranoside 79 
and codeine 17 in the presence of silver carbonate and anhydrous calcium sulfate in 
benzene155. We attempted this reaction with our compounds, but failed and both 










1.9 Attem pted Enzymic Coupling
P-Glucosidation has been reported to occur in the coupling reaction of o- 
nitrophenylglucopyranoside 80 and an excess of a suitable alcohol in the presence of p- 
glucosidase at pH 5.0j36. We attempted to couple 80 and 8 eq codeine 17 under these 
conditions over 24 hours. Although t.l.c. indicated starting materials remaining, the 
existence of a new compound was also revealed. Work up and chromatographic 
purification of this compound gave a colourless crystalline solid, but a *H n.m.r. 
spectrum indicated that the product was simply a salt of codeine. This was confirmed 
by basifying a sample of the product and comparing it directly with codeine.
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1.10 Couplings Using Silver Carbonate On Celite
Following an extensive literature search for acetyl-protected glycosyl coupling 
reactions, we found that the gibberellin 81 and bromo tetra-O-acetylglucopyranoside 
79 could be linked by boiling them together in toluene in the presence of silver 


















We were aware that the bromoglucoside 79 might be unstable, so in our first attempt 
at coupling this with codeine 17 in the presence of silver carbonate on celite, we 
restricted the temperature to 40°C (in boiling DCM). At this temperature no reaction 
took place, but at 112°C (toluene at reflux), we were pleased to note that two new 
compounds were formed. T.l.c. analysis showed these products to possess close Rf
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values although higher than that of codeine. Clean-up of the reaction mixture, 
however, proved to be more difficult than we had hoped. Flash chromatography gave 
poor separation of the two new compounds and hence a yield of 30% was obtained for 
the major product. However, a dark trail which had also run up the entire length of the 
t.l.c. plate whilst monitoring the reaction, was still present; this despite filtering the 
solution prior to flash chromatography. As a result, codeine-2,3,4,6-tetra-O- 
acetylglucopyranoside 82 could only be deduced as a product by n.m.r. 
spectroscopy with contamination by other unidentified compounds.
We used the same procedure to couple silylmorphine 57 to bromoglucoside 79 and this 
gave (3-silylmorphine)-2,3,4,6-tetra-(7-acetylglucopyranoside 83, but in less than 13% 






















1.10.1 Deprotection of Glucopvranoside Products fScheme 17)
Subsequent deprotection with sodium methoxide did not proceed to completion and 
we were unable to obtain a single product in either case since chromatographic 
purification is not possible. Even on reversed-phase silica tl.c., the products are eluted 
at the solvent front when 5% acetonitrile/water is used as the mobile phase. Despite 
our efforts to purify these deprotected products by extracting the impurities into ether, 
we still only obtained brown oils for codeine-6-glucoside 84, and 3-fBDMS-morphine- 
6-glucoside 85 and both in less than 40% yields. Following desilylation of glucoside 
85 using tetrabutylammonium fluoride (TBAF)143, we were faced with a major problem 
since morphine-6-glucoside 86 was highly water soluble and could not be separated 
from the water soluble salts. Attempts were made to extract 86 from water into the 
polar organic solvents, chloroform or nitrobenzene, but these efforts were 
unsuccessful. We were, therefore, required to alter our strategy by performing the 
desilylation step prior to deacetylation.
The crude reaction mixtures containing glucosides 82 and 83 were extracted from 
ether into 1% aqueous acetic acid, before basifying and back-extracting into 
chloroform. T.l.c. analysis then confirmed the presence of opioids in the chloroform 
phase with the absence of carbohydrate by-products. The dark trail on the plates 
which characterised our earlier analyses was also missing. However, flash 
chromatography still gave poor separation of these opioids, but eventually we managed 
to obtain pure codeine tetra-O-acetylglucopyranoside 82 in 28% yield. Similarly, 3- 
silylmorphine tetra-O-acetylglucopyranoside 83 was obtained in 14% yield, and
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subsequent desilylation of 83 with TBAF gave morphine-6-tetra-(9- 
acetylglucopyranoside 87 in 20% yield. Since the overall yield of 87 was so low, the 
coupling was attempted between bromo tetra-O-acetylglucopyranoside 79 and 3- 
acetylmorphine 47 giving 3-acetylmorphine-6-tetra-(9-acetylglucopyranoside 88 in 
27%, thus allowing deprotection in one step.
Deacetylation of codeine glucoside 82 was achieved with sodium methoxide in 
methanol and the product was extracted from chloroform into water giving pure 
codeine-6-glucoside 84 with 75% yield. Similarly, deacetylation of morphine tetra-O- 
acetylglucopyranoside 87 to morphine-6-glucoside 86 was achieved with 95% yield.
1.10.2 Glucuronidation Using Silver Carbonate On Celite (Scheme 18")
With these successes in hand, this methodology was implemented in the coupling 
reactions of methyl (bromo-2,3,4-tri-0-acetylglucopyranosyl) uronate 48 with codeine 
17 and 3-fbutyldimethylsilylmorphine 57. At the end of the reactions we found that the 
acetic acid extractions were much less effective than they had been in the analogous 
glucoside reactions. This resulted in a yield of only 6% for codeine-6-methyl(tri-(9- 
acetylglucopyranosyl) uronate 50. Better results were obtained for 3-silylmorphine-6- 
methyl(tri-(9-acetylglucopyranosyl) uronate 89 which was isolated in 36% yield after 
several acetic acid extractions. However, desilylation with TBAF only gave us an 
impure oil in 14%, even after flash chromatography. Fortunately, 3-acetylmorphine-6- 
methyl(tri-O-acetylglucopyranosyl) uronate 49 was synthesised from 3-acetylmorphine
69
47 in 45% yield via ice-cold 0.5N HC1 extractions. This method of isolation was also 
tried with codeine-6-methyl(tri-0-acetylglucopyranosyl) uronate 50, but only a slight 




3 - rB DM S - morphine 13 36
codeine 28 10
3-acetylmorphine 27 45
Further investigations on the coupling reaction have been carried out. Freshly 
prepared silver carbonate was mixed with celite (50:50 mixture) and used in place of 
the commercially available ‘silver carbonate on celite’ in the coupling of codeine 17 
and methyl (bromo-2,3,4-tri-0-acetylglucopyranosyl) uronate 48. Astonishingly, the 
t.l.c. analysis indicated a successful conversion, along with a side-product. 
Unfortunately, the work-up only gave a 7% yield of codeine-6-methyl(tri-<9- 
acetylglucopyranosyl) uronate 50, but this result compares reasonably with the 10% 
yield for the coupling using the commercial reagent.
Interestingly, when celite alone was substituted for silver carbonate on celite, tl.c. 
analysis indicated that the side-product was formed in very small amounts but most of 
the starting material was still present. This side-product was recovered by
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chromatography, although in only 3mg. n.m.r. and m.s. indicated the formation of 
codeine-6-acetate, presumably through displacement at a carbohydrate acetate centre, 
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2) oxalic acid
Scheme 18.
Subsequent hydrolyses with sodium methoxide in methanol and barium hydroxide were 
carried out as detailed in the Yoshimura paper118. The intermediate morphine-6- 
methylglucopyranosyl uronate 90 was synthesised but only after using boiling sodium 
methoxide in methanol, in 68% yield but n.m.r. spectroscopy indicated a significant 
amount of morphine-6-glucuronide 40, perhaps due to slight moisture presence 
allowing formation of sodium hydroxide which effects hydrolysis. Complete 
conversion of the ester 90 to morphine-6-glucuronide 40 was accomplished as 
described with aqueous barium hydroxide, which was removed by adding
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stoichiometric oxalic acid, forming the insoluble barium oxalate which was filtered off. 
Evaporation gave a colourless crystalline solid in 90% yield. Although spectroscopic 
methods indicated that we had prepared pure morphine-6-glucuronide, the elemental 
analysis showed C, H, and N percentages only about half the expected values. This 
could only be due to the presence of barium salts since the elemental analysis of the 
coupled glucuronate 49 was correct.
As a result of these problems, alternative deprotection methods were sought. One 
such reported ester hydrolysis method uses a boiling aqueous suspension of Dowex 
acidic ion-exchange resin158. In our case this would be attractive since there should be 
no inorganic salts remaining at the end of the hydrolysis.
The morphine glucuronate ester 90 was indeed converted to morphine-6-glucuronide 
40 by boiling in water containing Dowex 50 (H). Conversion was confirmed by n.m.r. 
spectroscopy but, as before, the elemental analysis gave values much lower than 
expected.
Next, we attempted to hydrolyse all the acetyl and methyl ester protecting groups on 
our fully protected morphine glucuronate 49 using the above method with Dowex 
resin, thereby giving us deprotection in one step. This reaction proceeded much 
slower than the previous hydrolysis and t.l.c. analysis only indicated partial reaction. 
Even after 24 hours at reflux, it was still difficult to ascertain to what extent the 
deprotection had proceeded. The reaction products have similar retention indices on 
t.l.c. and are poorly resolved, however, n.m.r. (D2O solvent) and m.s. spectra of the 
recovered material indicated that the hydrolysis of the methyl ester had occurred but 
the acetate groups had largely been unaffected.
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Since esters can be hydrolysed in acidic or basic conditions, we decided to try using a 
strongly basic ion-exchange resin instead, such as Amberlite IRA-410. After boiling 
the glucuronate 49 in an aqueous suspension of this resin for 3 days, the !H n.m.r. 
spectrum of the recovered material confirmed that hydrolyses of methyl ester had taken 
place as well as cleavage of all but one of the acetate groups. The product from this 
reaction was taken up in methanol and ammonia (2M) and left to stand for 2 days, but 
on work up a pure compound could not be isolated from the reaction mixture.
The procedure was repeated for the codeine glucuronate 50. After boiling in water in 
the presence of Amberlite resin for 12 hours, t.l.c. showed conversion to a material 
with lower RF value. To the reaction mixture was added concentrated ammonia148 
(giving a 2M solution) and methanol. After standing for 2 days, work-up of the 
reaction mixture gave a residue which was taken up in 1% acetonitrile/water and 
eluted through a Water Sep-pak C-18 cartridge with similar solvent mixture as the 
mobile phase. From the eluate the desired codeine-6-glucuronide 41 was recovered 
pure in 35%, after freeze-drying.
Sodium hydroxide should give faster hydrolysis of the protecting groups, whilst giving 
sodium acetate as the co-product. The latter should be less lipophilic than ammonium 
acetate, and therefore should be easier to separate on the C-18 cartridge. This was 
realised in practice and when codeine tetra-O-acetylglucopyranoside 82 was treated 
with sodium hydroxide (5 eq) in water for 10 minutes, quenching with acetic acid and 
purification using the C-18 cartridge gave pure codeine-6-glucoside 84 in 68%.
1.11 Alternative Claims
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During our investigations, a patent application by Ultrafine was submitted in which an 
alternative synthesis for morphine-6-glucuronide was claimed. This utilises a coupling 
between methyl(trichloroacetimidyl-2,3,4-tri-(9-isobutanoylglucopyranosyl) uronate 91 
and 3-acetylmorphine 47144 (scheme 19). Note, the protecting groups are isobutanoyl 
rather than acetyl in this case. The reported route is shown:
We investigated this route very carefully, achieving a synthesis of methyl (1,2,3,4- 
tetra-O-isobutanoylglucopyranosyl) uronate 92 in 43%, but failing to react this to yield 
93 with a solution of ammonia in DCM at 0°C, as described. However, when we used 
a continuous flow of ammonia at 20°C we were able to recover methyl (2,3,4-tri-O- 
isobutanoylglucopyranosyl) uronate 93 in 60%. A procedure for synthesising 






















claimed, in which the product is obtained as colourless needles from isopropanol. 
However, when we attempted to reproduce this methodology we found that the 
expected product 91 had reacted with isopropanol to give methyl (isopropyl-2,3,4-tri- 
O-isobutanoylglucopyranosyl) uronate in 25% yield. The reaction was repeated 
without crystallising, but instead purification gave us the desired product 91 in 75% 
yield as a colourless oil, which crystallised on standing.
Reaction between 3-acetylmorphine 47 and 2 eq imidate 91 in DCM in the presence of 
2 eq boron trifluoride etherate was achieved, although t.l.c. monitoring revealed the 
presence of at least two other compounds and unreacted 3-acetylmorphine. Work up, 
as described, and chromatographic purification gave 3-acetylmorphine-6-methyl- 
(2,3,4-tri-O-isobutanoylglucopyranosyl) uronate 95 in 15% yield.
Deprotection was performed by treating 95 with 5% sodium hydroxide in methanol, 
neutralising with acetic acid to pH 5.5, as described. However, the product did not 
precipitate and we only obtained crystals of sodium salts leaving morphine-6- 
glucuronide 40 in solution with the remainder of the sodium salts.
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2 CH. ISOSTERE TARGETS





Following an extensive literature search we found several examples of carbohydrate 
CH2 isosteres, referred to as ‘pseudosugars’159. One example gives the synthesis of a 
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The pseudosugar 96 is an epoxide which may possibly be ring opened with a suitable 
morphine derivative, but, in addition, opens the door to a range of other 
pseudoglucuronate precursors such as a substituted cyclohexanol or cyclohexyl 
bromide. The coupling to a morphine derivative might give separable diastereomers or 
alternatively a non-racemic route to pseudosugar 96 could be possible if the first step 
(Diels-Alder) is performed in an enantioselective fashion.
Since the route involves several steps (scheme 20), we attempted this work in parallel 
to our pursuit of an effective coupling technique for pseudoglucuronates and opioids.
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2.1.2 Synthesis of Epoxide Precursor
The first step in the reported procedure was the Diels-Alder reaction between acrylic 
acid 97 and furan 98 to produce 7-oxabicyclo[2.2.1]hept-5-ene-2-carboxylic acid 99, 
mostly as the required endo product16'1. However, this method has a reaction time of 
more than 2 months! We therefore searched for an alternative method, perhaps 
utilising a Lewis acid catalyst and discovered that the reaction of furan with methyl 
acrylate 10(1 can be performed in just 2 days in the presence of anhydrous zinc iodide 
at 40°C, but only gwes a 1:2 endo.exo ratio for the product 7-oxabicyclo[2.2.1]hept-5- 
ene-2-methylcarboxylate 101 i61 .
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Since the exo is the thermodynamic product, we attempted this reaction at the reduced 
temperature of 4°C and, after 2 days, t.l.c. analysis indicated partial conversion. The 
reaction was continued at 20°C for a further 2 days, after which time t.l.c. indicated 
virtually complete conversion. After work-up, analysis of the n.m.r. spectrum for the 
product mixture, recovered in 35% yield, indicated a 2:1 endoiexo ratio. No 
separation of these epimers was attempted at this stage since the saponification and 
lactonisation steps are performed in basic conditions in which further epimerization 
may occur.
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Despite the expected ease with which the hydrolysis and lactonisation steps should be 










However, none of the starting material was converted. The only change was that slow 
epimerisation of the starting ester 101 occurred giving a higher ratio of the exo 
compound.
Saponification of 101 has been reported to occur using aqueous sodium hydroxide in 
509?-. Also noted in this report was a lack of complete conversion and small recovery 
(<1 %) of endo ester. Instead, we first tried lithium hydroxide in a mixture of methanol 
and water as reagent and achieved a 91% yield of the carboxylic acid 99, but still as a 
mixture of epimers.
Bromolactonisation of 99 to the lactone 102 was achieved using bromine in aqueous 
sodium hydrogen carbonate, as reported, but in 55% compared with the literature yield 
of 91%. However, this result may be expected when considering the presence of 33% 
exo carboxylic acid in the starting material, since only the endo acid is lactonised. This 
was born out by analysis of the reaction mixture by t.l.c., which showed a high level of 
starting material remaining on the baseline. The reaction was repeated with sodium 
hydroxide in place of the sodium hydrogen carbonate in the hope that the proton
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located a  to the carboxyl group would be labile under these conditions and an 












However, no improvement was obtained with a recovery of 48%.
Worse still, our attempt to reproduce the reported conversion of the bromolactone 102 
to the dibromocyclohexane 103 gave only an 8.4% yield against the literature claim of 
64%.
Further problems beset us in the esterification of the acid 103 to the ester 104. Our 
yield was 66% against the literature claim of 96%. As a result the synthesis was put on 
hold until we could establish if the nucleophilic ring opening of the epoxide would 
succeed.
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2.1.3 Investigation of Coupling Methodology
i) Attempted Couplings From Epoxide Opening
We were required to find a model reaction to simulate this process and, considering 
our epoxide target above, our first attempts were made using cyclohexene oxide 105 
since epoxides may show reactivity towards alcohols.
The reported procedures make use of the nucleophilic hydroxyl group to attack at one 
of the centres of the activated epoxide. Activation of the epoxide has been claimed 
with both magnesium perchlorate163 and organotin phosphate condensates (OPC)164‘166. 
Despite the reported high ratio (10:1) of alcohol to epoxide starting materials, it was 
important that we achieve a higher yield based on the morphine derivative, and 
therefore we only used a 1:1 ratio of the starting materials. Attempting to link 3- 
acetylmorphine 47 to the epoxide 105 in the presence of 1 eq magnesium perchlorate, 
however, only had the effect of deacetylating 47 to morphine.
Methodology using OPC has been heavily reported164*166. The catalyst was prepared as 
described from dibutyltin oxide and di-"butylphosphate167 and was subsequently used in 









ether 60-80° for 4 days. T.l.c. analysis showed that no conversion had occurred, 
however, and the starting materials were still present. It is known, however, that 
epoxide openings of this type are often reversible with attack from the alkoxide to 
reform the epoxide, a step which is entropy favoured.
The reaction was repeated until, after 4 days, 1 eq 'BDMS chloride was added to trap 
any alkoxide which may be formed in an equilibrium process. After this the reaction 
was continued for a further 8 hours. However, this had no effect on the outcome and 
we observed no reaction.
In case some process was occurring which prevented rejuvenation of the catalyst, the 
above attempt was repeated with 1.3 eq OPC present, but again this did not bring 
about a reaction.
Rather than activating the epoxide, we turned our strategy to activating the silyl 
morphine 57 by forming the sodium salt using sodium hydride in THF. The mixture 
was stirred for 2 hours but t.l.c. analysis showed no conversion, so the mixture was 
boiled for 6 hours. This time morphine was recovered in ~80% showing that O- 





ii) Attempted Ether Couplings of Opioids With Cvclohexanol and Cyclohexvl 
Bromide
Rather than pursuing other reported methods for opening epoxides with alcohols, we 
turned our efforts to other reactive electrophile possibilities (scheme 22).
The first of these was carried out using cyclohexanol 59, converted in situ to the highly 
reactive triflate168 which was reacted with silyl morphine 57. T.l.c. analysis showed 
that a complicated mixture formed immediately but after 20 minutes, a single spot was 
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The reaction was repeated for codeine 17 using 3 eq pyridine to remove unwanted 
triflic acid. However, t.l.c. analysis indicated no reaction and only codeine was 
recovered.
Also tried was the reaction between codeine and cyclohexyl bromide 106 in toluene in 
the presence of silver carbonate on celite which had given us previous success in 
bromide displacements. T.l.c. analysis indicated the presence of several compounds 
but also one main compound consistent with codeinone.
An attempt was also made to couple 106 and the sodium salt of codeine 17 formed by 
the action of sodium hydride in THF. However, no reaction could be seen by t.l.c. 
either after stirring at 20°C for 12 hours or by boiling for 5 hours.
As a consequence of these disappointing results, we abandoned this line of research to 
pursue another goal, as shown below.
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3. C-Glucuronide Target 105
Our target here was to form a C-C link between morphine and glucuronic acid. Ideas 
for the coupling step were limited since relatively little work has been performed in the 
area of C-glycosides. Of great interest to us was tin radical chemistry169, and in 
particular, a method which may give us such a linkage with a (3 orientation on the 
glucuronide unit and a  orientation on the morphine unit. An example of the 













Our concern for this type of reaction is the specificity of radical coupling in the opioid 
moiety with respect to the aUylic system, since rapid equilibrium following radical
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generation is highly probable. Specificity for either the 6- or the 8- position is likely, 
however, with the steric bulk from the morphine structure. Prior to synthesis of a 
glucuronate precursor it was necessary to obtain an effective method and our initial 
precursor requirement was to obtain a-bromocodide (6p-bromocodide) 107.
Also of interest to us was a claim for codeine alkylations using an appropriate alkyl 
lithium cyanocuprate170 and 6-mesyl-codeine or 6-mesyl-isocodeine.
Since time was against us, these ideas can only be described for future work and our 
only achievement was to confirm a useful procedure for the synthesis of a- 
bromocodide (6p-bromocodide) 107. The only sited literature method is that of 
Schryver and Lees in 1901 using phosphorus tribromide171, in which the correct 
structure could not be deduced due to the lack of available data at that time. Since we 
have already synthesised a-chlorocodide in high yield using phophorus pentachloride, 
our first attempt was made using phosphorus pentabromide in a similar way. 
Unfortunately, however, we could only achieve the formation of a mixture of 














MeO Br MeO Br
X / < ^ NM e + V<7^NMe
Br’ Br
Scheme 23.
The orientation of the phenolic bromide could not be deduced although a 1-bromo
compound has been produced previously by Gates and Shepard170.
Instead, we followed the reported method using phosphorus tribromide to give a- 
bromocodide 107 and p-bromocodide (8 p-bromocodide) 108 as a 1:1 mixture which is 
difficult to separate by chromatography. Partial separation was achieved giving a- 
bromocodide 107 in 11% yield and p-bromocodide 108 in 3% yield.
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C. EXPERIMENTAL
All solvents were dry and distilled before use. ‘Petroleum ether’ refers to petroleum 
ether boiling in the range 60-80°C.
Hash chromatography was performed using Amicon Matrex 60A silica gel under 
medium pressure using a small hand bellow.
Thin layer chromatography (t.l.c.) was performed using aluminium backed 250|im 
silica gel plates containing fluorescent indicator. Visualisation was achieved by 
illumination under short wavelength (254nm) u.v. light when possible. Plates were 
developed by treatment with a 0.5% (w/v) aqueous solution of potassium 
permanganate, followed by wanning of the plate.
Melting points (m.p.) were determined on Electrothermal Mk III apparatus and are 
uncorrected.
Elemental micro-analyses were earned out using a Carlo-Erba 1106 Elemental 
Analyser.
Optical rotations were measured using a Perkin-Elmer 141 polarimeter with 
concentration (c) expressed in g/100 cm3.
Infrared spectra were recorded in the range 4000-600 cm"1 using a Perkin-Elmer 1310 
spectrophotometer and peaks are reported in wavenumbers (cm"1). Samples were 
prepared as chloroform solutions unless otherwise stated.
and 13C nuclear magnetic resonance (n.m.r.) spectra were recorded on a Jeol 
GX270 (270MHz) spectrometer. For 13C, operating frequency was 67.8 MHz, using
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90 and 135 DEPT pulse sequences to aid multiplicity determinations. Samples were 
prepared in solutions of CDCI3 unless otherwise stated.
8 values are expressed as parts per million (p.p.m.) downfield from tetramethylsilane 
internal standard.
Mass spectra were recorded on a VG 7070E mass spectrometer.
8C assignments for opioid carbons were based on other literature findings173.
For opioid glycosides, assignments for carbohydrate nuclei are in bold type.
1. Synthesis of methyl glucopvranosyl uronate 55
D-glucurono-6,3,lactone (8.0g, 44mmol) was added portion wise to a stirred solution 
of sodium hydroxide (40mg, 1.0 mmol) in methanol (80ml). On complete dissolution, 
the yellow solution was stirred for 12 hours. T.l.c. analysis indicated complete 
conversion and the solution was concentrated and dried in vacuo to an orange syrupy 
solid (9.05g, 96%).
Rf: 0.8 (mobile phase = 50% methanol/chloroform); 
m/z (C.I.) 209 (M++H), 191 (M+-OH).
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2. Synthesis of methyl L2.3.4-tetra-0-acetylglucopyranosyl uronate 56
A solution of methyl glucopyranosyl uronate 55 (9.0g, 43mmol) in pyridine (50ml) was 
stirred at -10°C and acetic anhydride (6.0ml, 64mmol) was carefully added. The 
solution was stirred at 20°C for 24 hours after which, t.l.c. analysis indicated complete 
conversion. The mixture was poured onto ice-water and extracted into chloroform 
(4x). The combined extracts were washed with 1M hydrochloric acid (100ml), dried 
over sodium sulfate, and concentrated in vacuo to a black oil which was crystallised 
from isopropanol at 4°C. This and two further crystallisations from the mother liquor 
afforded a colourless crystalline solid (12.5g, 77%).
Rf : 0.8 (mobile phase = 30% methanol/chloroform);
5h 5.77 (1 H, d, J  7.7, C'-H), 5.33 (1 H, t, J  9.0, C'-H), 5.24 (1 H, t, J  9.0, C-H), 
5.15 (1 H, t, 77.9, C'-H), 4.20 (1 H, d, J  9.3, C5-H), 3.75 (3 H, s, ester CH3), 2.12 (3 
H, s, OAc), 2.04 (9 H, 2s, 3xOAc),
m/2 (C.I.) 317 (M+-OAc)
3. Synthesis of methyl (bromo-2.3.4-tri-(9-acetylglucopyranosyl) uronate 48
A solution of methyl 1,2,3,4-tetra-O-acetylglucopyranosyl uronate 56 (400mg, 
1.06mmol) in 30% hydrogen bromide in acetic acid (4ml) was made up (some time and
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shaking required for dissolution) and stored at 4°C for 20 hours. T.l.c. analysis 
indicated complete conversion. The solution was concentrated in vacuo and diluted 
with chloroform (10ml), washed with ice-water which was subsequently extracted with 
chloroform, and the combined chloroform extracts were dried over sodium sulfate, 
concentrated in vacuo and crystallised from absolute ethanol (2ml) at 4°C gave 
colourless prisms which were collected by filtration and washed with petroleum ether 
(350mg, 83%).
Rf: 0.35 (mobile phase = chloroform);
8h 6.65 (1 H, d, J  4.0, C'-H), 5.62 (1 H, t, J  9.7, C^H), 5.24 (1 H, dd, J4,s 10.3, / 4>3 
9.5, C-H), 4.85 (1 H, dd, h 3 9.9, 72,i 4.0, C'-H), 4.58 (1 H, d, J  10.4, C’-H), 3.77 (3 
H, s, ester CH3), 2.06-2.11 (9 H, 3s, 3xOAc).
4. Synthesis of methyl 2.3.4-tri-(9-acetylglucopyranosyl uronate 58
A solution of methyl (bromo-2,3,4-tri-0-acetylglucopyranosyl) uronate 48 (5.8g, 
15mmol), silver carbonate (2.0g, 1.4 eq) and water (0.12ml, 1.0 eq) in dry acetone 
(15ml) was made up and stirred for 12 hours. T.l.c. analysis (mobile phase = 
chloroform) indicated complete conversion. The solution was filtered washing 4 times 
with acetone, and the combined filtrate and washings were concentrated and dried in 
vacuo to a colourless syrupy solid (4.3g, 88%).
Rf: 0.3 (mobile phase = 40% ethyl acetate/petroleum ether);
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6h 5.59 (1 H, t, J  9.7, C3-H), 5.55 (1 H, t, /iai.oh 3.0, C‘-H), 5.19 (1 H, t, J  10.1, C4- 
H), 4.91 (1 H, dd, h ,3 10.0, h ,\ 3.0, C2-H), 4.59 (1 H, d, J  10.1, C’-H), 3.82 (1 H, 
d(brd), J  3.0, OH), 3.75 (3 H, s, ester CH3), 2.04-2.09 (9 H, 3s, 3xOAc).
5. Synthesis of 3-'hutvldimethvlsilvlmorphine 57
Morphine (1.42g, 5.0mmol) was dissolved in a solution of sodium (130mg, 1.1 eq) in 
absolute ethanol (40ml). The solvent was evaporated in vacuo with trace amounts 
removed by forming an azeotrope with chloroform (4x), leaving the rapidly formed 
sodium morphinate. This was dissolved in THF (40ml) followed by slow addition of 
rbutyldimethylsilyl chloride (l.lg , 7.3mmol) and the solution was stirred for 12 hours. 
T.l.c. analysis (mobile phase = 10% methanol/chloroform) indicated complete 
conversion. The solution was concentrated in vacuo, dissolved in chloroform, washed 
with water, dried over sodium sulfate, concentrated in vacuo, and crystallised from 
ethyl acetate (1.88g, 94%).
Rf : 0.4 (mobile phase = 10% methanol/chloroform);
5h 6.61 (1 H, d, J  8.1, C?-H), 6.51 (1 H, d, J  8.3, C‘-H), 5.71 (1 H, d-m, h ,s 9.9, C7- 
H), 5.26 (1 H, dm, / 8,7 9.9, C®-H), 4.89 (1 H, dd, J5,6 6.6, J5,7 1.1, Cs-H), 4.19 (1 H, 
s(brd), C6-H), 3.54 (1 H, s(brd), C9-H), 3.05 (1 H, d, Jp;a 19.0, Cl0-Hp), 2.96 (1 H, 
s(brd), OH), 2.81 (1 H, dd(brd), Jtm 13.0, J i6,l5 Clfj-H«,), 2.59 (3 H, s, N-CH3), 2.5- 
2.7 (2 H, m, C14-H, C16-H»), 2.48 (1 H, dd, 7gem 19.0, J i 0 ,9  6.0, C10-Ha), 2.29 (1 H, td,
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Jgem; i5(i6 13.0, / i 5,i6 4.5, C15-H„), 1.90 (1 H, dd, Jgaa 13.0, J !5,i6 3.0, C15- ^ ) ,  0.99 (9 
H, s, fBuSi), 0.20 (3 H, s, CH3Si), 0.16 (3 H, s, CH3Si);
m/z (El; 70 eV) 399 (M+), 342 (M+- rBu).
6. Attempted synthesis of 3-fbutyldimethylsilylmorphine-6-(methvl 
glucopvranosyl uronatel
A solution (A) of 3-rbutyldimethylsilylmorphine 57 (400mg, l.Ommol) in THF (10ml) 
was made up with sonification. Meanwhile, a solution of triphenylphosphine (520mg, 
2 eq) and methyl glucopyranosyl uronate 55 (310mg, 1.5 eq) in THF (10ml) was made 
up and diethylazodicarboxylate (DEAD) (0.3ml, 1.7 eq) was added dropwise. The 
solution was stirred for 15 minutes before solution (A) was added dropwise and the 
reaction mixture was stirred for 48 hours. T.l.c. analysis (mobile phase = 10% 
methanol/chloroform) indicated no conversion with both starting materials (57, RF = 
0.35; 55, Rf = 0.5) remaining present although a new compound was indicated (RF = 
0.8). The mixture was evaporated to dryness in vacuo and flash chromatographed 
(mobile phase = 0- 10% gradient methanol/chloroform) to afford the new compound as 
a brown oil (380mg). Compound was shown to be a complex of DEAD and 
triphenylphosphine.
5h 7.6 (15 H, m, PPh3), 6.67 (1 H, s(brd), NH), 4.19 (4 H, q, J  7.2, C 02Et), 1.26 (6 H, 
t ,/7 .2 ,  C 02Et);
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7. Attempted synthesis of 3-fbutyldimethylsilylmorphine-6-rmethyl (2.3.4-tri-O- 
acetylglucopyranosyl) uronatel using the Mitsunobu technique
i) A solution of 3-'butyldimethylsilylmorphine 57 (400mg, l.Ommol), methyl 2,3,4-tri- 
(9-acetylglucopyranosyl uronate 58 (500mg, 1.5 eq) and triphenylphosphine (520mg, 2 
eq) in THF (10ml) was made up and DEAD (0.3ml, 1.7 eq) was added dropwise at 
20°C. The solution was stirred for 2 hours before t.l.c. analysis (mobile phase = 10% 
methanol/chloroform) indicated the presence of starting material 57 and at least 6 other 
compounds.
ii) A solution (A) of 3-'butyldimethylsilylmorphine 57 (200mg, 0.5mmol) in THF (5ml) 
was made up with sonification. Meanwhile, a solution of triphenylphosphine (260mg, 
2 eq) and mercuric bromide (310mg, 1.7 eq) in THF (3ml) was made up and DEAD 
(0.5ml, 5 eq) was added dropwise. The solution was stirred for 10 minutes before a 
solution of methyl 2,3,4-tri-O-acetylglucopyranosyl uronate 58 (250mg, 1.5 eq) in 
THF (3ml) was added dropwise and stirred was continued for a further 15 minutes. 
Solution (A) was added dropwise and the reaction mixture was stirred for 2 hours. 
T.l.c. analysis (mobile phase = 10% methanol/chloroform) indicated no conversion 
with both starting materials (58, Rf = 0.8) remaining present.
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8. Attempted synthesis of methyl cyclohexyl-2.3.4-tri-0-acetylglucopyranosyl 
uronate
i) A solution (A) of cyclohexanol 59 (95mg, 0.95mmol) in THF (18ml) was made up. 
Meanwhile, a solution of triphenylphosphine (350mg, 1.6 eq) and methyl 2,3,4-tri-<9- 
acetylglucopyranosyl uronate 58 (334mg, 1.05 eq) in THF (10ml) was made up and 
DEAD (0.18ml, 1.25 eq) was added dropwise. The solution was stirred for 15 
minutes before solution (A) was added dropwise. T.l.c. analysis (mobile phase = 40% 
ethyl acetate/petroleum ether) indicated no conversion with both starting materials (59, 
Rf = 0.9; 58, Rf = 0.5) remaining present.
ii) A solution (A) of cyclohexanol 59 (85mg, 0.85mmol) in THF (16ml) was made up. 
Meanwhile, a solution of triphenylphosphine (320mg, 1.6 eq), mercuric bromide 
(380mg, 1.25 eq) and methyl 2,3,4-tri-O-acetylglucopyranosyl uronate 58 (300mg,
1.05 eq) in THF (9ml) was made up and DEAD (0.16ml, 1.25 eq) was added 
dropwise. The solution was stirred for 15 minutes before solution (A) was added 
dropwise. T.l.c. analysis (mobile phase = 40% ethyl acetate/petroleum ether) indicated 
no conversion with both starting materials (59, Rf = 0.9; 58, Rf = 0.5) remaining 
present.
iii) A solution (A) of cyclohexanol 59 (llOmg, 1.1 mmol) in THF (10ml) was made up. 
Meanwhile, a solution of methyl 2,3,4-tri-O-acetylglucopyranosyl uronate 58 (334mg,
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1.05 eq) in THF (10ml) was made up and tributylphosphine (0.37ml, 1.6 eq) was 
added. The solution was cooled to -78°C and DEAD (0.18ml, 1.25 eq) was added 
dropwise. The solution was stirred for 10 minutes at 0°C before cooling again to - 
78°C and solution (A) was added dropwise. The solution was allowed slowly to warm 
to -5°C when a red colouration was noted. Reaction was continued at -5°C for 3 
hours after which time t.l.c. analysis (mobile phase = 40% ethyl acetate/petroleum 
ether) indicated the presence of starting material 58 and a new compound which was 
shown to be the hydrazine reduction product of DEAD.
5h 6.70 (2 H, s(brd), 2xNH), 4.20 (4 H, q, J 1 2 , C 02Et), 1.28 (6 H, t, /7 .2 , C 02Et);
iv) A solution (A) of cyclohexanol 59 (llOmg, l.lmmol) in THF (10ml) was made up. 
Meanwhile, a solution of methyl 2,3,4-tri-(9-acetylglucopyranosyl uronate 58 (334mg,
1.05 eq) and mercuric bromide (420mg, 1.25 eq) in THF (10ml) was made up and 
tributylphosphine (0.37ml, 1.6 eq) was added. The solution was cooled to -78°C and 
DEAD (0.18ml, 1.25 eq) was added dropwise. The solution was stirred for 10 
minutes at 0°C before cooling again to -78°C and solution (A) was added dropwise. 
The solution was allowed slowly to warm to 20°C; no red colouration was noted. 
Reaction was continued at 20°C for 3 hours after which time t.l.c. analysis (mobile 
phase = 40% ethyl acetate/petroleum ether) indicated the presence of starting materials 
58, 59 and DEAD.
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v) A solution (A) of cyclohexanol 59 (llOmg, l.lmmol) in acetonitrile (10ml) was 
made up. Meanwhile, a solution of methyl 2,3,4-tri-O-acetylglucopyranosyl uronate 
58 (334mg, 1.05 eq) in acetonitrile (10ml) was made up and tributylphosphine (0.37ml,
1.6 eq) was added. The solution was cooled to -78°C and DEAD (0.18ml, 1.25 eq) 
was added dropwise. The solution was stirred for 10 minutes at 0°C when a red 
colouration was noted, before cooling to -78°C and solution (A) was added dropwise. 
The solution was allowed slowly to warm to 20°C and stirred for 3 hours after which 
time t.l.c. analysis (mobile phase = 40% ethyl acetate/petroleum ether) indicated the 
presence of starting material 58 and a new compound which was consistent with the 
hydrazine reduction product of DEAD.
5h consistent with iii).
9. Attempted synthesis of 3-fbutyldimethylsilylmorphine-6-rmethvl f2.3.4-tri-0- 
acetylglucopyranosyD uronatel
i) A solution of methyl 1,2,3,4-tetra-O-acetylglucopyranosyl uronate 56 (376mg, 
lmmol) and 3-rbutyldimethylsilylmorphine 57 (420mg, 1.05 eq) in chloroform (0.5ml) 
was made up and cooled to 0°C. Boron trifluoride etherate (170mg, 0.15ml, 1.2 eq) 
was added dropwise and the solution was stirred at 20°C for 18 hours. T.l.c. analysis 
(mobile phase = 10% methanol/chloroform) indicated no conversion with both starting 
materials (56, RF = 0.9) remaining present.
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ii) A solution of methyl 1,2,3,4-tetra-O-acetylglucopyranosyl uronate 56 (376mg, 
lmmol) and 3-rbutyldimethylsilylmorphine 57 (420mg, 1.05 eq) in chloroform (0.5ml) 
was made up and cooled to 0°C. Boron trifluoride etherate (380mg, 0.33ml, 2.7 eq) 
was added dropwise and the solution was stirred at 20°C for 18 hours. T.l.c. analysis 
(mobile phase = 25% methanol/chloroform) indicated conversion to a new compound 
(Rf = 0.35). Water (5ml) was added and the new compound was extracted into 
chloroform (5ml). Separation and evaporation in vacuo gave the product as an off- 
white solid (210mg). Compound was consistent with morphine.
10. Attempted synthesis of methyl (ethyl-l-phenylpropenoateV2.3.4-tri-0- 
acetvlglucopyranosyl uronate 63
A solution of methyl 2,3,4-tri-O-acetylglucopyranosyl uronate 58 (334mg, l.Ommol) 
and sodium hydride (26mg, 1.1 eq) in THF (10ml) was made up and stirred for 30 
minutes. Ethyl phenyl propiolate (0.2ml, 1.2 eq) was added dropwise and the reaction 
mixture was maintained at 50°C. T.l.c. analysis (mobile phase = 20% 
methanol/chloroform) indicated no conversion with both starting materials remaining 
present.
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11. Attempted synthesis of methyl pyrimidyl-2.3.4-tri-(9-acetylglucopyranosyl 
uronate 64
A solution of methyl 2,3,4-tri-(9-acetylglucopyranosyl uronate 58 (334mg, l.Ommol) 
and sodium hydride (26mg, 1.1 eq) in THF (10ml) was made up and stirred for 30 
minutes. A solution of 2-chloropyrimidine (140mg, 1.2 eq) in THF (5ml) was added 
dropwise and the reaction mixture was maintained at 50°C. T.l.c. analysis (mobile 
phase = 20% methanol/chloroform) indicated no conversion with both starting 
materials (58, Rf = 0.9) remaining present.
12. Attempted synthesis of methyl (2-pyridinecarboxylateV2.3.4-tri-Q- 
acetylglucopvranosyl uronate 65
A solution of methyl 2,3,4-tri-O-acetylglucopyranosyl uronate 58 (668mg, 2.0mmol) 
and triethylamine (0.3ml, 2.2 eq) in DCM (10ml) was made up and a solution of 
picolinoyl chloride (prepared as described131) (312mg, 1.1 eq) in DCM (10ml) was 
added. After stirring at 50°C for 24 hours, t.l.c. analysis (mobile phase = 20% 
methanol/chloroform) indicated no conversion with both starting materials remaining 
present.
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13. Synthesis of methyl 2.3.4-tri-0-acetyl-6-triphenylmethylglucopyranoside
A solution of methyl a-D-glucopyranoside 68 (lO.Og, 52mmol) and triphenylmethyl 
chloride (14g, 1.0 eq) in pyridine (80ml) was stirred until complete dissolution (24 
hours) was achieved. Acetic anhydride (40ml, 420mmol) was added and the solution 
was stirred for a further 5 hours. The solution was poured onto ice-water (200ml) and 
the resulting colourless precipitate was collected by filtration, washed with water and 
recrystallised from ethanol (19.lg, 65%).
m.p. 130-134°C;
Sh 7.42 (6 H, m, CPh3), 7.42 (9 H, m, CPh3), 5.42 (1 H, t, J  10.0, C-H), 5.06 (1 H, t, 
J  10.0, C3-H), 5.01 (1 H, d, J  3.8, C‘-H), 4.92 (1 H, dd, J13 10.0, h ,\ 3.8, C-H ), 3.90 
(1 H, ddd, ./5.4 10.0, J5,6 5.0, J5.6 2.5, C-H), 3.46 (3 H, s, OMe), 3.18 (1 H, dd, 7gt»
10.5, J6,5 2.5, C-H), 3.10 (1 H, dd, 7gem 10.5, / 6,5 5.0, C-H ), 2.08 (3 H, s, OAc), 1.98 
(3 H, s, OAc), 1.72 (3 H, s, OAc).
14. Synthesis of methyl 2.3.4-tri-O-benzvl-6-triphenylmethylglucopyranoside
A solution of methyl 2,3,4-tri-(9-acetyl-6-triphenylmethylglucopyranoside (8.7g, 
15mmol) and sodium (35mg, 0.1 eq) in methanol (100ml) was made up and stirred for 
5 hours. T.l.c. analysis (mobile phase = ethyl acetate) indicated complete conversion 
so the solution was concentrated in vacuo to an oil. DME (100ml) was added,
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followed by sodium hydride (2.7g, 6.5 eq) portionwise with stirring. Benzyl bromide 
(15ml, 9 eq) was added and the solution was boiled for 8 hours. T.l.c. analysis (mobile 
phase = 10% ethyl acetate/petroleum ether) indicated complete conversion, plus benzyl 
by-product. The solution was quenched with methanol with stirring for 15 minutes, 
and concentrated in vacuo to a brown oil. Benzyl by-products were removed by 
distillation (100°C, 1.5mbar) to afford a brown syrup (5.5g, 52%).
Rf 0.2 (mobile phase = 10% ethyl acetate/petroleum).
15. Synthesis of methyl 2.3.4-tri-O-benzvlglucopyranoside
A solution of methyl 2,3,4-tri-(9-benzyl-6-triphenylmethylglucopyranoside (5.5g, 
7.4mmol) in glacial acetic acid (40ml) was cooled to 5°C and 45% hydrobromic acid in 
acetic acid (1.33ml, 1.0 eq) was added. The solution was stirred for 30 seconds and 
filtered. The filtrate was quenched with water (100ml) and extracted into chloroform 
which was neutralised with saturated sodium hydrogen carbonate, dried over sodium 
sulfate, and concentrated in vacuo to a brown oil which was flash chromatographed 
(mobile phase = 20-60% gradient ethyl acetate/petroleum ether) to afford a colourless 
oil (1.5g, 44%).
Rf 0.1 (mobile phase = 40% ethyl acetate/petroleum).
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16. Synthesis of methyl (met.hyl-2.3.4-tri-0-benzylglucopyranosyll uronate 70
A solution of methyl 2,3,4-tri-(9-benzylglucopyranoside (1.5g, 3.2mmol) in acetone 
(24ml) was cooled to 5°C and a solution of chromium trioxide (0.87g, 8.7mmol) in 
3.5M sulfuric acid (4ml) was added with stirring. After 10 minutes, the solution was 
stirred at 20°C for exactly 60 minutes, filtered (washing with acetone until washings 
were colourless) and the combined filtrate and washings were quenched with crushed 
ice. The organic solvent was evaporated in vacuo and the resulting aqueous solution 
was extracted with chloroform which was washed with water, dried over sodium 
sulfate, and concentrated in vacuo, to a yellow oil. This was dissolved in methanol and 
loaded onto a column of Amberlite IRA-400(OH) ion-exchange resin (4.6ml) and 
eluted with acetic acid/methanol/water (45:45:10), concentrating to afford a yellow oil 
(1.7g). This was treated with excess diazomethane in ether for 10 minutes and 
quenched with acetic acid. Evaporation of the solvents in vacuo gave a yellow oil 
>95% pure (1.6g, 100%!). The oil was flash chromatographed (mobile phase = 10- 
17% gradient ethyl acetate/petroleum ether) to afford an oil (0.7g, 44%).
Rf: 0.6 (mobile phase = 40% ethyl acetate/petroleum ether);
m^ax 2900 (s, arom C-H), 1750 (s, ester C=0);
8 h 7.20-7.37 (15 H, m, 3x Bn), 4.91 (1 H, d, Jgem 10.8, Ph-CH2), 4.83 (1 H, d, / gcra 
10.8, Ph-CH2), 4.82 (1 H, d, / gem 12.1, Ph-CH2), 4.79 (1 H, d, / gem 10.8, Ph-CH2), 
4.64 (1 H, d, / g™ 12.1, Ph-CH2), 4.59 (1 H, d, J  3.0, C‘-H), 4.57 (1 H, d, 10.5, 
Ph-CHj), 4.19 (1 H, d, /  9.9, C5-H), 3.98 (1 H, t, J  9.3, C3-H), 3.72 (1 H, dd, Jv  9.0,
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A ,5 9.9, C4-H), 3.71 (3 H, s, ester CH3), 3.57 (1 H, dd, J2,3 9.5, J2.i 3.5, C^-H), 3.40 (3
H, s, ether OCH3);
(Found: C, 71.1; H, 6.60. C29H32O7 requires C, 70.7; H, 6.55).
17. Attempted synthesis of methyl 2.3.4-tri-O-benzylglucopyranosyl uronate 69
i) A solution of methyl (methyl-2,3,4-tri-(9-benzylglucopyranosyl) uronate 70 (600mg,
I .2mmol) in glacial acetic acid (6ml) and acetic anhydride (1.1ml) was made up and 
stirred at 20°C. After 16 hours, t.l.c. analysis (mobile phase = 40% ethyl 
acetate/petroleum ether) indicated no reaction. The reaction was boiled for 8 hours, 
but t.l.c. analysis again showed no conversion. The mixture was concentrated in vacuo 
and n.m.r. confirmed the presence only of starting material.
ii) A solution of methyl (methyl-2,3,4-tri-O-benzylglucopyranosyl) uronate 70 (600mg, 
1.2mmol) in glacial acetic acid (6ml) and acetic anhydride (1.1ml) was made up and 
stirred at 5°C and concentrated sulfuric acid (0.07ml, 1.1 eq) in glacial acetic acid 
(lml) was added dropwise. The reaction was warmed and maintained at 40°C for 24 
hours. T.l.c. analysis (mobile phase = 40% ethyl acetate/petroleum ether) indicated no 
reaction. The temperature was raised to 60°C and after 12 hours the solution became 
dark while t.l.c. analysis indicated complete conversion to material running at the 
baseline. The reaction mixture was neutralised with saturated sodium hydrogen
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carbonate, extracted into DCM (2x50ml), washed with water, dried over anhydrous 
sodium sulfate and concentrated in vacuo to a crude oil. A solution of this oil and 
sodium (6mg, 0.2 eq) in methanol (12.5ml) was stirred for 10 hours. T.l.c. analysis 
(mobile phase = 20% ethyl acetate/petroleum ether) indicated the presence of at least 6 
compounds.
iii) A solution of methyl (methyl-2,3,4-tri-0-benzylglucopyranosyl) uronate 70 
(500mg, l.Ommol) in iodotrimethylsilane (0.5ml, 3.5 eq) was made up and stirred at 
20°C. After 16 hours, the solution was quenched with water and extracted into 
chloroform. However, t.l.c. analysis (mobile phase = 2% acetone/DCM) indicated 
complete conversion to material which was not eluted from the baseline, compared 
with a standard of target compound which ran with Rf = 0.3.
iv) A solution of methyl (methyl-2,3,4-tri-O-benzylglucopyranosyl) uronate 70 
(500mg, l.Ommol) in iodotrimethylsilane (0.16ml, 1.1 eq) was made up and stirred at 
20°C. After 16 hours, the solution was quenched with water and extracted into 
chloroform. T.l.c. analysis (mobile phase = 2% acetone/DCM) indicated complete 
conversion to material which was not eluted from the baseline (see above).
v) A solution of methyl (methyl-2,3,4-tri-O-benzylglucopyranosyl) uronate 70 (lOOmg, 
0.2mmol) in boron tribromide (0.3ml, 1.5 eq) was made up and stirred at 16°C. After
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1 hour, t.l.c. analysis (mobile phase = 10% ethyl acetate/petroleum ether) indicated 
complete conversion to material with Rf = 0.3. The reaction was quenched with 
saturated sodium hydrogen carbonate (5ml) and the product was extracted into ether 
(5ml). T.l.c. analysis (mobile phase = 40% ethyl acetate/petroleum ether) now showed 
only a new product which was not eluted from the baseline, compared with a standard 
of target compound which was eluted with RF = 0.4.
18. Attempted synthesis of methyl 1.2.3.4-tetra-O-benzylglucopyranosyl uronate
i) A solution of methyl glucopyranosyl uronate 55 (7.0g, 33.7mmol) in DME (100ml) 
was made up with stirring, and added to which were benzyl bromide (5.0g, 3.5ml, 8 
eq) and sodium hydride (6.0g, 8 eq). The solution was boiled for 3 days but t.l.c. 
analysis (mobile phase = ethyl acetate) indicated no conversion. Tetrabutylammonium 
iodide (2.5g, 0.2 eq) was added and the reaction was continued for 24 hours, but t.l.c. 
analysis again showed no conversion.
ii) A solution of methyl glucopyranosyl uronate 55 (5.9g, 27mmol) in DMF (80ml) was 
made up with stirring, and added to which were benzyl bromide (0.75ml, 1.1 eq) and 
sodium hydride (0.62g, 1.1 eq). The solution was heated to 100°C for 10 hours after 
which, t.l.c. analysis (mobile phase = ethyl acetate) indicated no conversion. Further
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portions (1.1 eq) of sodium hydride and benzyl bromide were added and the reaction 
was continued for 12 hours. Again, t.l.c. analysis suggested no conversion.
iii) A solution of methyl glucopyranosyl uronate 55 (1.2g, 5.5mmol) and benzyl 
trichloroacetimidate (7.3g, 6 eq) in DCM (10ml) was made up, and boron trifluoride 
etherate (470mg, 0.4ml, 0.6 eq) was added dropwise. The solution was stirred for 16 
hours after which time, a yellow precipitate had formed. The reaction was quenched 
with saturated sodium hydrogen carbonate and extracted into ethyl acetate (precipitate 
dissolved when ethyl acetate was added). T.l.c. analysis (mobile phase = ethyl acetate) 
indicated no conversion.
19. Synthesis of methyl rbutyldimethylsilyl-2.3.4-tri-6>-acetylglucopyranosyl
uronate 74
A solution of methyl 2,3,4-tri-(9-acetylglucopyranosyl uronate 58 (6.26g, 18.7mmol), 
imidazole (3.75g, 3 eq), and 'butyldimethylsilyl chloride (3.1g, 1.1 eq) in THF (100ml) 
was made up and stirred at 20°C. After 1 hour, t.l.c. analysis (mobile phase = 40% 
ethyl acetate/petroleum ether) indicated partial conversion with complete conversion 
after 2 days. 1M hydrochloric acid (200ml) was added and the product was extracted 
into ethyl acetate (4x100ml), dried over anhydrous sodium sulfate, and evaporated to 
dryness in vacuo to afford a colourless crystalline solid (7.8g, 92%).
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Rf 0.8 (mobile phase = 40% ethyl acetate/petroleum ether);
5h 5.26 (1 H, t, J lt2;lA 6.9, C'-H), 5.24 (1 H, t, / 3>4;3,2 6.9, C3-H), 4.97 (1 H, dq, J4,2
9.5, J4,5;4,3;4.i 7.0, C4-H), 4.79 (1 H, d, J5,4 7.5, C5-H), 4.03 (1 H, dt, J2,4 9.7, J2,w  6.9, 
C2-H), 3.75 (3 H, s, C 02Me), 2.03 (3 H, s, OAc), 2.02 (6 H, s, OAc), 0.87 (9 H, s, 
?Bu), 0.14 (3 H, s, SiMe), 0.11 (3 H, s, SiMe);
5C 170.2 (Ac), 169.3 (Ac), 169.0 (Ac), 167.1 (C02Me), 95.8 (1), 73.0 (5), 72.5 (3), 
72.1 (2), 69.5 (4), 52.8 (C02Me), 25.4 (CMe3), 20.6 (Me), 20.5 (Me), 17.8 (C(CH3)3);
m/z (FAB) 447 (M+-H), 391 (M+- rBu);
(Found: C, 50.9; H, 7.24. Ci9H32O10Si requires C, 50.9; H, 7.20%).
20. Synthesis of methyl 'butyldimethylsilvlglucopyranosyl uronate 75
i) Methyl 'butyldimethylsilyl-2,3,4-tri-0-acetylglucopyranosyl uronate 74 (224mg, 
0.5mmol) was dissolved in a solution of sodium methoxide in methanol, 0.5mg/ml, 
(4ml) and left to stand for 3 days. T.l.c. analysis (mobile phase = ethyl acetate) 
indicated partial (-50%) conversion with no further conversion after another 24 hours. 
The mixture was stood in a sonic bath for 2 days but this gave no further conversion. 
The solution was evaporated to dryness in vacuo to an oil which was flash 
chromatographed (mobile phase = 30-80% gradient ethyl acetate/petroleum ether) to
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afford a colourless crystalline solid (53mg, 33%) plus starting material (4mg, 2%) and 
inseparable impurities (21 mg). N.m.r revealed product as a 1:1 p:a anomeric mixture.
Rf 0.65 (mobile phase = ethyl acetate);
8h 5.26 (0.5 H, d, J  3.5, C‘-H(J (a-anomer», 4.80 (0.5 H, s(brd), OH), 4.55 (0.5 H, d, 
J  7.3, C‘-Ha (p-anomer)), 4.40 (0.5 H, s(brd), OH), 4.23 (0.5 H, d, J  9.0, C5-H (1 
anomer)), 3.80 (1.5 H, s, C02Me (1 anomer)), 3.79 (1.5 H, s, CC^Me (1 anomer)), 
3.5-3.88 (4 H, m, C3-H, C-H , C2-H (a-anomer), C5-H (1 anomer), OH), 3.38 (0.5 H, 
dd, J  9.0, J  7.5, C2-H (p-anomer)), 2.95 (0.5 H, s(brd), OH), 2.70 (0.5 H, s(brd), OH), 
0.92, 0.90 (9 H, 2s, 'Bu (2 anomers)), 0.15,0.13 (6 H, 2s, SiMe2);
m/z (FAB) 323 (M++H), 265 (M+-'Bu);
(Found: C, 47.4; H, 8.17. Ci3H260 7Si requires C, 48.4; H, 8.13%).
ii) A solution of methyl lbutyldimethylsilyl-2,3,4-tri-0-acetylglucopyranosyl uronate 74
(224mg, 0.5mmol) in methanol (5ml) was carefully added to a solution of potassium 
carbonate (700mg, 10 eq) in water (5ml) giving a colourless suspension. After 5 
minutes with vigorous stirring, t.l.c. analysis (mobile phase = 40% ethyl 
acetate/petroleum ether) indicated complete conversion to material which was not 
eluted from the baseline. Acetic acid was added very slowly to excess and the solution 
was partitioned between water and ether. The ether layer was collected while the 
aqueous layer was further extracted with DCM. T.l.c. analysis of all 3 layers revealed 
starting material in the ether layer, very little in the DCM layer and material which ran
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at the baseline remaining in the aqueous layer. The ether layer was evaporated to 
dryness in vacuo to afford starting material as a colourless crystalline solid (220mg, 
98%).
iii) A solution of methyl fbutyldimethylsilyl-2,3,4-tri-0-acetylglucopyranosyl uronate 
74 (224mg, 0.5mmol) in methanol (9ml) was carefully added to a solution of 
potassium carbonate (700mg, 10 eq) in water (1ml) giving a colourless suspension. 
After 1 hour with vigorous stirring, t.l.c. analysis (mobile phase = 40% ethyl 
acetate/petroleum ether) indicated complete conversion to material which was not 
eluted from the baseline. Acetic acid was added very slowly to excess and the solution 
was partitioned between water and ether. T.l.c. analysis of both layers revealed only 
material which was not eluted from the baseline, present in the aqueous layer only. 
This could not be extracted into DCM either.
iv) A solution of methyl rbutyldimethylsilyl-2,3,4-tri-0-acetylglucopyranosyl uronate 
74 (3.5g, 7.8mmol) and triethylamine (4g, 5.6ml, 5 eq) in methanol (100ml) was made 
up and stirred at 20°C. After 2 hours, t.l.c. analysis (mobile phase = ethyl acetate) 
indicated initial conversion to an intermediate with higher Rf than the desired product, 
plus a small amount of desired product. After 2 days, t.l.c. analysis revealed the 
product spot to be much more prominent with very little starting material remaining, 
and the conversion had not increased after a further 24 hours. The solution was 
evaporated to dryness in vacuo to an oil which was flash chromatographed (mobile
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phase = 50-64% gradient ethyl acetate/petroleum ether) to afford desired product as an 
off-white solid (1.7g, 68%), starting material as a colourless crystalline solid (830mg, 
24%) and a mixture of by-products (637mg). The new product was shown by n.m.r. 
to be -90% pure. Recrystallisation from hot isopropyl ether gave colourless prisms 
(834mg, 33%).
Data consistent with i).
v) A solution of methyl fbutyldimethylsilyl-2,3,4-tri-0-acetylglucopyranosyl uronate 74 
(255mg, 0.57mmol) and 2N ammonia (2.0ml, 7 eq) in methanol (6ml) was made up 
and left to stand for 7 days. T.l.c. analysis (mobile phase = ethyl acetate) after 4 days 
indicated partial conversion to the desired product, plus a large amount of by-product 
with much lower Rf value, but after 7 days there was little starting material remaining. 
The solution was evaporated to dryness in vacuo to an oil which was taken up in water 
and extracted into ether, dried over sodium sulfate, and evaporated again to an oil. 
Crystallisation from hot isopropyl ether gave colourless prisms (45mg, 25%).
Data consistent with i).
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21. Attempted synthesis of methyl 'butyldimethylsilyl-2.3.4-tri-Q- 
benzvlglucopyranosyl uronate
i) A solution of methyl 'butyldimethylsilylglucopyranosyl uronate 75 (322mg, l.Ommol) 
and benzyl trichloroacetimidate (880mg, 4 eq) in DCM (5ml) was made up and boron 
trifluoride etherate (0.05ml, 57mg, 0.4 eq) was added dropwise with stirring. After 1 
hour, t.l.c. analysis (mobile phase = 40% ethyl acetate/petroleum ether) showed 
conversion to at least 5 new compounds with no change after 17 hours. A further 
portion of 0.4 eq boron trifluoride etherate was added and the reaction was continued. 
After 2 hours, t.l.c. analysis showed even more spots than before and the reaction was 
abandoned.
ii) A solution of methyl 'butyldimethylsilylglucopyranosyl uronate 75 (161mg, 
0.5mmol), benzyl bromide (300mg, 0.2ml, 3.5 eq) and sodium hydride (45mg, 3.5 eq) 
in DME (10ml) was made up and boiled for 24 hours. T.l.c. analysis (mobile phase = 
40% ethyl acetate/petroleum ether) showed no conversion. A further portion of 4 eq 
sodium hydride was added and the reaction was continued. After 8 hours, t.l.c. 
analysis showed strong u.v. active spots eluted close to the solvent front consistent 
with expected benzyl by-products. A further portion of 2 eq benzyl bromide was also 
added and the reaction was continued for another 12 hours. T.l.c. analysis showed no 
change from previous.
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iii) A solution of methyl 'butyldimethylsilylglucopyranosyl uronate 75 (72mg, 
0.22mmol), benzyl bromide (382mg, 0.27ml, 10 eq) and sodium hydride (55mg, 10 eq) 
in DMF (3ml) was made up and stirred at 120°C for 24 hours. T.l.c. analysis (mobile 
phase = 40% ethyl acetate/petroleum ether) showed no conversion.
iv) A solution of methyl rbutyldimethylsilylglucopyranosyl uronate 75 (146, 0.45mmol), 
benzyl bromide (345mg, 0.24ml, 4.5 eq) and silver oxide (470mg, 4.5 eq) in DMF 
(10ml) was made up and stirred at 20°C for 4 days. T.l.c. analysis (mobile phase = 
10% ethyl acetate/petroleum ether) showed no conversion. The solution was heated at 
100°C and stirred for 12 hours. Again, t.l.c. analysis indicated no reaction. Further 
portions (10 eq) silver oxide and benzyl bromide were added and the temperature was 
raised to at 130°C. After 24 hours, t.l.c. analysis showed strong u.v. active spots 
eluted close to the solvent front consistent with expected benzyl by-products.
v) A solution of sodium hydride (60mg, 4.5 eq) in DMSO (1ml) was added dropwise 
to a solution of methyl 'butyldimethylsilylglucopyranosyl uronate 75 (187mg, 
0.58mmol) in DMSO (1ml) and stirred for 1 hour. Benzyl chloride (664mg, 0.60ml, 9 
eq) was added dropwise and the mixture was stirred at 20°C for 12 hours. T.l.c. 
analysis (mobile phase = 40% ethyl acetate/petroleum ether) showed no conversion. 
The temperature was raised to 120°C for 8 hours, but t.l.c. analysis showed no change.
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22. Synthesis of allvl glucopvranoside 73
A suspension of a-D-glucose (80g, 0.44mol) in ally! alcohol (170g, 200ml) was stirred 
while dry hydrogen chloride gas was bubbled through until the mass had increased by 
5g, 0.3 eq. The solution was stirred at 70°C for 7 hours when full dissolution was 
attained. After cooling, neutralisation with barium carbonate and filtration, the solvent 
was evaporated in vacuo leaving a brown syrup (120g) which was extracted with hot 
acetone (15x300ml) and concentrated in vacuo to a syrup. T.l.c. analysis (mobile 
phase = 33% toluene/acetone) showed starting material to still be present. An attempt 
at purifying by flash chromatography failed with all the material being recovered 
immediately. Recovery of syrup was 26g, 25% assuming 95% purity.
Rf 0.1 (mobile phase = 33% toluene/acetone).
23. Synthesis of allvl 6-triphenylmethylglucopvranoside
A solution of allyl glucopyranoside 75 (14.0g, 64mmol) and triphenylmethyl chloride 
(18g, 1.0 eq) in pyridine (120ml) was stirred, monitoring by t.l.c. analysis (mobile 
phase = 33% toluene/acetone). After 20 hours, t.l.c. analysis indicated almost 
complete conversion. The pyridine was evaporated in vacuo leaving an oil which was 
dissolved in ethyl acetate, washed with water, dried over sodium sulfate, concentrated
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in vacuo and flash chromatographed (mobile phase = 30% ethyl acetate/petroleum 
ether) to afford a colourless solid (14g, 48%).
RF 0.15 (mobile phase = 40% ethyl acetate/petroleum).
24. Synthesis of allvl 2.3.4-tri-0-benzyl-6-triphenylmethylglucopyranoside
A solution of allyl 6-triphenylmethylglucopyranoside (7.0g, 15mmol) in DME (100ml) 
was made up and sodium hydride (1.4g, 3.3 eq) was added portionwise with stirring. 
Benzyl bromide (6ml, 3.6 eq) was added and the solution was boiled for 5 hours. 
T.l.c. analysis (mobile phase = 10% ethyl acetate/petroleum ether) indicated complete 
conversion. The solution was filtered, and concentrated in vacuo to a brown oil. 
Flash chromatography gave a yellow syrup (8.9g, 80%).
Rf 0.25 (mobile phase = 10% ethyl acetate/petroleum).
25. Synthesis of allyl 2.3.4-tri-O-benzylglucopyranoside
A solution of allyl 2,3,4-tri-(9-benzyl-6-triphenylmethylglucopyranoside (8.9g, 
12mmol) and 1M hydrochloric acid (6ml, 6mmol) in acetone (54ml) was boiled for 2 
hours. T.l.c. analysis (mobile phase = 20% ethyl acetate/petroleum ether) indicated 
complete conversion. The acetone was evaporated in vacuo and the resulting oil was
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dissolved in sec-butanol, filtered and concentrated in vacuo to a brown oil which was 
flash chromatographed (mobile phase = 20% ethyl acetate/petroleum ether) to afford 
an oil (4.1g, 69%). lH n.m.r. indicates a 1:1 mixture of anomers.
Rf 0.25, 0.30 (mobile phase = 20% ethyl acetate/petroleum);
5h 7.35 (15 H, m, 3xOBn), 6.01 (1 H, m, OCH2CH=CH2), 5.30 (2 H, m, 
OCH2CH=CH2), 4.5-5.1 (8 H, m, 3xCH2OPh, OCH2CH=CH2), 3.5-4.3 (7 H, m, 
c i,2.3,4,5_Hj 2xC6-H), 1.80 (1 H, s(brd), OH).
26. Synthesis of methyl (allyl-2.3.4-tri-0-benzylglucopyranosyD uronate
A solution of allyl 2,3,4-tri-O-benzylglucopyranoside (4.1g, 8.4mmol) in acetone 
(40ml) was cooled to -10°C and a solution of chromium trioxide (2.2g, 15mmol) in 
3.5M sulfuric acid (9ml) was added with stirring. The solution was stirred at 20°C for 
exactly 3 hours before pouring onto crushed ice and extracting into DCM. This was 
dried over sodium sulfate, and concentrated in vacuo, to a yellow oil which was 
treated with excess diazomethane in ether for 10 minutes and quenched with acetic 
acid. Evaporation of the solvents in vacuo gave a yellow oil which was flash 
chromatographed (mobile phase = 10-17% gradient ethyl acetate/petroleum ether) to 
afford a clear oil (2.4g, 55%).
Rf 0.45 (mobile phase = 10% ethyl acetate/petroleum).
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27. Synthesis of methyl 2.3.4-tri-O-benzylglucopyranosyl uronate 69
A solution of methyl (allyl-2,3,4-tri-(9-benzylglucopyranosyl) uronate (2.4g, 4.6mmol), 
hydrated sodium acetate (1.61g, 16mmol) and palladium chloride (970mg, 1.2 eq) in 
acetic acid (10ml) was stirred for 3 days, after which, t.l.c. analysis (mobile phase = 
2% acetone/DCM) indicated complete conversion with a by-product. The solution 
was filtered, concentrated in vacuo, and flash chromatographed to afford a yellow 
crystalline solid (1.4g, 63%). lH n.m.r. indicates a 3:1 a : (3 mixture of anomers.
Rf 0.45 a , 0.65 (3 (mobile phase = 2% acetone/DCM);
m.p. 106-110°C, (lit. 110-112°C);
8h 7.3 (15 H, m, 3x Bn), 5.22 (0.75 H, d, J  3.5, C!-Hp (a  anomer)), 4.45-5.0 (7 H, m, 
3xPh-CH2, C5-H), 3.7-4.1 (2 H, m, C3-H, C4-H), 3.73 (0.25x3 H, s, ester CH3 ((3 
anomer)), 3.71 (0.75x3 H, s, ester CH3 (a  anomer)), 3.61 (0.75 H, dd, J2,3 9.0, J2ti 3.5, 
C2-H (a  anomer), 3.46 (0.25 H, dd, / 2>3 9.5, J2,i 8.5, C2-H ((3 anomer)).
28. Synthesis of methyl trichloroacetimidyl-2.3.4-tri-(9-benzylglucopyranosyl 
uronate 66
A solution of methyl 2,3,4-tri-(9-benzylglucopyranosyl uronate 69 (1.15g, 2.4mmol), 
trichloroacetonitrile (2.4ml, 10 eq) and sodium hydride (67mg, 0.7 eq) in DCM (25ml)
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was stirred for 15 minutes. T.l.c. analysis (mobile phase = 30% ethyl
acetate/petroleum ether) indicated almost complete conversion. The mixture was 
concentrated in vacuo, and flash chromatographed to afford a colourless oil which 
crystallised overnight (1.05g, 70%) and starting material (170mg, 15%). n.m.r. 
indicates presence only of a  anomer.
Rf 0.35 (mobile phase =10% ethyl acetate/petroleum);
8h 8.65 (1 H, s, NH), 7.25 (15 H, m, 3x Bn), 6.50 (1 H, d, J  3.5, C‘-H), 4.96 (1 H, d, 
/  11.0, OCH2Ph), 4.84 (1 H, d, J  11.0, OCH2Ph), 4.82 (1 H, d, J  10.5, OCH2Ph), 4.75 
(1 H, d, J  11.0, OCH2Ph), 4.70 (1 H, d, J  11.0, OCH2Ph), 4.59 (1 H, d, /  11.0, 
OCH2Ph), 4.42 (1 H, d, J  10.0, C5-H), 4.06 (1 H, t, J  9.5, C3-H), 3.70 (3 H, s, 
C 02Me), 3.7-3.9 (2 H, m, C2-H, C4-H).
29. Attempted synthesis of codeine-6-methvl 2.3.4-tri-O-benzylglucopyranosyl 
uronate
A solution of codeine (197mg, 0.66mmol) and methyl trichloroacetimidyl-2,3,4-tri-<9- 
benzylglucopyranosyl uronate 66 (490mg, 1.2 eq) in DCM (10ml) was made up and 
boron trifluoride etherate (0.1ml, 0.88mmol) was added dropwise with stirring. After 
3 hours, t.l.c. analysis (mobile phase = 10% methanol/chloroform) indicated no 
reaction of codeine although starting glycoside 66 was converted to methyl 2,3,4-tri- 
O-benzylglucopyranosyl uronate 69.
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30. Attempted synthesis of 3-fbutyldimethylsilylmorphine-6-methyl 2.3.4-tri-O- 
benzvlglucopyranosyl uronate
A solution of 3-rbuty ldimethylsilylmorphine 57 (lOOmg, 0.25mmol) and methyl 
trichloroacetimidyl-2,3,4-tri-(7-benzylglucopyranosyl uronate 66 (187mg, 1.2 eq) in 
DCM (1.8ml) was made up and boron trifluoride etherate (0.006ml, 0.2 eq) was added 
dropwise at -23°C with stirring. After 2 hours, t.l.c. analysis (mobile phase = 10% 
methanol/chloroform) indicated no reaction. A further portion of boron trifluoride 
etherate (0.03ml, 1.0 eq) was added and the reaction was continued for 1.5 hours. 
T.l.c. analysis indicated no reaction of 3-rbutyldimethylsilylmorphine although starting 
glycoside 66 was converted to methyl 2,3,4-tri-O-benzylglucopyranosyl uronate 69.
31. Synthesis of methyl cyclohexvl 2.3.4-tri-O-benzylglucopyranosvl uronate 76
A solution of cyclohexanol (25mg, 0.25mmol) and methyl trichloroacetimidyl-2,3,4-tri- 
(9-benzylglucopyranosyl uronate 66 (187mg, 1.2 eq) in DCM (1.8ml) was made up and 
boron trifluoride etherate (0.006ml, 0.2 eq) was added dropwise at -23°C with stirring. 
After 2 hours, t.l.c. analysis (mobile phase = 10% ethyl acetate/petroleum ether) 
showed the reaction to have formed a complex mixture. The solution was quenched 
with sodium hydrogen carbonate and extracted into DCM, dried over sodium sulfate, 
and evaporated to dryness in vacuo to an oil which was flash chromatographed (mobile 
phase =10%  ethyl acetate/petroleum ether). This gave product (22mg, 16%) which 
was further purified by t.l.c.* (16mg, 12%), and the glycoside by-product (88mg, 
61%).
118
Product was a mixture of anomers a : (3 69:31;
^elemental analysis suggests 8% silica impurity from preparative t.l.c. purification.
Rf 0.45 (mobile phase =10% ethyl acetate/petroleum);
8h 7.36-7.20 (15 H, m, 3x Ph), 5.00-4.55 (6.7 H, m, 3x CH2Ph + C'-Hp (a  anomer)), 
4.33 (0.31 H, d, J  9.9Hz, C'-Ha (p anomer)), 3.45-4.05 (4 H, m, C'-H, C3-H, C4-H, 
C5-H), 3.72 (3 H, 2s, CO2CH3 (2 anomers)), 1.20-2.00 (11 H, m, 1-0-cyclohexyl).
m/z (FAB) 561 (M++H) 560 (M+), 559 (M*-H);
(Found: C, 67.3; H, 6.61. C34H40O7 requires C, 72.8; H, 7.20. With 8% silica impurity, 
requires C, 67.3; H, 6.65).
32. Attempted synthesis of codeine-6-methvl 2.3.4-tri-O-benzylglucopyranosyl 
uronate
A solution of codeine (165mg, 0.55mmol) in THF (5ml) was stirred at 0°C and sodium 
hydride (14mg, 1.05 eq) was carefully added and the solution was stirred for 1 hour. 
A solution of dibenzo-18-crown-6 (lOmg) in benzene (20ml) was added and the 
solution was cooled to -15°C. A solution of methyl trichloroacetimidyl-2,3,4-tri-(9- 
benzylglucopyranosyl uronate 66 (380mg, 1.1 eq) in benzene (10ml) was added 
dropwise followed by addition of boron trifluoride etherate (0.086ml, 1.2 eq) with 
stirring. After 3 hours, t.l.c. analysis (mobile phase = 10% methanol/chloroform) 
indicated no reaction of codeine or glycoside.
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33. Synthesis of 6|3-chlorocodide 77
A solution of phosphorus pentachloride (2.25g, 10.8mmol) in chloroform (10ml) was 
made up at 0°C and codeine (2.0g, 6.7mmol) was added in portions. The solution was 
stirred at 20°C for 2 hours before ether (10ml) was added. The solvent (ether + 
chloroform) was decanted off and the golden residue was treated with saturated 
sodium carbonate giving a violet colour. The solution was gently heated until the 
colour disappeared and left to cool, allowing formation of brown crystals which were 
filtered off, washed with water and dried in vacuo (1.77g, 83%). Further purification 
by flash chromatography gave a light brown solid (1.59g, 75%).
Rf 0.7 (mobile phase = 10% methanol/chloroform);
[a ]“ -341° (lit. -383°);
8h 6.64 (1 H, d, J  8.2, C2-!!), 6.55 (1 H, d, J  8.2, C'-H), 5.95 (1 H, ddd, h ,8 9.5, Jlfi 
6.0, h , i4 3.0, C7-H), 5.64 (1 H, dd, h .i 9.5, JSM 2.0, C*-H), 5.23 (1 H, s, C5-H), 4.66 
(1 H, d, J6.7 6.0, C6-H), 3.84 (3 H, s, OMe), 3.31 (1 H, dd, 79,10a 6.0, J% 14 3.5, C9-H),
3.06 (1 H, d, 15.8, CI0-HP), 2.60 (1 H, dd, Jtem 12.0, / 16,15 5.0, C16-He,), 2.41 (3 
H, s, NMe), 2.3-2.5 (3 H, m, C14-H, C16-H«, C10-H«), 1.89 (1 H, d(brd), Jtm 12.0,
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34. Attempted synthesis of codeine-6-cyclohexylether
A solution of 6-p-chlorocodide 77 (318mg, l.Ommol) in THF (5ml) was added 
dropwise to a solution of cyclohexanol (120mg, 1.2 eq) and sodium hydride (30mg, 
1.2 eq) in THF (5ml) at 0°C and the solution was stirred at 20°C. After 2 hours, t.l.c. 
analysis (mobile phase = 10% methanol/chloroform) indicated no reaction.
35. Synthesis of methyl-2.3.4.6-tetra-0-benzylglucopyranoside
A solution of methyl a-D-glucopyranoside 68 (5.0g, 26mmol) and powdered 
potassium hydroxide (25g, 446mmol) in dioxane (15ml) was gently boiled while benzyl 
chloride (14.8g, 13.2ml, 4.4 eq) was added dropwise over 5 minutes and the solution 
was boiled for a further 1 hour. The solvent was removed in vacuo and the residue 
was taken up in water, extracted into ether, dried over sodium sulfate, and 
concentrated again in vacuo to an oil. Purification of the product by flash 
chromatography (mobile phase = 10% ethyl acetate/petroleum ether) gave a colourless 
solid (11.7g, 82%).
Rf 0.15 (mobile phase = 10% ethyl acetate/petroleum ether); 
m.p. 154°C (lit. 151-152°C);
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5h 7.2 (20 H, m, OBn), 5.00 (1 H, d, J  11.0, OBn), 4.4-4.9 (8 H, m, 7 H: OBn, + C1- 
H), 4.00 (1 H, t, J  9.5, C3-H), 3.5-3.8 (4 H, m, C4-H, C5-H, 2x C6-H), 3.57 (1 H, dd, 
72,3 9.0, J 2J 3.5, C2-H), 3.39 (3 H, s, OMe);
(Found: C, 74.6; H, 6.91. C35H-,806 requires C, 75.8; H, 6.91).
36. Synthesis of 2.3.4.6-tetra-O-benzylglucopyranoside
A solution of methyl-2,3,4,6-tetra-O-benzylglucopyranoside (11.7g, 21mmol) in glacial 
acetic acid (150ml) at 100°C was diluted with boiling 2N hydrochloric acid (54ml, 5.0 
eq). The solution was boiled for 2 hours before addition of a further portion of boiling 
2N hydrochloric acid (5 eq) and further boiling for 24 hours. The mixture was poured 
into 1 litre of water at left for 2 days. The resulting crystals were collected by filtration 
and recrystallised from isopropanol as a colourless solid (4.7g, 45%).
Rf 0.1 (mobile phase = 40% ethyl acetate/petroleum ether).
37. Synthesis of l-0-(2-ethylcarboxylate-l-phenvlethenyl)-2.3.4.6-tetra-0- 
benzvlglucopyranoside 60
2,3,4,6-tetra-O-benzylglucopyranoside (1.08g, 2.0mmol) was added to a stirred 
suspension of sodium hydride (55mg, 1.1 eq) in THF (10ml) and stirring was
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continued for 30 minutes. A solution of ethyl phenyl propiolate, (420mg, 0.4ml, 1.2 
eq) in THF (5ml) was added and the solution was stirred at 50°C for 3 hours before 
quenching with methanol, concentrated in vacuo and flash chromatographed (mobile 
phase =15% ethyl acetate/petroleum ether) giving the product as a brown oil (730mg, 
51%). Mixture of 2 geometric alkenic isomers and 2 anomers.
T.l.c.: 4 spots. Rf 0.6, 0.65, 0.7, 0.75 (mobile phase = 30% ethyl acetate/petroleum 
ether)
38. Synthesis of l-(9-(2-pyrimidyl)-2.3.4.6-tetra-0-benzylglucose 61
2,3,4,6-tetra-O-benzylglucopyranoside (1.08g, 2.0mmol) was added to a stirred 
suspension of sodium hydride (55mg, 1.1 eq) in THF (10ml) and stirring was 
continued for 30 minutes. A solution of 2-chloropyrimidine, (275mg, 1.2 eq) in THF 
(5ml) was added and the solution was stirred at 50°C for 3 hours before quenching 
with methanol, concentrated in vacuo and flash chromatographed (mobile phase = 
30% ethyl acetate/petroleum ether) giving the product as a yellow oil (700mg, 57%). 
Shown to be a 2:1 p:a mixture of anomers.
T.l.c.: 2 spots. Rf 0.6, 0.65 (mobile phase = 40% ethyl acetate/petroleum ether)
5h 8.50 (2 H, m, pyrim N-CH), 7.2 (20 H, m, OBn), 6.95 (1 H, m, pyrim C-CH), 6.67 
(1 H, d, J  3.5, C'-H (a  anomer)), 6.02 (1 H, d, J 7.5, C‘-H (p anomer)), 4.2-5.05 (9 
H, m, 4x OBn + C5-H), 3.6-3.9 (5 H, m, C2-H, C3-H, C4-H, 2x C6-H).
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39. Attempted synthesis of codeine-6-(23.4,6-tetra-(9-benzylg]ucopyranoside) 78
A solution of ]-0-(2-ethylcarboxylate-l-phenylethenyl)-2,3,4,6-tetra-0- 
benzylglucopyranoside 60 (355mg, 0.5mmol) and codeine (165mg, 0.55mmol) in 
acetonitrile (5ml) was made up and stirred at -40°C. Trimetliylsilyltriflate (122mg, 
0.1ml, 0.55mmol) was added dropwise and stirring was continued at -40°C. T.l.c. 
analysis (mobile phase = 10% methanol/chloroform) indicated no reaction. The 
solution was allowed slowly to warm to 20°C, monitoring by t.l.c. No change was 
observed.
40. Synthesis of codeine-6-(2.3.4.6-tetra-(9-benzylglucopyranoside) 78
A solution of 1 -0-(2-pyrimidyl)-2,3,4,6-tetra-(9-benzylglucopyranoside 61 (309mg, 
0.5mmol) and codeine (165mg, 0.55mmol) in acetonitrile (5ml) was made up and 
stirred at -40°C. Trimetliylsilyltriflate (122mg, 0.1ml, 0.55mmol) was added dropwise 
and stirring was continued at -40°C. T.l.c. analysis (mobile phase = 10% 
methanol/chloroform) indicated virtually complete conversion after 3 hours. The 
solution was quenched with saturated sodium hydrogen carbonate, extracted into 
chloroform, and flash chromatographed (mobile phase = 5% methanol/chloroform) to 
afford a sticky colourless solid (140mg, 35%). Shown to be 1:1 oc:(3 mixture of 
anomers.
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Rf 0.7 (mobile phase = 10% methanol/chloroform);
8h 7.18-7.53 (20 H, m, 4x Ph), 6.65 (1 H, 2d, J  8.0, C2-H (2 anomers)), 6.56 (0.5 H, 
d, J  8.0, C‘-H (1 anomer)), 6.52 (0.5 H, d, J  8.0, C‘-H (1 anomer)), 5.92 (0.5 H, d, /  
9.9, C7-H (1 anomer)), 5.83 (0.5 H, d, J  9.9, C7-H (1 anomer)), 5.30-5.40 (1.5 H, m + 
d, J  11.5, Cs-H, OBn (1 anomer)), 4.40-5.05 (11 H, m, 7.5 H: CH2Ph + C5-H, C ‘-H, 
C3-H (1 anomer), C5-H), 4.10 (0.5 H, t, J  9.2, C3-H (1 anomer)), 4.00 (1 H, m, C^-H), 
3.84 (1.5 H, s, OCH3 (1 anomer)), 3.69 (1.5 H, s, OCH3 (1 anomer)), 3.55-3.81 (4 H, 
C2-H, , C -H , 2x C6-H), 3.41 (1 H, m, C’-H), 3.10 (1 H, 2d overlap, J  19, CL0-HP), 
2.74 (0.5 H, m, C16-H»,), 2.67 (0.5 H, m, Cl6-H01), 2.48 (3 H, 2s, NCH3), 2.30-2.65 (3
H, m, Cl4-H, Cl6-H„, C'°-Ha), 2.00-2.20 (l H, 2s(brd), Cls-H„ (2 anomers)), 1.78-
2.00 (l H, 2m, Cl5-H„,);
8c 138.6 (4), 138.0 (3), 131.6 (7), 130.4 (12), 128.4 (8), 128.2 (Ph), 127.8 (Ph), 127.6 
(Ph), 127.4 (Ph), 126.9, 126.6 (11, anomers), 118.7 (2), 114.8, 113.5 (1, anomers), 
102.1, 98.7 (1, anomers), 91.3, 88.9 (5, anomers), 84.3, 81.7, 80.2, 77.6, 75.7, 74.8,
73.0 (5,3,2,4, anomers), 75.5 (CH2Ph), 74.4 (CH2Ph), 73.3 (2 CH2Ph), 70.4 (6), 68.8
(6), 58.8 (OCH3), 58.7 (9), 46.3 (16), 42.8 (NCH3), 40.9, 40.7 (14, anomers), 35.5
(15), 20.5(10);
m/z (FAB) 822 (M++H), 821 (M+), 820 (M+-H), 730 (M+-CH 2Ph);
(Found C, 74.5%; H, 6.65%; N, 1.72%. C52H55O8N requires C, 75.9%; H, 6.75%; N,
I.70%).
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41. Attempted synthesis of 3-fbutyldimethylsilylmorphine-6-(2.3.4.6-tetra-0-
benzvlglucopyranoside)
A solution of l-0~(2-pyrimidyl)-2,3,4,6-tetra-0-benzylglucopyranoside 61 (660mg, 
1.07mmoi) and S-'butyldimethylsilylmorphine 57 (480mg, 1.2mmol) in acetonitrile 
(15ml) was made up and stirred at -40°C. Trimethylsilyltriflate (288mg, 0.25ml, 
].3mmol) was added dropwise and stirring was continued at -40°C. T.l.c. analysis 
(mobile phase = 10c/c methanol/chloroform) indicated virtually complete conversion 
after 3 hours. The solution was quenched with saturated sodium hydrogen carbonate, 
extracted into chloroform, and flash chromatographed (mobile phase = 5% 
methanol/chloroform) to afford a yellow oil which was shown to be morphine (310mg,
0 0  c/ r ) .
42. Attempted synthesis of codeine-6-(2.3.4.6-tetra-(9-acetylglucopyranoside)
A solution of codeine (300mg, l.Ommol) in benzene (15ml) was added to a boiling 
solution of silver carbonate (1.2g, 4.4 eq) and calcium sulfate (0.6g, 4.4 eq) in benzene 
(45ml). A solution of bromo-2,3,4,6-tetra-(9-acetylglucopyranoside (1.2g, 3 eq) in 
benzene (45ml) was added dropwise to the boiling solution over 3 hours and the 
mixture was boiled using a Dean and Stark condenser. T.l.c. analysis (mobile phase = 
10c7r methanol/chloroform) indicated no reaction of codeine. The solvent was 
gradually removed by distilling off until ~10ml remained. The remaining solvent was
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removed in vacuo and the residue was flash chromatographed (mobile phase = 1.5-3% 
gradient methanol/chloroform) returning codeine (170mg, 57%).
43. Attempted synthesis of codeine-6-glucoside
A solution of o-nitrophenyl glucopyranoside (75mg, 0.25mmol) and codeine (600mg, 8 
eq) in phosphate buffer pH 5, 0.1M (0.8ml) was made up. The solution was shown to 
be at pH 8-9, so more dihydrogen phosphate plus a few drops of dilute hydrochloric 
acid were added until pH 5 was attained, p-glucosidase from almonds (250 units, 
65mg) was added and the solution was maintained at 25°C for 24 hours. T.l.c. 
analysis (mobile phase = 10% methanol/chloroform) indicated the presence of codeine 
and glucoside starting materials, plus a new compound (Rf = 0.3 c.f. codeine = 0.45). 
Evaporation in vacuo was followed by flash chromatography (mobile phase = 1.5-3% 
gradient methanol/chloroform) to afford the new product (lOOmg). Trituration with 
methanol gave a colourless crystalline solid (40mg). This was shown by n.m.r. to be a 
codeine-N salt, confirmed by basifying a small sample - t.l.c. analysis consistent with 
codeine.
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44. Attempted synthesis of codeine-6-(2.3.4.6-tetra-0-acetylglucopyranosidel 82
A solution of codeine (150mg, 0.5mmol), bromo-2,3,4,6-tetra-<9-
acetylglucopyranoside (411mg, 2.0 eq) and silver carbonate on celite 50% (l.lg , 8 eq) 
in DCM (5ml) was made up and boiled in darkness. After 3 days, t.l.c. analysis 
(mobile phase = 10% methanol/chloroform) indicated no reaction of codeine or 
glucoside starting materials.
45. Synthesis of codeine-6-(7.3A6-tetra-Q-acetylglucopyranosidel 82
i) A solution of codeine (150mg, 0.5mmol), bromo-2,3,4,6-tetra-0-
acetylglucopyranoside (411mg, 2.0 eq) and silver carbonate on celite 50% (l.lg , 8 eq) 
in toluene (5ml) was made up and boiled in darkness. After 5 hours, t.l.c. analysis 
(mobile phase = 10% methanol/chloroform) indicated complete conversion to 2 new 
compounds (Rf values: 0.6 and 0.7(main spot) c.f. codeine = 0.45). The mixture was 
cooled, filtered (washing with chloroform), and the filtrate was concentrated in vacuo 
and flash chromatographed (mobile phase = 1.5-3% gradient methanol/chloroform) to 
afford a brown oil (lOOmg, 30%).
8h as below.
ii) A solution of codeine (150mg, 0.5mmol), bromo-2,3,4,6-tetra-0-
acetylglucopyranoside (411mg, 2.0 eq) and silver carbonate on celite 50% (230mg, 1.0
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eq) in toluene (5ml) was made up and boiled in darkness. A further portion of silver 
carbonate on celite (1 eq) was added every 2 hours. After 10 hours, t.l.c. analysis 
(mobile phase = 10% methanol/chloroform) indicated complete conversion to 2 new 
compounds (Rf values: 0.6 and 0.7 (main spot) c.f. codeine = 0.45). The mixture was 
cooled, filtered (washing with chloroform), and the filtrate was concentrated in vacuo 
to a dark oil. This was taken up in ether and extracted into cold 1% acetic acid, 
basified with sodium hydrogen carbonate and extracted into chloroform. The organic 
layer was separated, dried over sodium sulfate, and concentrated in vacuo to an oil 
which was flash chromatographed (mobile phase = 1.5-3% gradient
methanol/chloroform) and the product was crystallised in isopropanol to afford 
colourless needles (88mg, 28%).
m.p. 180-181°C;
Rf 0.7 (mobile phase = 10% methanol/chloroform);
A™* 3014 (s(brd), arom C-H, C=C), 1754 (s, ester C=0);
5h 6.58 (1 H, d, J  8.0, C^-H), 6.47 (1 H, d, J  8.1, C'-H), 5.64 (1 H, d-m, / 7.8 9.5, C7- 
H), 5.28 (1 H, dm, Jin 10.0, C8-H), 5.24 (1 H, t, J  9.5, C3-H), 5.08 (1 H, t, J  9.7, C4- 
H), 5.04 (1 H, t, J  8.5, C2-H), 4.88 (2 H, d+m, / w 7.5, C^H, C^-H), 4.28 (1 H, 
s(brd), C6-H), 4.25 (1 H, dd, 7gen, 12.0, J6,s 4.4, C6-H), 4.11 (1 H, dd, / gem 12.0, J6,s
2.0, C6-H), 3.73 (4 H, s+m, OCH3, C5-H), 3.30 (1 H, m, C’-H), 3.00 (1 H, d, / gem
18.7, C10-Hu), 2.59 (1 H, s(brd), C14-H), 2.54 (1 H, dd(brd), / ge» 10.0, / i 6.is 4.0, C16- 
He,), 2.39 (3 H, s, N-CH3), 2.0-2.4 (2 H, m, C15-H„, C1,s-H„), 2.25 (1 H, dd, / gem
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19.0, /io .9 6.0, C10-H„), 2.11 (3 H, s, OAc), 2.03 (3 H, s, OAc), 1.99 (3 H, s, OAc), 
1.97 (3 H, s, OAc), 1.84 (1 H, dm, / gem 13.0, C15^ ) ;
5C 170.5 (OAc), 170.0 (OAc), 169.7 (OAc), 169.3 (OAc), 147.4 (4), 142.0 (3), 130.5 
(12), 130.3 (7), 128.8 (8), 127.0 (11), 118.8 (1), 113.3 (2), 98.1 (1), 88.3 (5), 72.8
(5), 72.1 (3), 71.8 (2), 71.2 (4), 68.5 (6), 61.9 (6), 58.7 (9), 56.2 (OCH3), 46.3 (16), 
43.5 (13), 43.0 (NCH3), 41.1 (14), 36.0 (15), 20.6 (Ac), 20.5 (2Ac), 20.4 (Ac), 20.3 
( 10);
m/z (FAB) 630 (M++H);
(Found: C, 60.5; H, 6.25; N, 2.16. C32H39Oi2N requires C, 61.0; H, 6.25; N, 2.23%).
46. Synthesis of 3-fbutyldimethylsilylmorphine-6-(2.3.4.6-tetra-0- 
acetylglucopyranosidel 83
A solution of 3-rbutyldimethylsilylmorphine 57 (600mg, 1.5mmol), bromo-2,3,4,6- 
tetra-O-acetylglucopyranoside (1.23g, 2.0 eq) and silver carbonate on celite 50% 
(3.3g, 8 eq) in toluene (15ml) was made up and boiled in darkness. After 8 hours, t.l.c. 
analysis (mobile phase = 10% methanol/chloroform) indicated complete conversion to 
2 new compounds (Rf values: 0.5 and 0.6 (main spot) c.f. 57 = 0.4). The mixture was 
cooled, filtered (washing with chloroform), and the filtrate was concentrated in vacuo 
to a dark oil. This was taken up in ether and extracted into cold 1% acetic acid, 
basified with sodium hydrogen carbonate and extracted into chloroform. The organic
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layer was separated, dried over sodium sulfate, and concentrated in vacuo to an oil 
which was flash chromatographed (mobile phase = 1.5-3% gradient
methanol/chloroform) to afford a brown oil (150mg, 14%).
Sh 6.56 (1 H, d, 7 8.1, C2-H), 6.43 (1 H, d, 7 8.1, C'-H), 5.74 (1 H, d-m, / 7.8 10.0, C7- 
H), 5.29 (1 H, dt, / 8,7 10.0, / 8 ,u  2.5, C*-H), 5.23 (1 H, t, 7 9.3, C’-H), 5.12 (1 H, t, 7
9.5, C -H ), 5.02 (1 H, dd, J 2 3  9.0, J2,i 8.0, C2-H), 4.90 (1 H, d, 7U 8.0, C‘-H), 4.84 (1 
H, dd, J5fi 6.0, J5:7 1.0, C5-H), 4.25 (1 H, dd, 7gm 12.0, J6,s 5.0, C6-H), 4.23 (1 H, m, 
C6-H), 4.15 (1 H, dd, /g™ 12.0, 7W 2.5, C6-H), 3.77 (1 H, ddd, J5A 9.5, / 5>6 5.0, / 5,6
2.5, C5-H), 3.35 (1 H, dd, J9,10* 5.5, J9M 2.0, C9-H), 3.02 (1 H, d, 18.7, C‘°-Hp),
2.6 (2 H, m, C'4-H, C16-He,), 2.44 (3 H, s, N-CH3), 2.0-2.5 (2 H, m, C15-H», C16-H„), 
2.32 (1 H, dd, /gen , 18.7, 7,0,9 5.5, C10-Ha), 2.08 (3 H, s, OAc), 2.06 (3 H, s, OAc),
2.04 (3 H, s, OAc), 2.02 (3 H, s, OAc), 1.84 (1 H, d(brd), 12.0, C15-He,), 0.97 (9 
H, s, 'BuSi), 0.18 (3 H, s, CH3Si), 0.14 (3 H, s, CH3Si).
47. Synthesis of morphine-6-(2.3.4.6-tetra-(9-acetylglucopyranosidel 87
A solution of 3-rbutyldimethylsilylmorphine-6-(2,3,4,6-tetra-(9-acetylglucopyranoside) 
83 (70mg, O.lmmol) and TBAF in THF (1.1M, 0.45ml, 5 eq) in THF (1ml) was stirred 
for 15 hours after which time, t.l.c. analysis (mobile phase = 10%
methanol/chloroform) indicated complete conversion. The solution was concentrated 
in vacuo to a dark oil. This was taken up in ether and extracted into cold 1% acetic
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acid, basified with sodium hydrogen carbonate and extracted into chloroform. The 
organic layer was separated, dried over sodium sulfate, and concentrated in vacuo to 
an oil which was flash chromatographed (mobile phase = 1.5-3% gradient 
methanol/chloroform) to afford a colourless solid (12mg, 20%).
Rf 0.4 (mobile phase = 10% methanol/chloroform);
8h 6.65 ( l H , d , ;  8.2, C2-H), 6.47 (1 H, d, J  8.2, C‘-H), 5.72 (1 H, d-m, / 7.8 9.9, C7- 
H), 5.30 (1 H, dm, / 8>7 10.0, C8-H), 5.28 (1 H, t, J  9.3, C3-H), 5.10 (1 H, t, J  9.7, C4- 
H), 5.08 (1 H, dd, / 2,3 9.5, J2,. 7.5, C2-H), 4.82 (1 H, d, .h , 6  6.5, C’-H), 4.74 (1 H, d,
7i,2 7.6, C'-H), 4.25 (1 H, dd, Jim 12.5, J6,s 4.5, C‘-H), 4.20 (1 H, m, C6-H), 4.13 (1 
H, dd, ./gem 12.5, 5 2.5, C6-H), 3.77 (1 H, m, Cs-H), 3.39 (1 H, s(brd), OH), 3.27 (1
H, m, C9-H), 3.00 (1 H, d, Jgm 18.7, CKI-Hp), 2.70 (1 H, s(brd), C14-H), 2.67 (1 H, 
dm, /gem 12.0, C'^’-He,), 2.47 (3 H, s, N-CH3), 2.0-2.5 (2 H, m, C15-H„, C16-H„), 2.35 
(1 H, dd, 18.7, Jto,9 6.0, Cl0-H„), 2.18 (3 H, s, OAc), 2.07 (3 H, s, OAc), 2.04 (6 
H, s, 2x0Ac), 1.90 (1 H, d(brd),/gcnl 12.0, C15- ^ ) .
48. Synthesis of 3-acetylmorphine-6-(2.3.4.6-tetra-Q-acetylglucopyranoside) 88
A solution of 3-acetylmorphine 47 (200mg, 0.61 mmol), bromo-2,3,4,6-tetra-<9- 
acetylglucopyranoside (500mg, 2.0 eq) and silver carbonate on celite 50% (250mg, 1 
eq) in toluene (5ml) was made up and boiled in darkness. A further portion of silver 
carbonate on celite (1 eq) was added every 2 hours. After 10 hours, t.l.c. analysis
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(mobile phase = 10% methanol/chloroform) indicated complete conversion to 2 new 
compounds (Rp values: 0.55 and 0.65(main spot) c.f. 47 = 0.45). The mixture was 
cooled, filtered (washing with chloroform), and the filtrate was concentrated in vacuo 
to a brown oil. This was taken up in ether and extracted into cold 1% acetic acid, 
basified with sodium hydrogen carbonate and extracted into chloroform. The organic 
layer was separated, dried over sodium sulfate, and concentrated in vacuo to an oil 
which was flash chromatographed (mobile phase = 1.5-3% gradient
methanol/chloroform) to afford a brown oil (llOmg, 27%).
Rp 0.65 (mobile phase = 10% methanol/chloroform);
A,max 3022 (s(brd), arom C-H, C=C), 1752 (s, ester C=0);
5,i 6.73 (1 H, d , ./ 8.0, C:-H), 6.56 ( I H, d , ./8.2, C'-H), 5.71 (1 H ,d -m J 7,« 9.9, C7- 
H), 5.30 ( I H, dt. ./*.; 10.0, ./x.,4:x.f. 3.0, C*-H), 5.25 (1 H, t, J  9.0, C*-H), 5.11 (1 H, t, 
J 9.5, C'-H), 5.10 (1 H, dd,  9.7, Ju  7.5, C2-H), 4.90 (1 H, d, J5.6  6.0, C5-H), 4.81 
(1 H. d,  ,/,,2 7.5, C'-H), 4.25 (2 H, dd+s(brd), 9.5, J6,s 4.5, C*-H, C6-H), 4.15 (1 
H, dd, 9.5, ./„,5 2.2. C‘-H), 3.78 (1 H, ddd, JM 9.5, Js,« 4.5, / M 2.2, C*-H), 3.40 (1 
H, m. C'-H), 3.06 ( I H, d, 19.2, Cl0-Hp). 2.69 (2 H, m, C14-H, C-HU,), 2.46 (3 
H, s, N-CH.O, 2.0-2.4 (3 H, m, Cl5-Hax, Cl6-H„, Cl0-H„), 2.32 (3 H, s, ArOAc), 2.11 
(3 H, s, OAc), 2.07 (3 H, s, OAc), 2.04 (3 H, s, OAc), 2.02 (3 H, s, OAc), 1.93 (1 H, 
dm, ./gem 12.0, C i!-H«|);
132.0(3), 130.5(12), 132.6 (7). 128.6 (8). 119.2 (1), 121.9 (2), 99.8 (1), 89.8 (5),
73.9 (5), 72.7 (3), 71.9 (2), 71.2 (4), 68.3 (6), 61.9 (6), 58.7 (9), 46.2 (16), 43.0
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(NCFF), ^0.9 (14), 34.1 (15), 20.7 (2Ac), 20.6 (2Ac), 20.6 (Ac), not visible (5xOAc, 
4, ] 1, 13, 10);
m/z (FAB) 658 (M+fH);
(Found: C, 58.8; H, 6.21; N, 1.88. C33H39O13N.H2O requires C, 58.3; H, 6.13; N, 
2.06%).
49. Synthesis of codeine-6-glucoside 84
Codeine-2,3,4,6-tetra-(9-acetylglucopyranoside 82 (80mg, 0.13mmol) was dissolved in 
a solution of sodium hydroxide (25mg, 5 eq) in water (5ml) and stood for 1 hour. 
T.l.c. analysis (mobile phase = 80% methanol/chloroform) indicated complete 
conversion to a new compound, Rf = 0.25. Acetic acid (0.5ml) was added and the 
solution was concentrated in vacuo, dissolved in 1% acetonitiile/water and passed 
through a Waters Sep-pak C-18 cartridge, flushing with the same mobile phase to 
afford a colourless solid (40mg, 68%).
m.p. 240-260°C (dec.);
Rjv 0.3 (mobile phase = 80% methanol/chloroform);
8h (DiO) 6.85 (1 H, d , .7 8.1, C’-H), 6.71 (1 H, d, J  8.1, C‘-H), 5.77 (1 H, d, / 7,s 9.7, 
C7-H), 5.37 (1 H, d, Jsj 9.7, C8-H), 5.21 (1 H, d, / 5,6 5.8, C5-H), 4.67 (1 H, d, / 1>2 7.7, 
C'-H), 4.53 (1 H, s(brd), C6-H), 4.02 (1 H, s(brd), C9-H), 3.79 (3 H, s, OCH3), 3.4 (1
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H, m, C5-H), 3.50 (1 H, t , ./ 9.0, C'-H), 3.32 (1 H, t, J 9.0, C -H ), 3.40 (1 H, t, J  8.5, 
C2-H), 3.21 (1 H, d, ,/fcn, 19, Cl0-Hp), 3.2 (1 H, m, C14-H), 2.9 (1 H, t(brd), J  14, C16- 
H«), 2.83 (3 H, s, N-CH,), 2.8-2.9 (2 H, m, C16-H«,, Cl0-Ha), 2.26 (1 H, t(brd), J  13, 
C ’-Hax), 2.12 (1 H, d(brd), 13, C‘5-He(|);
8C 148.4 (4), 143.9 (3), 133.2 (7), 131.3 (12), 128.9 (8), 127.0 (11), 122.4 (1), 116.3 
(2), 103.8 (1), 90.9 (5), 78.1 (5), 77.6 (3), 75.3 (2), 75.1 (4), 71.6 (6), 62.0 (9), 58.5 
(OCHi), 48.6 (16), 44.0 (13), 42.9 (NCH,), not visible (10), (14), (15).
50. Synthesis of morphine-6-glucoside 86
A solution of morphine-6-(2,3,4,6-tetra-(9-acetylglucopyranoside) 87 (12mg,
0.02mmol) in sodium methoxide in methanol (0.4ml, 0.2 eq) was stirred and monitored 
by t.l.c. (mobile phase = 30% methanol/chloroform). Complete reaction was observed 
after 2 hours and the solution was concentrated in vacuo, dissolved in ether and 
extracted several times into water. Concentration in vacuo yielded a colourless solid 
(9mg, 95%).
m.p. 250-280°C (dec.);
R f  0.3 (mobile phase = 80% methanol/chloroform);
5h (D30 )  6.57 (2 H. 2d, J  8.0, C:-H, C*-H), 5.75 (1 H, d, / 7,8 9.5, C7-H), 5.40 (1 H, d, 
./a., 9.5, C*-H), 5.10 (1 H, d, ./5„ 6.0, C'-H), 4.68 (1 H, d, / w 7.9, C‘-H), 4.50 (1 H, 
s(brd), C'-H), 3.83 (I H, d, 12.0, C"-H), 3.65 (1 H, d, 12.0, C*-H). 3.3-3.7 (5
135
H, m, C'-H. C2-H, C ’-H, C4-H, C5-H), 3.08 (1 H, d, 19.0, C^-Hf,), 3.15 (1 H, m, 
Ci4-H), 2.70 (1 H, m, Cl6-Hi»), 2.48 (3 H, s, N-CH3), 2.5-2.6 (2 H, m, C16- ^ ,  C10- 
H„), 2.10(1 H, t(brd), J  13.0, C15-H»), 1.85 (1 H, d(brd), 13.0, C^-He,).
5C (DgO) 149.3 (4), 141.9 (3), 134.7 (7), 133.0 (12), 130.3 (8), 127.4 (11), 123.9 (1),
121.3 (2), 105.2 (1), 91.9 (5), 79.7 (5), 79.3 (3), 76.8 (2), 76.6 (4), 73.1 (6), 64.3 (6),
63.6 (9), 50.2 (16), 45.6 (13), 44.4 (NCHj), 41.4 (14), 35.7 (15), 26.8 (10).
m/z (FAB) 448 (M++H), 470 (JVT+Na).
51. Synthesis of eodeine-6-methy] (tri-O-acetylglucopyranosyl) uronate 50
A solution of codeine (150mg, 0.5mmol), methyl (bromo-2,3,4-tri-0-
acetylglucopyranosyl) uronate 48 (41 ling, 2.0 eq) and silver carbonate on celite 50% 
(230mg, 1.0 eq) in toluene (5ml) was made up and boiled in darkness. A further 
portion of silver carbonate on celite (1 eq) was added every 2 hours. After 10 hours, 
t.l.c. analysis (mobile phase = 10% methanol/chloroform) indicated complete 
conversion to 2 new compounds ( R f  values: 0.6 and 0.7( main spot) c.f. codeine = 
0.45). The mixture was cooled, filtered (washing with chloroform), and the filtrate 
was concentrated in vacuo to a dark oil. This was taken up in ether and extracted into 
ice-cold 0.5M hydrochloric acid, basified with sodium hydrogen carbonate and 
extracted into chloroform. The organic layer was separated, dried over sodium sulfate, 
and concentrated in vacuo to an oil which was flash chromatographed (mobile phase =
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1.5-3% gradient methanol/chloroform) to afford an oil which was triturated with 
ether/petroleum ether (30mg, 10%).
m.p. 177-179°C;
R f 0.7 (mobile phase = 10% methanol/chloroform);
A,max 3019 (s(brd), arom C-H, C=C), 1756 (s, ester C=0);
5,t 6.63 (1 H, d, J 8.2, C-H), 6.52 (1 H, d, J 8.2, C‘-H), 5.68 (1 H, ddt, /,.« 9.9, h ,6
3.0, ,/7.5 1.6, C7-H), 5.34 (1 H, t , ./ 9.2, C3-H), 5.30 (1 H, dt, / 8.7 10.0, 3.0, C8- 
H), 5.25 (1 H, t , ./ 9.5, C4-H), 5.10 (1 H, dd, ./2,3 9.0, / 2,i 7.5, C2-H), 4.98 (1 H, d, / 2,2
7.5, C'-H), 4.94 (L H, dd, JSA 6.0, Jsj 1.3, Cs-H), 4.38 (1 H, dtd, J6,5 6.0, 76,7;6.8 3.0, 
J„.u 2 0. C'-H), 4.12 (1 H, d , ./ 9.5, C5-H), 3.76, 3.78 (6 H, 2s, OCH3+CO2CH3), 3.35 
(1 H, m, C'-H), 3.04 (1 H, d, ,/gcm 18.9, C10-Hs), 2.66 (1 H, m, C14-H), 2.60 (1 H, dd, 
./fC,„ 12.0, J 1 6 . 1 3  4.0, Cl6-Hcq), 2.44 (3 H, s, N-CHj), 2.40 (1 H, td 3 Jgem;16,15ax 12.0,
5«h 3.5. C'"-Hax), 2.31 (1 H, dd, 19.0, Jw.,  6.5, C -H c), 2.16 (3 H, s, OAc),
2.04 (3 H, s, OAc), 2.03 (3 H, s, OAc), 2.0-2.1 (1 H, m, C*5-H«), 1.88 (1 H, dm, / gem
12.0, Cj5-H.„):
8c 170.0 (OAc), 169.7 (OAc), 169.4 (OAc), 167.4 (C02CH3), 147.3 (4), 142.1 (3), 
130.6 (12), 130.2 (7), 128.8 (8), 127.0 (11), 118.9 (1), 113.2 (2), 97.9 (1), 88.0 (5),
72.7 (5), 72.1 (3), 71.8 (2), 71.2 (4), 69.5 (6), 58.8 (9), 56.2 (OCH3), 52.8 (C02CH3),
46.4 (16), 43.4 (13), 43.0 (NCHO, 41.0 (14), 35.9 (15), 20.4 (10);
m/z (FAB) 616 (M++H);
137
(Found: C. 3 0 ;  H, 5.XI; N, 2.30. CdiFh70,2N requires C, 60.5; H, 6.06; N, 2.28%).
52. Synthesis of 3-acetvlmorphine-6-methyl (tri-O-acetylglucopyranosyl) uronate 
49
A solution of 3-acetyhnorphine 47 (240mg, 0.74mmol), methyl (bromo-2,3,4-tri-(9- 
acetylglucopyranosyl) uronate 48 (600mg, 2.0 eq) and silver carbonate on celite 50% 
(600mg, 1.5 eq) in toluene (10ml) was made up and boiled in darkness. A further 
portion of silver carbonate on celite (1.5 eq) was added every 3 hours. After 6 hours, 
t.l.c. analysis (mobile phase = 10% methanol/chloroform) indicated almost complete 
conversion to 2 new' compounds ( R f  values: 0.55 and 0.65( main spot) c.f. 47 = 0.45). 
The mixture was cooled, filtered (washing with chloroform), and the filtrate was 
concentrated in vacuo to a dark oil. This was taken up in ether and extracted into ice- 
cold 0.5M hydrochloric acid, basified with sodium hydrogen carbonate and extracted 
into chloroform. The organic layer was separated, dried over sodium sulfate, and 
concentrated in vacuo to an oil which was flash chromatographed (mobile phase = 1.5- 
3% gradient methanol/chloroform) to afford a light oil (210mg, 45%).
m.p. 168-169°C;
R f 0.65 (mobile phase = 10% methanol/chloroform);
/Vmax 3014 (s(brd), arom C-H, C=C), 1757 (s, ester C=0);
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5n 6.73 (1 H, d ,./ 8.1, C2-H), 6.55 (1 H, d, J  8.2, C'-H), 5.69 (1 H, d -m ,/7,8 9.9, C7- 
H), 5.31 (1 H, dt, .6,7 10.0, ■6j.U;8.Ci 3.0, C8-H), 5.30 (1 H, t , 7 7.0, C3-H), 5.26 (1 H, t, 
7 7.0, C“-H), 5.10 (I H, td, J 2Ji2,i 7.0,7 2.5, C2-H), 4.91 (1 H, dd, 75,6 6.6 ,75,7 1.0, C5- 
H), 4.90 (1 H, d, 7,,2 7.5, C‘-H), 4.31 (1 H, dtd, 76,5 6.0, J 6 ,r,6» 3.0, J6M 2.0, C6-H), 
4.12 (1 H, d, 7 7.0, Cs-H), 3.74 (3 H, s, C 02CH3), 3.37 (1 H, dd, 7,,10o 6.0, 79,i4 3.1, 
C9-H), 3.05 (1 H, d, 7|i« 18.9, C10-H|b), 2.65 (1 H, m, C14-H), 2.60 (1 H, dd, 7gem 12.0,
7.6..5 4.5, CK'-He„), 2.43 (3 H, s, N-CH,), 2.0-2.4 (3 H, m, C15-H„, C16-H», C10-Ha), 
2.31 (3 H, s, ArOAc), 2.11 (3 H, s, OAc), 2.04 (6 H, s, 2xOAc), 1.92 (1 H, dm, 7gem
11.0, C15-Heq);
8c 170.1 (OAc), 169.3 (OAc), 169.2 (OAc), 168.7 (OAc), 167.4 (C02CH3), 150.1 (4),
132.3 (3). 131.6 (11), 131.4 (12), 130.2 (7), 128.8 (8), 121.8 (2), 119.1 (1), 99.1 (1),
89.4 (5), 73.3 (5), 72.6 (3), 71.9 (2), 71.1 (4), 69.2 (6), 58.6 (9), 52.8 (C02CH3), 46.2
(16), 43.5 (13), 43.5 (NCH3). 41.0 (14), 35.6 (15), 20.6 (2Ac), 20.5 (2Ac), 20.8 (10);
m/z (FAB) 644 (M++H);
(Found: C, 59.3; H, 5.81; N. 2.17. C32H37Ol3N requires C, 59.7; H, 5.79; N, 2.18%).
53. Synthesis of codeine-6-methvl (oi-O-acetylglucopyranosyD uronate 50
A solution of codeine (lOOmg, 0.33mmol), methyl (bromo-2,3,4-tri-(9- 
acetylglucopyranosyl) uronate 48 (280mg, 2.0 eq), silver carbonate (170mg, 2.0 eq)
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and celite (50()g) in toluene (5ml) was made up and boiled in darkness. A further 
portion of silver carbonate (2 eq) was added every 3 hours. After 6 hours, t.l.c. 
analysis (mobile phase = 10% methanol/chloroform) indicated complete conversion to 
2 new compounds (Rr values: 0.6 and 0.7( mam spot) c.f. codeine = 0.45). The 
mixture was cooled, filtered (washing with chloroform), and the filtrate was 
concentrated in vacuo to a dark oil. This was taken up in ether and extracted into ice- 
cold 0.5M hydrochloric acid, basified with sodium hydrogen carbonate and extracted 
into chloroform. The organic layer was separated, dried over sodium sulfate, and 
concentrated in vacuo to an oil which was flash chromatographed (mobile phase = 1.5- 
3% gradient methanol/chloroform) to afford an oil which was triturated with 
ether/ethyl acetate (15mg, 7%).
bn as previous.
54. Attempted synthesis of codeine-6-methvl ftri-O-acetylglucopyranosyl) uronate 
50
A solution of codeine (lOOmg, 0.33mmol), methyl (bromo-2,3,4-tri-0- 
acetylglucopyranosyl) uronate 48 (280mg, 2.0 eq) and celite (500g) in toluene (5ml) 
was made up and boiled in darkness. After 6 hours, t.l.c. analysis (mobile phase = 10% 
methanol/chloroform) indicated slight conversion to a new compound (Rf = 0.6 c.f. 
codeine = 0.45). The mixture was cooled, filtered (washing with chloroform), and the 
filtrate was concentrated in vacuo to a dark oil. This was taken up in ether and
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extracted into ice-cold 0.5M hydrochloric acid, basified with sodium hydrogen 
carbonate and extracted into chloroform. The organic layer was separated, dried over 
sodium sulfate, and concentrated in vacuo to an oil which was flash chromatographed 
(mobile phase = 1.5-3% gradient methanol/chloroform) to afford an oil which was 
triturated with ether/petroleum ether (3mg). Data suggests formation of codeine-6- 
acetate.
8h 6.67 (1 H, d , ./ 8.1, C'-H), 6.55 (1 H, d, J  8.3, C‘-H), 5.65 (1 H, d-m, Jljs 9.9, C7- 
H), 5.44 (1 H, d t , ./8.7 9.9, 2.5, Cs-H), 5.09 (1 H, dd, J5 ,6  6.6, J5j  1.1. Cs-H),
4.21 (1 H, s(brd), C6-H), 3.45 (1 H, s(brd), C9-H), 3.86 (3 H, s, OMe), 3.05 (1 H, d,
19.0, C'°-Hu), 2.49 (3 H, s, N-CH,),.2.0-2.85 (5 H, m, CI0-Ha, C14-H, C16- ^ ,  
Cl5-HiK, Ck'-H,„). 2.17 (3 H. s, OAc), 1.90 (1 H, dd,./gei„ 13.0, J tSM 3.0, Cl5-H^);
m/z (FAB) 342 (M++H).
55. Synthesis of morphine-6-methvl glucopvranosyl uronate 90
3-Acetylmoiphine-6-methyl (tri-O-acetylglucopyranosyl) uronate 49 (160mg,
0.24mmol) was dissolved in a solution of sodium in methanol, 0.22mg/ml (5ml, 0.2 eq) 
and boiled, monitoiing by t.l.c. analysis (mobile phase = 25% methanol/chloroform). 
After 3 hours, the reaction was complete. The mixture was concentrated in vacuo to 
an oil, to which was added water (10ml) and the impurities were extracted into ethyl 
acetate. The aqueous layer was collected and concentrated in vacuo to an off-white
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solid (8()mg, 68c/c). Data indicated presence of 40 so crude material was earned 
through to next step.
56. Synthesis of morphine-6 -glucuronide 40
i) A solution of morphine-6 -methy] glucopyranosyl uronate 90 (55mg, 0.115mmol) in 
0.43N barium hydroxide (0.2ml, 0.75 eq) was stood for 1 hour before 2N oxalic acid 
was added to pH 6 . The resulting suspension was filtered, and the filtrate was 
concentrated in vacuo to afford an off-white crystalline solid (48mg, 90%). This was 
shown to contain inorganic contaminants.
m.p. 230-280°C (dec.);
Rr 0.3 (mobile phase = 80% methanol/chloroform);
5,1 (D20 )  6.73 (1 H, d, J  8.0, C°-H), 6.65 (1 H, d, /  8.0, Cl-H), 5.82 (1 H, d, h ,„ 9.9, 
C7-H), 5.37 (1 H, d, Jt j  9.9, C8-H), 5.22 (1 H, dd, J5.6 5.7, C5-H), 4.71 (1 H, d, J ll2
7.7, C '-H), 4.56 (1 H ,m ,C 6-H), 4.15 (1 H, m, C9-H), 3.71 (1 H, d, J  9.0, Cs-H), 3.53 
(1 H ,t,./9 .0 , C ’-Hi, 3.48(1 H, t, -h.yj.i 8 .0 , C 2-H), 3.37 (1 H, t , /9 .0 ,  C4-H), 3.22(1 
H, d(brd), 21, C l0-H,j), 2.95 (3 H, s, N-CH,), 2.8-3.4 (4 H, m, , C14-H, C16- ^ ,  
C16- ^ ,  C 10-Ha), 2.32 (1 H, tin, J 9, C'-’-HLJ, 2.13 (1 H, d m ,/gen, 13.0, C^-He,);
m/z (FAB) 462 (M++H).
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ii) A stirred suspension of morphine-6-methyl glucopyranosyl uronate 90 (lOmg, 
0.02mmol) and Dowex 50(H) ion-exchange resin (2mg) in water (1ml) was boiled for 
8 hours. T.l.c. analysis (mobile phase = 80% methanol/chloroform) indicated 
conversion to material with lower Rf value. The solution was cooled, filtered, and 
concentrated in vacuo to an off-white solid (6mg, 60%).
R f 0.3 (mobile phase =  80% methanol/chloroform);
8 h (D20 )  6.73 (J H, d, J  8.0, C2-H), 6.65 (1 H, d, J 8.0, C‘-H), 5.82 (1 H, d, 77,s 9.9, 
C?-H), 5.37 (1 H, d, ,/r7 9.9, C*-H), 5.22 (1 H, dd, J5,6 5.7, C^-H), 4.71 (1 H, d, 7U
7.7, C '-H), 4.56 (1 H, m, C6-H),4.15 (1 H, m, C9-H), 3.71 (1 H, d , /9 .0 ,  Cs-H), 3.53 
(I H, t , ./ 9.0, C '-H), 3.48 (1 H, t , ./2„w  8.0, C 2-H), 3.37 (1 H, t, J  9.0, C4-H), 3.22 (1 
H, d(brd), ./|i:„ 21, C l0-Hp), 2.95 (3 H, s, N-CH,), 2.8-3.4 (4 H, m, , C14-H, C16-He„ 
Cl6-H„, CI0-Ho), 2.32 (1 H, t m 9, C 15-H.*), 2.13 (1 H, dm ,7 ^ .  13.0, C ,5-H«1);
8C 180.9 (C 02H), 154.1 (4), 146.4 (3), 139.6 (7), 137.5 (12), 134.8 (8 ), 131.8 (11),
128.9 (I), 126.3 (2), 1 10.2 (1), 96.6 (5), 83.6 (5), 83.2 (3), 81.5 (2), 81.3 (4), 79.6 
(6 ), 69.1 (9), 55.7 (16), 49.7 (NCH.O, 29.4 ( 1 0 ), 50.0 (13), 47.0 (14), 40.9 (15).
m/z (FAB) 462 (M++H);
(Found: C, 51.4; H, 6.02; N, 2.45. C2 ,H:70,N .1.1H 20  requires C, 51.0; H, 5.93; N,
2.37%).
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iii) A stirred suspension of 3-acetylmorphine-6-methyl (tri-O-acetylglucopyranosyl) 
uronate 49 (170mg, 0.26mmol) and Dowex 50(H) ion-exchange resin (30mg) in water 
(10ml) was boiled for 5 hours. T.l.c. analysis (mobile phase = 80% 
methanol/chloroform) indicated very slight conversion to material with lower RF value. 
The reaction was continued for a further 20 hours when Ll.c. analysis indicated 
complete conversion. The solution was cooled, filtered, and concentrated in vacuo to 
an off-white solid (113mg). N.m.r. extremely complex with several acetate peaks 
present, no methyl ester peak, and an NMe shift at 2.95 p.p.m.
5h (D20 ) 6.65 (2  H, m, C*-H, C2-H), 2.95 (3 H, s, N-CH3), 2.16, 2.11, 2.05, 2.04,
2.01 (~7 H, 5s, OAc);
m/z (FAB) 630 (M++H), 588 (-Ac), 546 (-Ac), 504 (-Ac), 462 (-Ac).
iv) A stirred suspension of 3-acetylmorphine-6 -methyl (tri-O-acetylglucopyranosyl) 
uronate 49 (125mg, 0.2mmol) and Amberlite IRA-410 ion-exchange resin (5mg) in 
water (10ml) was boiled for 3 days. T.l.c. analysis (mobile phase = 80% 
methanol/chloroform) indicated complete conversion. The solution was cooled, 
filtered, and concentrated in vacuo to an off-white solid (59mg) which was shown by 
n.m.r. to contain an acetate group. The product was taken up with methanol (5ml) and 
2N ammonia (1ml) was added. After standing for 1 day, evaporation in vacuo gave an 
off-white solid (49mg, 55%).
8 h as i).
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57. Synthesis of code i n e- 6 - g 1 ucuron i de 41
A stirred suspension of codeine-6 -methyl (tri-O-acetylglucopyranosyl) uronate 50 
(20mg, O.Q33mmo]) and Amberlite TRA-410 ion-exchange resin (5mg) in water (5ml) 
was boiled for 12 hours. T.l.c. analysis (mobile phase = 80% methanol/chloroform) 
indicated complete conversion to a new compound, Rf = 0.3. The solution was 
cooled, filtered, and concentrated ammonium hydroxide (2ml) in water (3ml) and 
methanol (5ml) was added. The mixture was left to stand for 2 days before t.l.c. 
analysis indicated complete conversion to another new compound, Rf = 0.25. The 
solution was washed with chloroform and concentrated in vacuo to an oil which was 
dissolved in 1% acetonitrile/water and passed through a Waters Sep-pak C-18 
cartridge, flushing with the same mobile phase to afford a colourless solid which was 
shown still to contain ammonium acetate. This impurity was removed by freeze-drying 
(5mg, 35%).
m.p. 240-260°C (dec.);
R f  0.3 (mobile phase = 80% methanol/chloroform);
5ii (D30 )  6.90 (J H, d , ./ 8.4, C2-H), 6.75 (1 H, d, J  8.4, C‘-H), 5.82 (1 H, d, J7,8 9.7, 
C’-H). 5.37 (] H, d. ./s.7 9.9, C*-H), 5.25 (1 H, d, J5,6 5.7, Cs-H), 4.68 (1 H, d, 7.9, 
C ‘-H), 4.38 (] H, m, C6-H), 4.18 (1 H, m, C9-H), 3.81 (3 H, s, OCH3), 3.71 (1 H, d, J  
9.3, Cs-H), 3.54 (I H, t , ./ 9.0, C '-H), 3.50 (1 H, t, J  9.5, C4-H), 3.36 (1 H, t, J  8.5, 
C 2-H), 3.26 (1 H, d(brd), 20, C‘°-Hp), 2.97 (3 H, s, N-CH3), 2.85-3.15 (4 H, m,
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Ci4-H. C ’-H,,), 2.33 (1 H, t(brd), J  12, C,5-H»), 2.12 (1 H, d(brd),
9, C l5-Heq);
Sc 176.5 (CCFH), 147.2 (4), 142.9 (3), 125.0 (11), 129.7 (12), 132.4 (7), 126.8 (8 ),
115.2 (2), 121.3 (1), 102.3 (1), 89.3 (5), 77.1 (5), 76.2 (3), 73.9 (2), 73.5 (4), 72.6
(6 ), 61.3 (9), 57.2 (OCH,), 42.6 (16), 41.5 (NCH3), 19.0 (10), not visible (13), (14), 
(15);
m/z (FAB) 476 (M++H).
58. Synthesis of methyl (1,2,3,4-tetra-O-isobutanoylglucopyranosyl) uronate 92
A solution of methyl glucopyranosyl uronate 55 (11.8 g, 55mmol) in pyridine (34ml) 
and DCM (35ml) was cooled to 0°C and isobutanoyl chloride (53.2g, 52.3ml, 4.8 eq) 
was added dropwise over 2 hours. The solution was stirred at 20°C for 2 days and 
t.l.c. analysis (mobile phase = 40% ethyl acetate/petroleum ether) showed complete 
conversion to a new compound, Rf = 0.9. The solution was diluted with DCM 
(150ml), washed with dilute hydrochloric acid (100ml) and subsequently with saturated 
sodium hydrogen carbonate, dried over sodium sulfate, filtered, and concentrated in 
vacuo to a black oil which was crystallised from petroleum ether to afford colourless 
prisms (8.13g). A 2nd batch was obtained after concentrating the mother liquor giving 
an off-white solid which was recrystallised from petroleum ether to afford more 
colourless prisms (3.72g, =11.8g total, 43%).
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R f 0.9 (mobile phase = 40% ethyl acetate/petroleum ether);
8 n 5.XI (1 H. d, ./ 7.7. C'-H), 5 .3 5  (1 H, t , ./ 9.0, C3-H), 5.29 (1 H, t, J  9.0, C -H ), 
5.18 (1 H, t , ./ 7.9, C:-H), 4.25 (1 H, d, J  9.3, C5-H), 3.78 (3 H, s, ester CH3), 2.55 (4 
H, m, 4x 0C (0)C H (C H jh), 1.10 (24 H, m, 8 x ’butanoyl-CH.).
59. Attempted synthesis of methyl (2.3.4-tri-O-isobutanoylglucopyranosyr) uronate 
93
Dry ammonia gas was bubbled through DCM (200ml) at -4°C over 1 hour before 
methyl (l,2,3,4-tetra-<9-isobutanoylglucopyranosyl) uronate 92 (8.0g, 16mmol) was 
added and the solution was stirred at ()°C for 3.5 hours. T.l.c. analysis (mobile phase = 
409f- ethyl acetate/petroleum ether) indicated no reaction. The solution was 
concentrated in vacuo giving complete recovery of the starting material as a colourless 
solid (8 .0 g).
60. Synthesis of methyl (2.3,4-tri-O-isobutanoylglucopyranosyl) uronate 93
A solution of methyl (l,2,3<4-tetra-<9-isobutanoylglucopyranosyl) uronate 92 (8.0g, 
l6 mmol) in DCM (200ml) was made up and dry ammonia gas was bubbled through at 
0°C for 12 hours. T.l.c. analysis (mobile phase = 40% ethyl acetate/petroleum ether)
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indicated partial conversion to a new compound, Rf = 0.55. Bubbling of ammonia gas 
was continued at 2()°C for a further 10 hours during which time the solution had 
concentrated to around 80ml. T.l.c. analysis now showed almost complete conversion. 
Nitrogen gas was bubbled through the mixture for 20 minutes and the solution was 
washed with ice-cold 10% hydrochloric acid and subsequently with water, dried over 
sodium sulfate, filtered, and concentrated in vacuo to an oil which was flash 
chromatographed to afford a colourless crystalline solid (4.1g, 60%).
R f  0.55 (mobile phase = 40% ethyl acetate/petroleum ether);
5„ 5.57 (1 H, t, ./ 9.5, C'-H), 5.50 (1 H, d, ./ 7.8, C]-H), 5.24 (1 H, t, J  9.5, C4-H), 
5.11 (1 H, d d ,./2.3 9.0, J2.i 8.0, C2-H), 4.25 (1 H, d, J  9.5, C5-H), 3.76 (3 H, s, ester 
CH3), 3.15 (1 H, s(brd), OH), 2.55 (3 H, m, 3x 0C(0)CH (CH 3)2), 1.15 (18 H, m, 6 x 
'butanoyl-CH3).
61. Attempted synthesis of methyl (trichloroacetimidyl-2,3.4-tri-0- 
isobutanovlglucopvranosyl) uronate 91
A solution of methyl (2,3,4-tri-(9-isobutanoylglucopyranosyl) uronate 93 (3.9g, 
9.3mmol) in DCM (40ml) was made up and trichloroacetonitrile (5.8g, 4.0ml, 
40mmol) was added. The solution was stirred for 10 minutes before potassium 
carbonate (1.3g, 2 charge eq) was added and the reaction was monitored by t.l.c. 
(mobile phase = 40% ethyl acetate/petroleum ether). After 2 hours, partial conversion 
was shown and ~70% conversion was indicated after 24 hours. After 2 days, t.l.c.
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analysis indicated lower conversion, suggesting an equilibrium which was shifting back, 
possibly due to the volatility of trichloroacetonitrile. A further portion (4ml) was 
added and after 2 hours, t.l.c. analysis indicated over 90% conversion. The solution 
was filtered, washed with water, dried over sodium sulfate, and concentrated to an oil 
which was crystallised and recrystallised from isopropanol to colourless prisms (1.3g, 
25%). This was shown to be the coupling product of 91 and isopropanol as the (3 
anomer.
Rf 0.85 (mobile phase = 40% ethyl acetate/petroleum ether);
5.1 5.33 (1 H, t, J  9.3, C'-H), 5.22 (1 H, t , ./ 9.7, C4-H), 5.01 (1 H, dd, h ,3 9.3, J2.i 8.0, 
C'-H), 4.65 (1 H, d . ./ 7.7, C'-H), 4.07 (1 H, d, J  9.7, C5-H), 3.96 (1 H, sept, J  6.0, 
'propyl CH), 3.74 (3 H, s, ester CH,), 2.50 (3 H, m, 3x 0C (0)CH (CH 3)2), 1.05-1.25
(24 H, m, 6 x 'butanoyl-CPT + 'propyl CH3).
m/z (FAB) 461 (M++H) 418 (VT+H-OH) 401 (M+-butanoyl).
62. Synthesis of methyl (trichloroacetimidyl-2.3.4-tri-0- 
isobutanoylglucopyranosyl) uronate 91
A solution of methyl (2,3,4-tri-O-isobutanoylglucopyranosyl) uronate 93 (1.3g,
3.1 mmol) in DCM (20ml) was made up and trichloroacetonitrile (4.35g, 3.0ml, 
30mmol) was added. The solution was stirred for 10 minutes before potassium 
carbonate (500mg, 2.2 charge eq) was added and the reaction was monitored by t.l.c.
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(mobile phase = 40% ethyl acetate/petroleum ether). After 24 hours, t.l.c. analysis 
indicated over 90% conversion. The solution was filtered, washed with water, dried 
over sodium sulfate, and concentrated to an oil which was flash chromatographed 
(mobile phase = 12% ethyl acetate/petroleum ether) to afford a colourless solid (1.36g, 
15%). Product shown to be the a  anomer.
Rf 0.85 (mobile phase = 40% ethyl acetate/petroleum ether);
5,i 8.75 (1 H, s(brd), 6.55 (1 H, d, J  3.5, C‘-H), 5.58 (1 H, t, J  9.5, C3-H), 5.22 (1 H, 
t , ./ 9.5, C'-H), 5.1(1 (1 H, dd, .A, 9.0, J 2 . 1  3.5, C’-H), 4.36(1 H, d, J  9.5, C^-H), 3.78 
(3 H, s, ester CH,), 2.60 (3 H, 111, 3x 0C(0)CH(CH3)2), 1.10 (18 H, m, 6x 'butanoyl- 
CH,).
63. Synthesis of 3-acetvlmorphine-6-methyl (tri-O-isobutanoylglucopyranosyl)
uronate 95
A solution of 3-acetylmorphine 47 (0.186g, 0.57mmol) and methyl
(trichloroacetimidyl-2,3,4-tri-CMsobutanoylglucopyranosyl) uronate 91 (640mg, 2.0 
eq) in DCM (2ml) was made up and boron trifluoride etherate (162mg, 0.14ml, 2.0 eq) 
was added dropwise. The mixture was stirred, monitoring by t.l.c. analysis (mobile 
phase = 10% methanol/chloroform). After 16 hours, several compounds were present, 
including both starting materials and a new compound giving a strong spot, Rf = 0.7. 
The mixture was quenched with saturated sodium hydrogen carbonate, extracted into
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DCM and concentrated in vacuo to an oil which was taken up in ether and extracted 
into ice-cold 0.5M hydrochloric acid, basified with sodium hydrogen carbonate and 
extracted into chloroform. The organic layer was separated, dried over sodium sulfate, 
and concentrated in vacuo to an oil which was flash chromatographed (mobile phase =
1.5-3% gradient methanol/chloroform) to afford an oil which was triturated with 
ether/petroleum ether (60mg, 15%).
m.p. 186°C (lit. 188-189°C);
R f  0.80 (mobile phase = 10% methanol/chloroform);
8m 6.72 (1 H. d ,./ 8.1, C -H ), 6.54 (1 H, d, J  8.1, C‘-H), 5.68 (1 H, d-m, / 7,s 9.9, C7-
H), 5.32 (1 H, t , . /8 .1 ,C ’-H), 5.30 (1 H ,d , Js.7 10.0, Cs-H), 5.30 (1 H, t, J  8.5, C -H ), 
5.15 (1 H, dd, 8.1, Ji,i 7.5, C2-H), 4.95 (1 H, d, / u  7.5, C '-H ), 4.91 (1 H, d, J ,,6
5.8, C5-H), 4.31 (1 H, dd. ./<,5 5.5, ./„.7 2.0, C6-H), 4.14 (1 H, d, J  9.0, C5-H), 3.73 (3 
H, s. CO;Me). 3.35 ( I H, m, C'-H), 3.05 (1 H, d, ./S:« 18.8, C lo-H|0,), 2.44 (3 H, s, N- 
CH,), 2.3-2.7 (7 H. in, CIJ-H, Clc’-H„, C10-Ha, 3x 0C (0)CH (CH 3)2),), 2.04
(1 H, td, ,/?cm;,5 12.0, J ,5j 5.0, C i5-H„),1.92 (1 H, d(brd), Jga„ 12.0, C15-He,);
m/z (FAB) 728 (M++H).
64. Synthesis o f m orphine-6-glucuronide 40
3-acety]morphine-6-methyl(2,3,4-tri-(9-isobutanoylglucopyranosyl) uronate 95 (40mg, 
0.055mmol) was dissolved in a solution of sodium hydroxide (23.5mg, 10 eq) in water 
(0.47ml) and methanol (2ml) and stood for 1 hour. T.l.c. analysis (mobile phase = 
80% methanol/chloroform) indicated complete conversion to a new compound, Rf = 
0.25. Acetic acid (0.54ml) was added and the solution was refrigerated for 2 days. A 
small amount (<5mg) colourless solid had crystallised out. This was collected by 
filtration but was later shown to contain no opioid material. The filtrate was treated 
twice with Amber!ite 1RC-50S ion-exchange resin and concentrated in vacuo to an off- 
white solid (K)mg). This was shown by n.m.r. to contain target product but was also 
shown to be impure with inorganic salts.
5n consistent with previous products 40
Elemental analysis gave low values.
65. Synthesis of DL-7-oxabicvclol2.2.11hept-5-ene-2-m ethylcarboxylate 101
A mixture of furan (76g, 1.1 mol), methyl acrylate (80g, 83ml, 0.9mol) and zinc iodide 
(32g, 0.1 mol) was made up and stored at 4°C. After 2 days, t.l.c. analysis (mobile 
phase = 40% ethyl acetate/petroleum ether) indicated slight conversion. The mixture 
was stored at 20°C for 4 days after which, t.l.c. analysis indicated almost complete
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conversion. The solution was diluted with ethyl acetate (11) and washed with 0.1M 
sodium thiosulfate (700ml), dried over sodium sulfate and concentrated in vacuo to an 
oil which was flash chromatographed (mobile phase = ethyl acetate) to afford a 
colourless oil (53.2g, 35%). Shown to be -2:1 endo:exo adduct mixture.
8f] 6.44 (0.7 H, m, exo H-2, H-3), 6.36 (0.65 H, d, J2,3 6.0, enclo H-2), 6.21 (0.65 H, d, 
2 6.0, endo H-3), 5.14 (J H, s(brd), H -l), 5.05 (0.35 H, s, exo H-4), 5.00 (0.65 H, s, 
endo H-4), 3.71 (1.05 H, s, exo C 0 2Me), 3.62 (1.95 H, s, endo C 0 2Me), 3.09 (0.65 H, 
s, endo H-6), 2.41 (0.35 H, s, exo H-6), 2.1 (1 H, m, H-5eq), 1.6 (1 H, m, H-5„).
66. Attempted synthesis of DL-2-mY;-bromo-4.8-dioxatricyclor4.2.1.01nonan-5-one 
102
A solution (A) of I)L-7-oxabicvclo|2.2.l]hept-5-ene-2-methylcarboxylate 101 (1.75g,
11.4mmol) in acetic acid (10ml) was made up. Meanwhile, a solution of silver acetate 
(3.6g, 1.9 eq) and bromine (1.73g, 0.56ml, 0.95 eq) in acetic acid (40ml) was stirred 
for 10 minutes before solution (A) was added and stirred for 1 hour. A solution of 
water (0.205ml, 1.0 eq) in acetic acid (5ml) was added and the mixture was stirred at 
1 ()()°C, monitoring by t.l.c. analysis (mobile phase = 40% ethyl acetate/petroleum 
ether). After 5 hours, no conversion was indicated but slow epimerisation had 
occurred, giving a stronger spot for the exo compound.
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67. Synthesis of DL-7-oxabicyelo[2.2.11hept-5-ene-2-carboxylic acid 99
A solution of DL-7-oxabicyc]o[2.2.1]hept-5-ene-2-methylcarboxylate 101 (1.4g, 
9.1mmol) and lithium hydroxide monohydrate (760mg, 2.0 eq) in water/methanol 1:2 
(20ml) was made up and stirred. After 4 hours, t.l.c. analysis (mobile phase = 40% 
ethyl acetate/petroleum ether) indicated complete conversion. The solution was 
concentrated in vacuo to an oil to which water was added, acidified with 0.1M 
potassium hydrogen sulfate, and extracted into ethyl acetate (5x50ml), dried over 
sodium sulfate, and concentrated in vacuo to a near colourless oil which crystallised to 
a yellow solid on vacuum drying (1.19g, 93%).
m.p. 96-98°C (lit. 97-100°C);
8h 6.46 (0.65 H, dd, Ao 5.9, A j J .7, endo H-2), 6.42 (0.35 H, dd, A,3 5.8, J2,i 1.7, exo 
H-2), 6.36(0.35 H, dd, ./3.2 5.9, A.-i 1.7, exo H-3), 6.30 (0.65 H, dd, A.2 5.9, A,4 1.5, 
endo H-3), 5.25 (0.35 H, dd, A.2 1.5, A.3 0.5, exo H -l), 5.20 (0.65 H, ddd, J h6eq 4.8, 
A.2 i .6, A .3 0.6, endo H -l), 5.11 (0.35 H, d, JAJ5eq 4.8, exo H-4), 5.05 (0.65 H, d, J4,5eq
4.8, endo H-4), 3.17 (0.65 H, ddd, J6,5eq 9.3, J6.5ax 5.0, A,i 4.8, endo H-6), 2.47 (0.35 
H, dd, y6.5„v 8.5, A.5,, 4.0, H-6), 2.15 (0.35 H, ddd, Jgm 11.5, J5A 4.8, J5>6 4.0, exo
H-5et|), 2.15 (0.65 IT ddd, ./}U,n 11.5, A.6 9.3, J5A 4.8, endo H-5eq), 1.60 (0.35 H, dd, 
A eni 11.5,./5.6 8.5, exo H-5aN), 1.57 (0.65 H, dd, / gem 11.5, A,6 5.0, endo
154
68 . Synthesis of DL-2-e.v<7-bromo-4,8-dioxatricyclor4.2.1.01nonan-5-one 102
i) A solution of DL-7-oxabicycIo[2.2.1]hept-5-ene-2-carboxylic acid 99 (600mg, 
4.2mmol) and sodium hydrogen carbonate (415mg, 1.2 eq) in water (15ml) was stirred 
and bromine (820mg, 0.26ml, 1.2 eq) was added dropwise. The mixture was stirred 
and monitored by t.l.c. (mobile phase = 40% ethyl acetate/petroleum ether) which 
partial conversion after 1 hour with no improvement after 16 hours. The mixture was 
filtered, basified with saturated sodium hydrogen carbonate, and extracted into ethyl 
acetate (2x 50ml), dried over sodium sulfate, and concentrated in vacuo to a colourless 
crystalline solid (470mg, 55%).
8h 5.43 (1 H, t, 4.8, H-l ), 4.97 (1 H, d, J2.\ 4.8, H-2), 4.78 (1 H, d , J4,5eq 5.0, H- 
4), 3.95 (1 H, s, H-3), 2.77 (1 H, ddd, Jb.5eq 11.0, J6A 5.0, ,/6,5„  2.0, H-6), 2.32 (1 H, 
dd, ./oCI11 1 4 . 0 , 1 1 . 0 ,  ,/5.4 5.3, H-5CI|), 2.1 1 (1 H, dd, ./gc,„ 14.0, J5.6 2.0, H-5»).
ii) A solution of DL-7-oxabicyclo[2.2.1]hept-5-ene-2-carboxylic acid 99 (6000mg, 
4.2mmol) and sodium hydroxide (200mg, 1.2 eq) in water (15ml) was stirred and 
bromine (820mg, 0.26ml, 1.2 eq) was added dropwise. The mixture was stirred and 
monitored by t.l.c. (mobile phase = 40% ethyl acetate/petroleum ether) which partial 
conversion after 1 hour with no improvement after 16 hours. The solution was shown 
to be acidic so a further portion (1.2 eq) sodium hydroxide was added and the reaction 
was continued. After 2 hours, t.l.c. analysis indicated further conversion but starting 
material remained. The mixture was extracted into ethyl acetate (3x 50ml), dried over
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sodium sulfate, and concentrated in vacuo to a colourless solid (448mg, 48%). Data 
consistent with above.
69. Synthesis of DL-( 13.5/2.4)-23-diacetoxy-4.5-dibromocyclohexane-l- 
carboxvlic acid 103
A solution of DL-2-6,V0-bromo-4,8-dioxatricyclo[4.2.1.O]nonan-5-one 102 (1.6g, 
7.0mmol) in 20% hydrogen bromide in acetic acid (5ml) was sealed in a thick walled 
glass tube and heated at 80°C for 2 days. The solution was poured onto ice-water and 
the resulting precipitate was filtered as a grey solid which was recrystallised from 
ethanol as a mixture of black solid and colourless prisms (0.5g), but this was shown by 
n.m.r. and t.l.c. analyses as containing only starting material. The filtrate was 
concentrated in vacuo and crystallised from ether as colourless needles (235mg, 
8.4%).
m.p. 202-4°C (lit. 206-7°C);
5h (DMSO) 1.99 (3 H, s, OAc), 1.89 (3 H, s, OAc).
] 56
70. Synthesis of me.t h y i D L - (1 A ^^yD ^J-diacetoxy^^-dibrom ocyclohexane-l- 
carboxvlate 104
A solution of DL-( l,3,5/2,4)-2,3-diacetoxy-4,5-dibromocyclohexane-l-carboxylic acid 
103 (184mg, 0.46mmol) in methanol (3.7ml) was stirred at 0°C and acetyl chloride 
(61 mg, 0.055ml, 1.7 eq) was added dropwise. The solution was boiled for 2 hours and 
monitored by t.l.c. (mobile phase = 40% ethyl acetate/petroleum ether) which showed 
3 compounds present. The reaction was continued for a further 2 hours but no change 
was observed. The solution was neutralised with solid sodium hydrogen carbonate and 
concentrated in vacuo to an oil to which was added acetic acid (1ml) and pyridine 
(lml) and the solution was stirred for 3 days. T.l.c. analysis showed conversion to one 
product. The solution was diluted with ethyl acetate (50ml), washed with 1M 
hydrochloric acid (50ml) and subsequently saturated sodium hydrogen carbonate, dried 
over sodium sulfate and concentrated in vacuo to a colourless solid (117mg, 66%).
m.p. 180-2°C (lit. 182.5-184.5°C):
8h 3.69 (3 H, s, CCTMe), 2.09 (3 H, s, OAc), 1.99 (3 H, s, OAc);
71. Attempted synthesis of 3-acetvlmorphine-6-(2-hydroxycyclohexyl)ether
A solution of 3-acetylmorphine 47 (177mg, 0.54mmol), cyclohexene oxide (53mg, 1.0 
eq) and magnesium perchlorate (120mg, 1.0 eq) in acetonitrile (2ml) was boiled for 8
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hours. T.l.c. analysis (mobile phase = 10% methanol/chloroform) indicated complete 
conversion to a new compound, Rr = 0.15 and 2 other minor by-products, Rf = 0.25 
and 0.3. The mixture was concentrated in vacuo to an oil which was flash 
chromatographed to afford the main product (72mg). Shown to be morphine.
72. Synthesis of dibutvltin bis(dibutvl phosphate) (OPC)
A solution of dibutyltin oxide (2.5g, lOmmol) and dibutylphosphate (4.2g, 4.0ml, 2 eq) 
in benzene (200ml) was boiled under Dean and Stark conditions. After 12 hours, the 
benzene was evaporated in vacuo leaving a colourless solid which was dissolved in hot 
chloroform-hexane. The impurities were filtered off and the filtrate was left to cool. 
No crystals had formed so the solution was concentrated in vacuo leaving a colourless 
solid (4 .15g, 63%).
73. Attempted synthesis of 3-/butyldimethylsilylmorphine-6-(2- 
hydroxycyclohexvDether
i) A solution of 3-'butyldimethylsilylmoiphine 57 (200mg, 0.5mmol), cyclohexene 
oxide (49mg, 1.0 eq) and OPC (lOOmg, 0.3 eq) in petroleum ether (5ml) was boiled
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for 4 days. T.l.c. analysis (mobile phase = 10% methanol/chloroform) indicated no 
reaction with all 3 starting materials unaffected.
ii) A solution of .Vbutyldimethylsilylmorphine 57 (200mg, 0.5mmol), cyclohexene 
oxide (49mg, 1.0 eq) and OPC (lOOmg, 0.3 eq) in petroleum ether (5ml) was boiled 
for 4 days. 3-'butyldimethylsilyl chloride (75mg, 1.0 eq) was added and the solution
was boiled for a further 8 hours. T.l.c. analysis (mobile phase = 10%
methanol/chloroform) indicated no reaction with all 3 starting materials unaffected.
iii) A solution of 3-,butyldimethylsilylrnorphine 57 (200mg, 0.5mmol), cyclohexene 
oxide (49mg, 1.0 eq) and OPC (425mg, 1.3 eq) in petroleum ether (5ml) was boiled 
for 2 days. T.l.c. analysis (mobile phase = 10% methanol/chloroform) indicated no 
reaction with all 3 starting materials unaffected.
iv) A solution of 3-,butyldimethyJsi1ylmorphine 57 (200mg, 0.5mmol), cyclohexene 
oxide (49mg, 1.0 eq) and OPC (425mg, 1.3 eq) in petroleum ether (5ml) was boiled 
for 2 days. 3-fbuty.Idimethylsilyl chloride (75mg, 1.0 eq) was added and the solution
was boiled for a further 8 hours. T.l.c. analysis (mobile phase = 10%
methanol/chloroform) indicated no reaction with all 3 starting materials unaffected.
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v) A solution of 3-'butyldimethy]silylmorphine 57 (200mg, 0.5mmol), cyclohexene 
oxide (49mg, 1.0 eq) and sodium hydride (13mg, 1.1 eq) in THF (5ml) was stirred for 
2 hours. T.l.c. analysis (mobile phase = 10% methanol/chloroform) indicated no 
reaction. The mixture was boiled for 6 hours, after which, t.l.c. analysis indicated 
-80%  to a new compound, Rf = 0.15. The solution was quenched with aqueous acetic 
acid, washed with ethyl acetate, basified with saturated sodium hydrogen carbonate, 
and extracted into ethyl acetate (7x), dried over sodium sulfate and concentrated in 
vacuo to a dark solid. Crystallisation from ether gave an off-white solid which was 
shown by n.m.r. to be morphine (78mg, 55%).
74. Attempted synthesis of 3-'butyldimethvlsibdmorphine-6-cyclohexylether
A solution of cyclohexanol (50mg, 0.5mmol) and pyridine (60mg, 1.5 eq) in DCM 
(2ml) was stirred at -23°C, triflic anhydride (140mg, 0.084ml, 1.0 eq) was added 
dropwise and the solution was stirred for 1 hour. 3-'butyldimethylsilylmorphine 57 
(200mg, 0.5mmol) in DCM (0.5ml) was added dropwise and the solution turned red. 
After warming to 20°C the colour changed to light brown and t.l.c. analysis (mobile 
phase = 10% methanol/chloroform) revealed the presence of several compounds. 
After a further 20 minutes, the solution had turned dark and t.l.c indicated conversion 
to 1 main product, Rf = 0.15. The solution was quenched with aqueous acetic acid, 
washed with ethyl acetate, basified with saturated sodium hydrogen carbonate, and
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extracted into ethyl acetate (6x), dried over sodium sulfate and concentrated in vacuo 
to a red oil which was shown to contain only morphine (80mg, 56%).
5h consistent with that of morphine.
75. Attempted synthesis of codeine-6-cyclohexvlether
i) A solution of cyciohexanol (60mg, 0.6mmol) and pyridine (142mg, 3.0 eq) in DCM 
(2ml) was stirred at -23°C, triflic anhydride (0.1ml, 1.0 eq) was added dropwise and 
the solution was stirred for 1 hour. Codeine (150mg, 0.5mmol) in DCM (0.5ml) was 
added dropwise. The solution was warmed to 20°C and t.l.c (mobile phase = 10% 
methanol/chloroform) indicated conversion to 1 main product, Rf = 0.25. The solution 
was concentrated in vacuo, diluted with ethyl acetate and extracted into ice-cold 1M 
hydrochloric acid. This was basified with saturated sodium hydrogen carbonate and 
the product was extracted into ethyl acetate (5x), dried over sodium sulfate and 
concentrated in vacuo to a colourless solid which was shown to contain only codeine 
(49mg, 32%). Different Rf assumed to be due to triflate salt.
ii) A solution of codeine (300mg, l.Ommol), cyclohexyl bromide (325mg, 0.245ml, 2.0 
eq) and silver carbonate on celite (3.0g, 5 eq) in toluene (5ml) was boiled for 8 hours. 
T.l.c. analysis (mobile phase = 10% methanol/chloroform) indicated partial conversion 
to a new compound, Rf = 0.5. The mixture was cooled, filtered (washing with
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chloroform), and the filtrate was concentrated in vacuo to a dark oil. This was taken 
up in ether and extracted into ice-cold 1M hydrochloric acid, basified with sodium 
hydrogen carbonate and extracted into chloroform. The organic layer was separated, 
dried over sodium sulfate, and concentrated in vacuo to a light brown solid (llOmg). 
Product was shown by n.m.r. to contain no cyclohexyl group and was consistent with 
the by-product from previous reactions of codeine using silver carbonate on celite.
iii) A solution of codeine (15()mg, 0.5mmol) and sodium hydride (29mg, 2.4 eq) in 
THF (5ml) was stirred for 10 minutes before cyclohexyl bromide (163mg, 0.12ml, 2.0 
eq) was added dropwise. After 2 hours, t.l.c. analysis (mobile phase = 10% 
methanol/chloroform) showed no reaction so a further portion (2.5 eq) sodium hydride 
was added and the reaction was continued for 12 hours, during which time the solution 
turned red but t.l.c. analysis still indicated no conversion. The solution was boiled for 
5 hours, but t.l.c. analysis still indicated no conversion.
7 6. A tie mpted synthesis of a-bromocodide (6[3-bromocodide) 107
A solution of phosphorus pentabromide (2.16g, 5.0mmol) in chloroform (5ml) was 
made up at 0°C and codeine (900mg, 3.0mmol) was added in portions. The solution 
was stirred at 20°C for 5 hours and t.l.c. analysis (mobile phase = 10% 
methanol/chloroform) indicated complete conversion. The solution was quenched with
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water followed by saturated sodium hydrogen carbonate and stirred with heating until 
the red colouration disappeared. Extraction into ethyl acetate and concentration in 
vacuo gave an oil which was flash chromatographed to afford a colourless solid which 
was shown to be the dibromide (920mg, 69%) mostly as 1,6-dibromocodide.
m/z (C.l.) 442 (M++H), 360, 362 (M++H-Br);
8h 6.86 (1 H, s, C2-H), 6.05 (1 H, ddd, ,/7,8 11.0, h ,6 6.5, J1M 3.0, C7-H), 5.63 (1 H, 
dd, 11.0, 4 2.5, Cs-H), 5.21 (1 H, s, Cs-H), 4.66 (1 H, d, h ,7 6.0, C6-H), 3.84 (3
H, s, OMe). 3.39 (1 H, dd, 6.0, JUi 3.5, C?-H), 3.08 (1 H, d, Jgaa 15.8, C10-Hp), 
2.62 (1 H, dd, 12.0, ,/l£,J5 5.0, 2.44 (3 H, s, NMe), 2.3-2.5 (3 H, m, C14-
C"'-H„). 1.86(1 H, d(brd). 12.0, C15-He<1).
77. Synthesis of a-bromocodide (6[3-bromocodide) 107
A solution of codeine (315mg, 1.15mmol) and phosphorus tribromide (476mg, 0.17ml,
I.5 eq) in DCM (10ml) was stirred for 12 hours, after which, t.l.c. analysis (mobile 
phase = 10% methanol/chloroform) indicated conversion to 3 new compounds, Rf = 
0.1, 0.80, and 0.82. The solution was neutralised with saturated sodium hydrogen 
carbonate, extracted into ethyl acetate and concentration in vacuo gave an oil which 
was flash chromatographed to afford oils, P-bromocodide (8p-bromocodide) 108 
(13mg, 3%), and a-bromocodide (6p-bromocodide) 107 (47mg, 11%).
107 :
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8n 6.67 ( I H, cl,./ 8.2. C:-H), 6.57 (1 H, d , ./ 8.2, C'-H), 6.02 (1 H, ddd, / 7>8 9.5, J7,6
6.0, .h.u 3.0, C7-H), 5.65 (1 H, dd, Jkj 9.5, J».u  2.0, Cs-H), 5.20 (1 H, s, C5-H), 4.66 
(1 H, d, h i  6.0, C'-H), 3.84 (3 H, s, OMe), 3.39 (1 H, dd, / , . IOa 6.0, J9M 3.5, C9-H), 
3.08 (1 H, d, Jt c 15.8, Cl0-Hp), 2.62 (1 H, dd, / gOT 12.0, J t6,[5 5.0, CI6-H„,), 2.44 (3
H, s, NMe), 2.3-2.5 (3 H, m, C l4-H, C16-Ha„ C10-Ho), 1.86 (1 H, d(brd), / gem 12.0, 
C '5-Hcl|);
m/z (FAB) 360 (M++H).
108:
8,i 6.72 (1 H, d , ./ 8.2, C2-H), 6.65 (1 H, d, J  8.2, C'-H), 6.05 (1 H, dd, J7,6 10.4, J7,s
I.5, C’-H), 5.69 (1 H, dt, ./«.7 10.4, 3.3, C'-H), 5.04(1 H, d, J5.6 3.3, C5-H), 4.13 
(1 H, ddd, ./s.u 10.1, yg.6 3.4,./8J 1.5, C'-H), 3.84 (3 H, s, NMe), 3.57 (1 H, d d , /9,ioa
6.0, A.u 2.7, C9-H), 3.08 (1 H, d, ,/gem 18.9, C l0-Hp), 2.73 (1 H, dd, Ju.% 9.9, J u s  2.7, 
C1J-H), 2.45 (3 H, s, NMe), 2.5 (1 H, m, C16-He<1), 2.40 (1 H, dd, 7genl 18.7, J t0s  6.0, 
C -Ha), 2.28 (1  H. td, -c,, 12.1, .7 i6 .i5c9 3.7, C16-Hax), 1.94 (1 H, td, */gem;15,16ax
12.3, ./l?.K,e, 5.1, C l:;-H«), 1.78(1 H ,ddd ,./gcm 12.5,715 ,16ax 3.7, J ]5.16eq 1.5, C^-Heq).
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A Synthesis of Morphine-6-glucuronide
Christopher Lacy and Malcolm Sainsbury 
School o f Chemistry, University o f  Bath, Claverton Dow n, Bath BA2 7AY
Abstract. A  practical synthesis o f m orphine-6-glucuronide from 3-acetylm orphine 
and m ethyl 2-a-bromo-3,4,5-tri-<9-acetylglucuronate is described. Sim ilar syntheses 
o f codeine-6-glucuronide, codeine-6-glucoside and m orphine-6-glucoside are also 
documented
The m orphine metabolite m orphine-6-glucuronide (M 6G, 1) is a m ore effective and longer lasting 
analgesic drug than m orphine (2) with fewer side effects.1 U nfortunately m orphine is also m etabolised to 
m orphine-3-glucuronide (M 3G, 3), a compound which antagonises the analgesic effect o f morphine. Since 
M 3G is form ed in greater abundance than M6G, there is much interest in using the latter, rather than 
morphine, as a pain killing drug.2
M6G has been obtained through the selective hydrolytic cleavage o f m orphine-3,6-diglucuronide (4), 
using p-glucuronidase as a catalyst,3 but an efficient synthesis involving direct monocoupling between 
m orphine, or codeine, and a glucuronic acid derivative has not yet been fully realised.
Syntheses o f M 6G and codeine-6-glucuronide (5) have been reported by Yoshim ura et al.,4 but we have 
been unable to reproduce the methods described and to obtain the final products in a pure form. Similarly, a 
patent application describes,5 as the key step, a reaction between the im idate (6) and 3-acetylm orphine (7). 
The yield o f the ‘adduct g lycoside’ is claimed as 63% , and it is stated that this may be converted into M6G 
by treatment with 5% NaOH and crystallisation o f the product from  HOAc. However, although we can 
routinely prepare the adduct by this route in yields o f  10-15%, the M 6G obtained from it cannot be purified 
by crystallisation, as stated, and it is contam inated with NaOAc. The use o f o ther bases presents similar 
difficulties and, since the glucuronide is highly water soluble, this constitutes a m ajor problem  if the method 
is to be adopted on a large scale.
W e have significantly improved the coupling procedure by refluxing (7) (240 mg) in toluene (10 cm 3) 
with the 2a-brom oglucuronate (8) (600 mg) in the presence o f silver carbonate on Celite (1:1)6 (2.5 g), 
which was added in 0.5 g portions over 3h. This gives the ‘adduct’ (9) (210 mg, 45%), which can be 
successfully deprotected by either treatment with 0.1M NaOH aq., and then neutralising with HOAc 
(20mM ), or by heating it in H20  (20mM) with Am berlite IRA410 resin for 10 h., prior to treatment with
0.1M  NaOH, and evaporation. In both cases the residue is redissolved in the m inim um  o f 1% MeCN in H20  
and eluted through a W aters Sep-pak C-18 cartridge with this solvent mixture. Initial fractions are rich in 
inorganic salts and later ones give pure M6G in 85% yield.
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This route has also been applied to the syntheses o f  the glycosides (5) [from codeine (10) and (8)], (11) 
[from (7) and 2a-bromo-tetra-<9-acetylglucose (12)], and (13) [from (10) and (12)], in overall yields close to 
those for M6G. The weak point in our route is the use o f Celite, which appears to promote the 
decom position o f the ‘adducts’. W e have tried m any other supports and m ethods but, so far, without 
improvement, for exam ple, a com m only recom m ended m eans o f activating a pyranose is via the imidate 
derivative,7 however, in our hands a reaction between cyclohexanol and the im idate (14) gives only a 69:31 
a:p-selectivity and only a 12% com bined yield o f  the corresponding ‘adducts’. Furthermore, no coupling is 
observed between this activated sugar and codeine, whereas in the reaction o f 2-[2,3,4,6-tetra- 
-0-benzyl-a,p-glucopyranosyl]oxy 2-pyrim idine (15)8 and codeine both a- and p-‘adducts’ are formed in 
equal amounts, and in only 35% yield.
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12, * R=a-Br, 2R=Ac; 3R=CH2OAc
14. •r ^C N H IC C I}; 2R=Bn; 3R=C02Me
15.1 R=0-2-pyrimidate;2R=Bn;3R=CH20Bn
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